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1.
General introduction and 
outline
81.1 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative 
disorder, and the most prevalent form of dementia in late life, making up 60-
80% of all dementia cases. Currently, 36 million people are suffering from 
dementia worldwide1, and effective treatment options are unavailable. Since 
AD prevalence is age-related and average life-span is lengthening among the 
population, an increase of the disease is expected in the coming decades, 
though incidence is probably declining per age category in high income 
countries2,3, altogether making it urgent to find valid diagnostic tools and 
therapeutic strategies. 
Several genes encoding the amyloid precursor proteins, presenilin-1 and 
presenilin-2, can directly cause familial AD. The patients carrying these genes 
often display an early onset of dementia in their forties, which can manifest 
in several members of the same family. They, however, account for only 1% of 
all cases of AD. The remaining 99% of sporadic AD occurs predominantly in 
patients older than 65 years, and is referred to as late onset AD, in whom the 
aging related pathophysiology is still not deciphered. 90% of all patients with 
this sporadic form AD are 75 years or older.
Symptoms of AD
AD is characterized by a cluster of symptoms, of which memory complaints are 
its most prominent defined feature. The progression of the disease relevantly 
differs between patients, with symptoms worsening over the course of 3-10 
years from diagnosis, leading to loss of independence, institutionalization 
and together with causally or non-causally related comorbidity eventually 
leading to death. The early clinical presentation of AD includes disturbances 
in memory functions, especially episodic memory, and one or more of 
other cognitive functions such as spatial orientation impairments, language 
difficulties, and changes in personality. In contrast, memory for facts such as 
vocabulary and concepts (semantic memory) often becomes impaired in later 
stages of the disease. While symptoms develop gradually and highly variable, 
patients ultimately decline to such an extent that they need constant care and 
supervision support for daily activities in the final stage of the disease4,5.
Pathogenesis: amyloid cascade hypothesis 
AD is characterized pathologically by a progressive loss of neurons and 
synapses, starting in the subcortical regions (especially the hippocampus) and 
entorhinal cortex, expanding to the cortex with secondary enlargement of the 
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ventricles. On a microscopical level, two characteristic features of AD pathology 
can be identified: amyloid plaques and neurofibrillary tangles.  
Accumulation of amyloid plaques containing the amyloid beta (Aβ) protein 
in the brain is one of the hallmarks of AD pathology and a key component of 
the amyloid cascade hypothesis6. This hypothesis proposes that deposition 
of amyloid plaques in the brain is a crucial event in the pathology of AD and 
that an imbalance in Aβ production and clearance leads to an increase in Aβ 
load. Aβ peptides are produced from the amyloid precursor protein (APP) and 
cleaved by β-secretase and γ -secretase. Neurons release monomeric Aβ in 
response to neuronal activity, which normally remains soluble allowing their 
clearance into the cerebrospinal fluid or blood. However, at high concentrations, 
specifically in the isoform Aβ42, Aβ is more prone to aggregation into insoluble 
amyloid fibrils that are resistant to degradation. These amyloid fibrils deposit 
extracellularly in neurons in dense neurotoxic formations known as amyloid 
plaques, or in less dense aggregates as diffuse plaques.
According to this amyloid hypothesis, deposition of amyloid plaques initiates 
tau pathology, another important player in the pathophysiology of AD, although 
tau pathology has also been shown to develop independently form amyloid 
plaques7. 
Tau is a microtubule-associated protein that aids in microtubule assembly and 
stabilization. In AD, tau becomes hyperphosphorylated (p-tau) and aggregates. 
The accumulation of p-tau into intracellular  neurofibrillary tangles may cause 
disruption of normal cytoskeletal architecture, with subsequent neurotoxicity 
and neuronal cell death8.
While the amyloid cascade hypothesis is currently the dominant theory in the 
pathogenesis of AD, recent research has casted doubt on whether amyloid 
plaques are really the main cause of the neurodegeneration of AD9, leaving the 
theory up for debate. Among the reasons for criticism is the fact that the density 
of amyloid plaques in patients with AD has been shown to be the same in a high 
percentage of healthy elderly persons without AD10,11.  It is postulated that Aβ 
is likely the key initiator of a complex pathogenic cascade that causes AD, but 
acts primarily as a trigger for other downstream processes, tau aggregation in 
particular12. 
Diagnosis
The recommended standard diagnostic procedure in suspected cases of AD 
is as follows: a general assessment of the patient, a physical, neurological 
and psychiatric examination, and laboratory tests, all according the national 
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dementia guideline, which adheres to the National Institute of Neurological and 
Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease 
and Related Disorders Association’s (ADRDA) criteria13. Additional tests include 
neuropsychological tests (NPT), magnetic resonance imaging of the cerebrum 
(MRI) to detect neurodegeneration, and cerebrospinal fluid (CSF) biomarker 
analysis, which were later added to the NINCDS-AEDA14 and later on to the 
National Institute on Aging-Alzheimer’s Association NI-AA working group on 
diagnostic guidelines in 201215.
As part of this diagnostic work-up, both Aβ and tau can be measured in the 
CSF of patients with suspected AD in whom other data are not sufficiently 
clear, and can be obtained with a lumbar puncture (LP). The pathophysiological 
changes in extracellular and interstitial environment of the brain are thought to 
be reflected in concentrations in the CSF, making the concentrations of both 
Aβ and tau suitable as biomarkers. They are used to support a diagnosis of 
AD (in addition to standard clinical diagnosis), but are not yet recommended 
for routine diagnostic purposes15. Such tests can add more certainty to the 
clinical diagnosis of AD and are especially useful in early-onset and atypical 
presentations of AD for the differential diagnosis of other non-amyloid 
neurodegenerative diseases. In general, a low CSF Aβ42 (or higher Aβ42:Aβ40 
ratio) combined with an increased CSF total tau and phospho-tau is considered 
indicative of AD16. In this diagnostic CSF analyses our laboratory uses ELISA 
assays (Innogenetics NV, Ghent, Belgium) to measure Aβ42, t-tau and p-tau, and 
cut-offs for clinical interpretation of ELISA are set respectively at 500 pg/ml, 350 
pg/ml, and 85 pg/ml, for Aβ42, t-tau, and p-tau.
Risk factors for AD
The most important known predictors for AD are age, a positive family history, 
a number of life style factor and genetic factors, of which advancing age is 
the greatest known predictor. Most individuals with the disease are 65 years 
or older and the likelihood of developing AD doubles about every five years 
after age 65. In addition, several gene polymorphisms have been discovered 
that seem to be involved in AD. The best characterized genetic risk factor in 
late-onset AD is the apolipoprotein E4 (ApoE4) genotype with ApoE4 carriers 
having a 4- to 10-fold increased odds ratio of developing AD17-19. In addition, 
presenilin-1 and presenilin-2 show a strong correlation with non-sporadic AD.
Other risk factors for AD are lifestyle-related, adding up to 35% of the 
population attributable risks20, some of which have the advantage of being 
modifiable. The most important modifiable risk factors for AD are cognitive 
reserve, physical and social activity and exercise, midlife obesity, depressed 
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mood, and alcohol intake. Many treatable medical conditions are also risk 
factors for AD, including stroke, hearing loss, diabetes, midlife hypertension, 
and midlife hypercholestoremia21. Recent evidence suggests that poor 
sleep in mid-life is also a potential risk factor for AD. In this thesis, I will be 
focusing on sleep disruption as a potential risk factor for AD and explore the 
pathophysiological mechanisms behind it.
BASICS OF SLEEP.
Sleep is an important phenomenon of physiological restoration in 
humans, and critical for normal functioning during the day. Sleep 
serves to clear waste from the brain, and support learning and memory. 
Normal sleep can roughly be divided into non–rapid eye movement 
(NREM) and rapid eye movement (REM) sleep. NREM sleep is further 
divided into progressively deeper stages of sleep: stage N1, stage 
N2, and stage N3 (deep or delta-wave sleep) (see table 1). Typically, 
N3 sleep is mostly present in the first third of the night, whereas REM 
sleep predominates in the last third of the night (see figure 1). Sleep 
can be measured by polysomnography (PSG), which is a combination 
between electrocephalography (EEG), which measures brain activity, 
electrooculography (EOG), which measures eye movements and 
cardiorespiratory parameters.
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Figure 1: Hypnogram of a typical night with 8 hours of sleep. The brain alternates between 
the different brain stages during the night. Most of the N3 sleep occurs in the first third of the 
night, while the amount of REM sleep increases in both frequency and length near the morning.
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1.2. THE BI-DIRECTIONAL RELATIONSHIP 
BETWEEN SLEEP DISRUPTION AND AD 
Sleep disorders are a symptom of various neurodegenerative diseases, 
including AD22,23. They are prevalent throughout the entire course of the disease 
and worsen with disease progression24. Studies have estimated that 44% of AD 
patients are affected with some sort of sleep disorder25,26, and that these sleep 
disorders are more severe compared to healthy aging27. The most common 
sleep disorders in AD include daytime hypersomnia, night time insomnia, 
delayed circadian phase, and sundowning (i.e. increased confusion starting the 
end of the day)28. Obstructive sleep apnea (OSA), a primary sleep disorder, is 
particularly common in AD29,30. 
More specifically, AD patients are shown to have a decreased sleep efficiency, 
less slow wave sleep (SWS) (even compared to age matched healthy elderly) as 
well as decreased rapid eye-movement (REM) sleep and an increased latency 
Stages of sleep
NR
EM
 sl
ee
p
EEG
N1
N2
The lightest form 
of NREM sleep 
and is considered 
the transition 
between wake 
and NREM. 
Alpha waves 
(8-12 Hz) of wake 
drops out to make 
place for theta 
waves (4-8 Hz). 
2-5% TST
N3 The deepest form 
of NREM sleep. 
Also called slow 
wave sleep.
>20 % Delta slow 
waves (0.5 -4 Hz)
5-15% TST
The most 
prevalent form of 
sleep. 
Theta waves 
(4-8 Hz) with sleep 
spindles and 
k-complexes.
45-55% TST
REM sleep Dreaming. Rapid 
eye-movements.
Mixed frequency 
EEG similar to 
stage 1 with saw 
tooth waves. 
20-25% TST
Table 1: Explanation of different sleep stages and how they present themselves on the EEG. 
TST: total sleep time.
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for REM sleep31. Earlier research has recorded a direct correlation between 
amyloid deposition in the brain and alterations in sleep. Amyloid burden in 
the medial prefrontal cortex has shown to be associated with a decrease in 
SWS in healthy older adults32. Patients also show more awakenings during 
the night, which in turn results in more fragmented sleep in AD patients. Due 
to wandering at night and the subsequent risk of injury, nighttime insomnia 
increases morbidity and mortality directly, and therefore is a common reason 
for institutionalization31,33-35.  
The exact cause of frequent sleep disorders in AD is currently unknown, but 
one hypothesis highlights neurodegeneration in important sleep regulating 
areas and pathways in the brain as the cause. Parts of the ascending arousal 
pathway (AAS), including the nucleus basalis of Meynert (involved in REM sleep) 
in the basal forebrain, thalamus and several nuclei in the brainstem; the locus 
coeruleus (LC), the upper raphe nuclei and the tegmentopontine reticular 
nuclei36 are those primarily affected. The LC even loses up to 70% of its neurons 
in AD. Neurodegeneration in the suprachiasmatic nucleus (SCN), the circadian 
rhythm pacemaker of the brain, has also been suggested to be the cause of 
sleep disorders as seen in AD37. 
Increasing evidence suggests that circadian and sleep disturbances, which 
have long been considered a symptom of AD, may in fact drive pathogenesis, 
supporting the role of a bi-directional relationship between sleep disturbances 
and AD as proposed in figure 2. Observational studies show that patients with 
insomnia or sleep disruptions in mid-life to old age have an increased risk of 
pathological changes that precede AD (such as amyloid burden), as well as an 
Disrupted 
sleep ↑ Aβ load ↑ risk of AD
↑ tau load
Neurodegeneration of sleep regulating areas
↑ Aβ plaques
↑ NFT
Neuronal 
death
Figure 2: Proposed mechanisms linking sleep and AD. This schedule summarizes the 
proposed mechanisms by which poor sleep could potentially influence the pathophysiological 
mechanism of AD. NFT: neurofibrillary tangles.
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increased risk of AD. Insomnia38, self-reported sleep disturbances39,40, a decline 
in sleep duration41, impaired sleep quality as measured by PSQI 42, impaired 
sleep consolidation43, delayed or decreased circadian rhythms44, and sleep 
disordered breathing (SDB)45, have all been shown to increase the risk of AD. 
In addition, fragmented sleep has further been shown to be an indicator of 
cognitive impairment 46,47. Sleep fragmentation typically worsens with increasing 
age and is associated with a 1.5-fold increased risk of developing dementia 
after a 6-year follow-up period47. 
In recent years, several studies aimed to further explore the pathophysiological 
mechanism between sleep disturbances and AD, by investigating the link 
between amyloid and poor sleep. Using actigraphy to assess sleep efficiency, Ju 
et al. found that cognitively normal adults with positive cerebral Aβ deposition 
on Pittsburgh Compound B (PiB) amyloid-positron emission tomography (PET) 
imaging had significantly worse sleep efficiency than those without PiB-positive 
plaques48.  In addition, Spira et al. found that cognitively normal older adults 
with self-reported poor sleep were more likely to have Aβ plaque pathology 
in the precuneus, as also assessed by PiB PET imaging49. Together, these two 
studies show that people with amyloid pathology develop detectable declines 
in sleep efficiency before the onset of cognitive decline. Therefore, sleep 
disturbances in mid-life to old age may be a risk factor or a biomarker for AD 
and AD type changes may be leading to sleep disturbances before cognitive 
decline.
1.3. MODULATION OF SLEEP IN A 
PRODUCTION AND CLEARANCE
In the past few years, increasing evidence in both animals and humans has 
accumulated to support the hypothesis that the production and/or clearance 
of Aβ peptides in the brain is closely related to the sleep-wake cycle, with 
high extracellular levels during wakefulness and low extracellular levels during 
sleep50-53.  Kang et al. was the first to show that ISF Aβ levels show a diurnal 
rhythm in mice, where levels of ISF Aβ were highest during the dark phase 
(when mice are usually awake), and lowest during the light phase (when mice 
are usually asleep)50. ISF Aβ levels were negatively correlated with the amount 
of time spent asleep. This negative correlation was even stronger with NREM 
sleep. A study by Roh et al. demonstrates comparable results, with a normal 
sleep wake cycle and diurnal fluctuation in ISF Aβ in the brain of the APPswe/
PS1δE9 mouse model of AD before Aβ plaque formation51. It therefore seems 
15
General introduction and outline
1.
that sleep and wakefulness are capable of modulating ISF Aβ in rodents. 
Experiments in humans using lumbar catheters to collect cerebrospinal fluid 
(CSF) showed similar diurnal oscillations in CSF Aβ levels as were observed 
in the ISF of mice. In human studies, the levels were lowest around 10AM, 
corresponding to a nadir in ISF levels at 4AM in mice (as there is a 6 hour lag 
for brain soluble Aβ to reach the lumbar space as showed by Bateman et al.54). 
This time point of 4 AM in humans, is the time before which most SWS has on 
average already occurred.
The effect of sleep deprivation on ISF amyloid
Up until now, the effect of sleep deprivation on amyloid has only been 
investigated in animal studies. The effect of directly manipulating sleep 
is important to prove that the diurnal fluctuations observed in Aβ are 
specifically tied to and modulated by sleep. Kang et al. found that prolonged 
sleep deprivation in mice resulted in an increase in Aβ plaque burden in 
transgenic mice that express AD associated mutant forms of human APP and 
presenilin-150. The plaque burden was decreased after treatment with the 
orexin antagonist almorexant, which increased total sleep time. Rothman at el 
showed similar results in a mouse model for AD 3xTgAD that expresses human 
APP, PS1, and human tau transgenes, who also demonstrated an increase in 
cortical Aβ plaque burden following chronic sleep deprivation55. This specific 
effect of sleep deprivation in mice supports the role of sleep in the modulation 
of Aβ levels, where prolonged sleep deprivation possibly causes elevated levels 
of ISF Aβ overtime, increasing the chance of developing amyloid plaques, which 
can in turn be prevented by increasing total sleep time. This effect of sleep 
deprivation has not only been shown in rodents, but also in the Drosophila fly 
that over expresses Aβ, who also demonstrated an increase in Aβ accumulation 
after sleep deprivation and a decrease in Aβ accumulation with sleep increase56.
1.4. FOCUS AND OUTLINE OF THIS THESIS
This thesis will focus on how poor sleep in midlife affects the risk of AD and the 
pathophysiological mechanism behind it. To this end, we conducted a series 
of studies to gather cumulative evidence on the effect of sleep deprivation on 
CSF Aβ in humans, including examining alternatives to commonly observed 
challenges in its measurement. 
As a first step, we performed a study to investigate the effect of one night 
of total sleep deprivation on CSF Aβ and tau in healthy male volunteers in 
16
chapter 2. As a next step, we wanted to investigate the specific contribution of 
SWS on CSF Aβ in humans, as SWS is associated with a period of diminished 
neuronal firing and is expected to be associated with less Aβ production. 
For this purpose, we developed an automated protocol which disrupts SWS 
with the aid of auditory tones in chapter 3. This protocol was used to disrupt 
SWS in healthy volunteers to measure the specific effect of SWS on CSF Aβ 
in chapter 4. Another important unexplored topic in the field is the effect of 
chronic sleep deprivation in humans, which has been proven difficult due to 
the heterogeneity that exists within populations with sleep disorders. A well-
defined working population (maritime pilots) with irregular sleep due to their 
profession enabled us to properly investigate the effects of chronic poor sleep 
in mid-life on cognition. From this still ongoing SCHIP study, we show the 
preliminary results in chapter 5. Although the main focus of this thesis has been 
on the relationship between poor sleep in mid-life and the risk for AD, we would 
like to elaborate on the treatment methods of several sleep disorders in patients 
already burdened with dementia, in chapter 6.
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ABSTRACT 
Background
Increasing evidence suggests a relationship between poor sleep and the risk 
of developing Alzheimer disease. A previous study found an effect of sleep 
on β-amyloid (Aβ), which is a key protein in Alzheimer disease pathology. The 
objective was to determine the effect of 1 night of total sleep deprivation on 
cerebrospinal fluid Aβ42 protein levels in healthy middle -aged men. 
Design
The Alzheimer, wakefulness, and Amyloid Kinetics (AWAKE) study at the 
Radboud Alzheimer Center, a randomized clinical trial that took place between 
June 1, 2012, and October 1, 2012. Participants were cognitively normal middle 
-aged men (40-60 years of age) with normal sleep (n = 26) recruited from the 
local population. Participants were randomized to 1 night with unrestricted 
sleep (n = 13) or 1 night of total sleep deprivation (24 hours of wakefulness) 
(n = 13).
Main Outcomes and Measures
Sleep was monitored using continuous polysomnographic recording from 3 
pm until 10 am. Cerebrospinal fluid samples were collected using an intrathecal 
catheter at defined times to compare cerebral Aβ42 concentrations between 
evening and morning.
Results
A night of unrestricted sleep led to a 6% decrease in Aβ42 levels of 25.3 pg/
mL (95% CI [0.94, 49.6], P = .04), whereas sleep deprivation counteracted this 
decrease. When accounting for the individual trajectories of Aβ42 over time, 
a difference of 75.8 pg/mL of Aβ42 was shown between the unrestricted 
sleep and sleep deprivation group (95% CI [3.4, 148.4], P = .04). The individual 
trajectories of evening and morning Aβ42 concentrations differed between the 
unrestricted sleep and sleep deprivation groups (p = .04) in contrast to stable 
Aβ40, tau, and total protein levels.
Conclusions and Relevance
Sleep deprivation, or prolonged wakefulness, interferes with a physiological 
morning decrease in Aβ42. We hypothesize that chronic sleep deprivation 
increases cerebral Aβ42 levels, which elevates the risk of Alzheimer disease.
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2.1 INTRODUCTION
The amyloid cascade hypothesis of Alzheimer disease (AD) argues that this 
disease is initiated by deposition of the β-amyloid (Aβ) protein, of which the 
Aβ42 isotype is known to be the greatest contributor. Causes for this Aβ 
deposition remain unknown in sporadic AD but are thought to reflect an 
imbalance between production and clearance of Aβ. 
Epidemiological studies have identified many potential risk factors for 
AD and increasing evidence suggests that poor sleep is among these 
factors1-4.  Mechanistic studies suggest that neural activity leads to increased 
production and secretion of Aβ5,6 such that wakefulness (increased activity) 
augments Aβ production. In turn, sleep (reduced activity) is associated with 
increased clearance of Aβ and lower Aβ production6-8.  Indeed, Aβ levels in 
the cerebrospinal fluid (CSF) in both humans and rodents showed a marked 
decrease during sleep, compared with wakefulness7,9. Moreover, rodent studies 
revealed increased cerebral Aβ levels and subsequent deposition of Aβ after 
extended wakefulness7. These findings suggest that poor sleep through chronic 
partial sleep deprivation may interfere with a physiological sleep-related 
decrease in cerebral Aβ, leading to sustained higher Aβ levels and, possibly, Aβ 
accumulation. 
We assessed the effect of 1 night of total sleep deprivation (24 hours of 
wakefulness) on CSF Aβ42 levels in healthy men. We hypothesized that sleep 
deprivation would lead to higher CSF Aβ42 levels compared with a night 
with unrestricted sleep. Because of its strongest contribution to Aβ plaque 
formation, CSF Aβ42 was chosen as the main outcome parameter. We included 
CSF Aβ40, phosphorylated tau (p-tau), and total tau (t-tau) as secondary 
outcome parameters because they are typically affected in a later stage in the 
development of AD and are thought to be biomarkers that may be initiated 
independently from Aβ10.  The total protein level was chosen as a control 
parameter. 
2.2 SUBJECTS AND METHODS  
Participants
We recruited 26 healthy men who were medication free, were cognitively 
normal with a Mini-Mental State Examination score greater than 28, and had 
normal sleep quality defined as a Pittsburgh Sleep Quality Index of 5 or more 
(Table 1). Participants were randomized to a sleep deprivation group (n = 13) or 
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Age, y
BMI
MMSE score
Total
NREM
Evening
Morning
Evening
Morning
Evening
Morning
Evening
Morning
Evening
Morning
REM
PSQIb
WASO, min
Sleep 
Efﬁciency, %
49.4(±5.5)
25.7(±3.4)
29.5(±0.8)
2.4(±1.2)
92.2(±49.4)
77.3(±12.1)
50.4(±4.9)
25.6(±1.8)
29.8(±0.6)
2.9(±1.3)
NA
NA
0.63
0.95
0.27
382(±59)
355(±98)
72.4(±28.9)
19(±32)
9.3(±17)
4.5(±14.4)
<.001
<.001
426(±181)
401(±165)
474(±126)
477(±148)
0.16e
0.04f
6153(±1863)
7041(±2719)
6907(±2251)
7769(±2993)
0.15e
0.27f
36.9(±13.5)
42.5(±14.3)
34.4(±14.5)
36.9(±16.8)
0.47e
0.12f
61.5(±15.7)
67.7(±20.4)
72.9(±28.0)
70.8(±33.5)
0.02e
0.61f
313(±94)
341(±95)
313(±96)
336(±96)
0.20e
0.42f
<.001
0.27
NA
NA
Unrestricted 
Sleep (n=13)
Sleep 
Deprivation 
(n=13)
p-value
Baseline 
characteristica
Polysomnographic
variablec
Sleep, min
Aβ42, pg/ml
Aβ40, pg/ml
P-tau, pg/ml
T-tau, pg/ml
Total protein, pg/ml
CS
F 
Va
lu
ed
Table 1: Overview of baseline characteristics, CSF and sleep data
Abbreviations: Aβ, β-amyloid; BMI, body mass index (calculated as weight in kilograms divided 
by height in meters squared); CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination; 
NA, not applicable; NREM, nonrapid eye movement; PSQI, Pittsburgh Sleep Quality Index; P-tau, 
phosphorylated tau; REM, rapid eye movement; T-tau, total tau; WASO, wake after sleep time 
onset.
25
Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: 
a randomized clinical trial
2.
Figure 1: CONSORT flow diagram
a No group differences were observed on baseline. 
b A score of 5 or lower is considered as normal sleep.
c Variables show successful sleep deprivation, contrasted by sufficient sleep in the unrestricted 
sleep group. 
d Levels are presented as the average of the 3 morning or evening samples for the unrestricted 
sleep group and sleep deprivation group. 
e P value represents the difference in evening CSF levels between the unrestricted sleep and 
sleep deprivation groups. 
f P value represents the difference in the morning CSF levels between the unrestricted sleep and 
sleep deprivation groups. 
 Individuals   
 assessed for eligibility
Enrolled
 Excluded
           5    Did not meet the inclusion criteria    
           4    Chose not to participate
Randomized
         Sleep deprivation group
DropoutsDropouts
Analyzed Analyzed
         Unrestricted sleep group
35 
26
26
13
0 0
13
13
9
13
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a group with unrestricted sleep (n = 13). They were blinded for group allocation 
until arrival at the study center. Figure 1 shows the flow diagram for this 
study. At baseline, groups were similar in their CSF profiles except for a minor 
difference in t-tau, which was, however, within the normal range in both groups 
(Table 1). Concentrations of CSF Aβ42 for all participants were well above a 
previously determined cutoff level of 192 pg/mL (Figure 2)11, suggesting that 
these participants were devoid of cerebral amyloid deposition.
This study was approved by the institutional review board at Radboud University 
Medical Center and was performed according to good clinical practice rules. 
Written informed consent was obtained from all participants. 
0
200
400
600
800
Healthy
elderly
AD
patients
Sleep
deprivation
Normal
sleep
CS
F 
Aβ
42
 (p
g/
m
l)
Figure 2: Individual Cerebrospinal Fluid β-Amyloid 42 (Aβ42) Concentrations. Mean 
individual cerebrospinal fluid Aβ42 concentrations of both the sleep deprivation and unrestricted 
sleep groups in comparison with individual cerebrospinal fluid Aβ42 concentrations of healthy 
elderly patients and patients with Alzheimer disease in a previous serial sampling study. Dotted 
line indicates the cutoff value of 192 pg/mL; solid lines, mean cerebrospinal fluid concentration 
of Aβ42.
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Study design
During the entire study period, blood pressure, temperature, pulse, and 
the catheter insertion point were monitored. Intravenous saline at 100 ml/h 
was administered to guarantee hydration and reduce the risk of postspinal 
headache12. The unrestricted sleep group was instructed to go to sleep at 12 
am. Continuous polysomnographic recording was performed from 3 pm until 
10 am using a Titanium ambulant electroencephalogram recording system 
(Embla Systems). Sleep monitoring and scoring were performed according to 
the American Academy of Sleep Medicine guidelines. 13
CSF collection and analysis
An indwelling catheter was placed at the L3/L4 interspace under local 
anesthesia and aseptic conditions by an experienced anesthesiologist. 
Samples of CSF were taken at 5, 8, 9, and 10 pm and 8, 9, and 10 am. The sleep 
deprivation group had extra sample collections at 12, 2, 4, and 6 am; these 
were not collected in the unrestricted sleep group to avoid sleep disruption. 
Sampling during the night has shown to be a major confounder on the sleep 
quality in our previous serial sampling study14. Each CSF sample was collected 
in duplicate (each 3 ml) to decrease intraindividual variation. All samples were 
clear on visual inspection. Within 30 minutes after collection, samples were 
centrifuged at 2000g for 5 minutes and stored in aliquots at −80°C in 2 -ml 
polypropylene tubes. 
Cerebrospinal fluid, Aβ42, p-tau, and t-tau were determined using the xMAP-
based Innobia assay (Innogenetics) and CSF Aβ40 was measured using an 
enzyme-linked immunosorbent assay (The Genetics Company). The total 
protein level was determined by a turbidimetric assay using benzethonium 
chloride. All CSF samples were analyzed in duplicate and all samples from the 
same participant were measured in the same plate to avoid interplate variation. 
Statistical analysis
All analyses were performed using SPSS version 20.0 (IBM). Statistical 
significance was set at p < .05. The primary analysis for both the primary (Aβ42) 
and secondary (Aβ40, t-tau, and p-tau) outcomes was a paired t-test comparing 
the average of the 3 evening samples with the average of the 3 morning 
samples.
As secondary analyses, we investigated the relationship between sleep duration 
and Aβ42 levels using a Pearson correlation test between the parameters total 
sleep time and the difference in Aβ42 level between the first (5 pm) and last (10 
28
am) samples.
Finally, we compared the individual trajectories of all CSF markers in both 
groups using random-intercept mixed-modeling analysis. Statistical analyses 
were performed with raw data and were repeated after log transformation of 
these raw data because of the known large intraindividual variability in these 
CSF biomarkers14. The sample size for this study was based on the primary 
analysis, with 80% power to detect a 10% reduction (17% was previously 
observed in rodents7 ) in CSF Aβ42 with 13 in each group, based on CSF Aβ42 
data as observed in a previous study14.
2.3 RESULTS 
Sleep patterns 
The unrestricted sleep group slept an average of 6.4 hours with a normal sleep 
architecture.  The sleep deprivation procedure was successful in the sleep 
deprivation group (Table 1).
Effect of sleep and sleep deprivation on CSF Total Protein, 
Aβ42, Aβ40, p-tau, and t-tau levels
Figure 3A shows the CSF Aβ42 values for both groups. Baseline data of the 3 
evening samples in the unrestricted sleep and sleep deprivation group did not 
differ (95% CI [−78.7, 173.5 pg/mL], P = .45). In the unrestricted sleep group, the 
lowest Aβ42 values were observed at 10 am. Despite the expected relatively 
large interindividual variation in Aβ42 levels, the average of the 3 morning sam-
ples was 6% lower than the average of the 3 evening samples for unrestricted 
sleep (25.3 pg/mL, 95% CI [0.94, 49.6], P = .04), but not for sleep deprivation. 
Neither sleep nor sleep deprivation affected Aβ40, t-tau, or p-tau (Table 1).
Total sleep duration was correlated with the maximum reduction in Aβ42 
(r = −0.50, p = .04) (Figure 4). This largest reduction in Aβ42 (−38.4 pg/mL, 95% 
CI [3.9, 149.9], P = .04) was observed between the 2 times, 5 pm and 10 am 
(Figure 3A). This effect was not found for Aβ40, p-tau, and t-tau.
The individual trajectories of the serial CSF Aβ42 concentrations as assessed by 
mixed modeling differed between individuals who were allowed unrestricted 
sleep or were sleep deprived (75.8 pg/mL, 95% CI [3.4, 148.4], P = .04) ( Figure 
3A). After log transformation of the data, this effect remained (p = .01). Again, 
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Figure3: Cerebrospinal Fluid (CSF) β-Amyloid 42 (Aβ42) and Total Protein Concentrations 
Over Time. Mean CSF concentrations (all in pg/ml) over time in the unrestricted sleep group and 
in the sleep deprivation group. The grey areas depict the time the light was turned off for the 
unrestricted sleep group. A: Aβ42 levels. *indicates that the individual trajectories of the CSF 
Aβ42 samples differed between the groups (p=0.04) B: total protein levels. Standard errors are 
indicated by vertical lines.  ■unrestricted sleep  ▲ sleep deprivation 
Figure 4: Relationship between total sleep time and reduction in Aβ42
Relationship between the reduction in CSF Aβ42 in pg/ml between 5 pm and 10 am and the total 
sleep time in minutes. r=-0.50, p=0.04
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this effect was not observed for Aβ40, p-tau, and t-tau. In both groups, we 
observed increases over time of the individual trajectories of CSF Aβ40, p-tau, 
and t-tau (Figure 5). The CSF total protein levels remained stable in both the 
unrestricted sleep and sleep deprivation groups during the entire period. 
Figure 3B illustrates that the morning decrease observed for CSF Aβ42 was not 
found for CSF total protein levels.
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Figure 5: Cerebrospinal Fluid (CSF) β-Amyloid 40 (Aβ40) and Tau Concentrations Over Time. 
Mean CSF concentrations of Aβ40 (A), phosphorylated tau (P-tau) (B), and total tau (T-tau) (C) over 
time in the unrestricted sleep group and in the sleep deprivation group. Shaded areas indicate 
the time the light was turned off in the unrestricted sleep group; error bars, standard error. 
■unrestricted sleep  ▲ sleep deprivation
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2.4 DISCUSSION
We showed that CSF Aβ42 levels decrease during a night of sleep in healthy 
human individuals. The magnitude of this decrease correlated with the total 
amount of sleep. Moreover, 1 night of total sleep deprivation abolished this 
decrease in Aβ42. These sleep-related effects were not observed for CSF Aβ40, 
p-tau, t-tau, and total protein levels.
Unrestricted overnight sleep has previously been associated with a decrease 
in CSF Aβ levels. Rodents have a 25% decrease in interstitial fluid levels of Aβ 
during sleep (human Aβ1-x in transgenic mice and murine Aβx-40 in wild -type 
mice)7. In human CSF, an amplitude-mesor ratio of 8.3% in Aβ42 was observed 
over a 24-hour period, with the lowest values observed in the morning9. 
We confirmed this morning effect, and these combined data suggest that a 
morning decrease in CSF Aβ42 levels is a normal physiological phenomenon 
related to sleep. Interestingly, this morning decrease was most prominent at 10 
am. In a previous human study9 it was also found that the lowest levels were at 
10 am and that Ab42 was inversely correlated with sleep after a 6 -hour delay9. 
The authors attributed this effect to the previously reported delay in clearance 
of Aβ from interstitial fluid to the CSF15. Although previous studies7,9 suggested 
that this sleep-related decrease also applied to Aβ40, we were unable to 
confirm this. It is not unlikely that the metabolism of the different isoforms of Aβ 
is not the same in response to physiological changes. This assumption is based 
on various levels of evidence that the metabolism of Aβ42 is different from that 
of Aβ40: (1) it is well established that Aβ42 aggregates faster than Aβ40; (2) 
Aβ40 and Aβ42 may each be produced at different intracellular locations and 
by different mechanisms in neurons16,17; and (3) Aβ42 and Aβ40 may be cleared 
from the brain by different mechanisms18,19.
Aside from showing an effect of sleep on CSF Aβ42, we demonstrated 
that sleep deprivation abolishes this morning decrease in CSF Aβ42. Sleep 
deprivation has been applied in a transgenic rodent model, where a short 
period of sleep deprivation, compared with periods of normal sleep, resulted 
in a 16.8% increase in hippocampal interstitial fluid levels of human Aβ1-x7. Our 
data show that a comparable effect is present in healthy middle-aged men.  
We hypothesize that this effect of sleep deprivation (i.e., extended wakefulness) 
on Aβ42 is mainly explained by the relationship between neuronal activity, 
synaptic strength, and Aβ42 production. In animal models, wakefulness and 
brain activation increase synaptic strength and Aβ levels, while periods of sleep 
or reduced brain activation decrease synaptic strength and Aβ levels20-23. In 
humans, brain activation has also indirectly been linked to Aβ production5. Brain 
areas that display the highest levels of activity during wakefulness, the so-called 
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default mode network, are also the regions most prone to Aβ aggregation5. In 
patients with traumatic brain injury, higher levels of consciousness (compared 
with coma) led to higher interstitial fluid levels of Aβ24. A decrease in Aβ 
clearance during sleep deprivation may exaggerate the increase in CSF 
Aβ. A recent rodent study observed a 60% increase in the interstitial space 
volume during periods of sleep, relative to the awake status using real-time 
iontophoresis8. As a result of higher CSF flow through the dilated interstitial 
space, there was twice as much clearance of radiolabelled Aβ during sleep 
compared with the awake status8. 
Previous studies of CSF serial sampling suggested that both high sample 
frequency and a large sampling volume could lead to linear increases in CSF Aβ 
levels25. One hypothesis for this linear increase is that Aβ is not homogeneously 
distributed in the extracellular fluid and that serial sampling affects the flow to 
the subarachnoid space to increase lumbar CSF Aβ to concentrations that may 
reflect brain vesicular levels25. A very important point of discussion is that the 
4 extra CSF samples taken from the sleep deprivation group during the night 
could have augmented any sampling-related increases over time. In contrast 
to these considerations, Figure 5 clearly illustrates that there were no effects 
of sample frequency on CSF Aβ40, p-tau, and t-tau in both groups, which was 
also confirmed in the mixed -modeling analyses. The tau protein has previously 
been proven to be a relatively stable protein in CSF, with a much longer in vivo 
turnover rate than Aβ (11-day half-life)26. A response of CSF t-tau to physiological 
changes such as decreased neuronal activity can only be detected after several 
days and will likely not be present in our experimental design. Therefore, major 
changes in CSF t-tau would only reflect changes in CSF composition due to 
serial sampling. The absence of differences between the 2 groups in t-tau 
supports the fact that the 4 extra samples in the sleep deprivation group did 
not affect the composition of CSF. In addition, CSF total protein levels remained 
stable in both groups, even during the periods of extra sampling in the sleep 
deprivation group, further supporting our conclusion that the difference in 
sampling frequency in the 2 groups is likely not the cause of the observed 
differences in Aβ42 protein (Figure 3B).
A previous study has demonstrated that an increase over time for either Aβ or 
tau protein levels is not observed when the sampling frequency is once every 
2 hours25. This is in line with our sampling frequency during the night in sleep-
deprived participants. Taken together, and also considering that the decrease 
in Aβ42 in the unrestricted sleep group is correlated with the total amount of 
sleep, we argue that there is no evidence to suggest the extra samples in the 
deprivation group affected the concentration of Aβ42.
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2.5 CONCLUSION
We have shown that 1 night of total sleep deprivation increases CSF Aβ42 
levels relative to normal sleep in a group of healthy middle-aged men. One 
night of total sleep deprivation has previously been shown to have similar 
effects on behavioral alertness, reductions in working memory performance, 
and cognitive performance that are similar to those as observed in cases with 
chronic sleep restriction to 6 hours or less per night for 14 days27. This suggests 
total sleep deprivation mimics physiological processes as seen in chronic partial 
sleep deprivation. Therefore, we hypothesize chronic partial sleep deprivation, 
as seen in disrupted sleep, might contribute to gradual Aβ42 accumulation, 
which may initiate Aβ oligomer formation and Aβ42 deposition. This hypothesis 
is supported by several studies that suggest disrupted sleep is an increased 
risk factor for cognitive decline and AD1-4. Specifically, sleep quality, more than 
sleep duration per se, may play an important role in Aβ deposition28. Because 
our study already showed an effect in a limited number of participants, it 
is important to further investigate this effect in a larger sample and extend 
observations over a longer period. It would be especially interesting to study 
the effects of chronic sleep deprivation on amyloid accumulation, using CSF 
Aβ42 or amyloid imaging to further unravel the role of sleep deprivation in the 
development of AD.
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ABSTRACT
Background
Slow wave sleep (SWS) plays an important role in neurophysiologic restoration. 
Experimentally testing the effect of SWS disruption previously required highly 
time-intensive and subjective methods. Our goal was to develop an automated 
and objective protocol to reduce SWS without affecting sleep architecture. 
New Method
We developed a custom Matlab™ protocol to calculate electroencephalogram 
spectral power every 10 seconds live during a polysomnogram. If 
measurements met criteria for SWS and artifact was excluded, increasingly 
louder tones were delivered through earphones. Middle-aged healthy 
volunteers (n=10) each underwent 2 polysomnograms, one with the SWS 
disruption protocol and one with sham condition.
Results
The SWS disruption protocol reduced SWS compared to sham condition, as 
measured by spectral power in the delta (0.5-4 Hz) band, particularly in the 0.5-
2 Hz range (mean 20% decrease). A compensatory increase in the proportion 
of total spectral power in the theta (4-8 Hz) and alpha (8-12 Hz) bands was seen, 
but otherwise normal sleep features were preserved. N3 sleep decreased from 
20 ± 34to 3 ± 6 min, otherwise there were no significant changes in total sleep 
time, sleep efficiency, or other macrostructural sleep characteristics.   
Comparison with existing method
This novel SWS disruption protocol produces specific reductions in delta band 
power similar to existing methods, but has the advantage of being automated, 
such that SWS disruption can be performed easily in a highly standardized and 
operator-independent manner.
Conclusion
This automated SWS disruption protocol effectively reduces SWS without 
impacting overall sleep architecture.
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3.1 INTRODUCTION
Slow wave sleep (SWS)1 is characterized by high-amplitude delta frequency 
range (0.5-4 Hz) electroencephalogram (EEG) waves, signifying synchronous 
relative quiescence of cortical neurons1. SWS represents the deepest part of 
non-rapid eye movement (NREM) sleep, and day-to-day variations in cortical 
activity and preceding sleep affect the distribution and amplitude of SWS at 
night2,3. SWS plays a key role in synaptic downscaling and other processes that 
underlie plasticity and memory consolidation4,5 and has been hypothesized 
to be important in neurophysiologic restoration. SWS is linked with lower 
amyloid-β (Aβ) levels likely due to decreased synaptically driven Aβ release6 
as well as to an increased rate of glymphatic metabolite clearance in the brain, 
such as clearance of amyloid proteins7. In turn, neurodegenerative amyloid 
plaques inhibit both the amount of NREM sleep8 and the normal propagation 
of slow waves9. Given the tight interaction between SWS and neurological 
physiology from the biochemical to the behavioral levels, many groups 
have sought to experimentally disrupt or enhance SWS in humans10-12. Prior 
methods of SWS disruption have typically relied on highly-trained individuals 
subjectively interpreting EEG in real time, and delivering auditory or other 
stimuli to cause arousals out of deep NREM sleep. Therefore, these existing 
methods are highly subject to inter-operator variability in EEG scoring, selection 
of stimuli, and delivery of stimuli. Our aim was to develop an automated and 
operator-independent SWS disruption protocol, using on-line spectral power 
analysis and auditory tones, to reduce specifically SWS without affecting sleep 
architecture in healthy middle-aged participants.
3.2 METHODS
Participants
We recruited 11 healthy participants aged 45-65 years from a community-based 
research participant registry in Saint Louis, Missouri, USA. One participant was 
lost to follow-up prior to completing the study; therefore 10 participants were 
included in the final analysis of the study. Participants had no comorbidities, 
took no neuro-active medications, and were cognitively normal (Mini Mental 
Status Examination score >27/30). Participants had regular sleep schedules with 
bedtime between 8PM-12AM and wake time between 4AM-8AM, confirmed 
by >5 days of actigraphy immediately prior to polysomnograms. Participants 
did not have obstructive sleep apnea or periodic limb movement disorder, 
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as defined as an apnea-hypopnea index >5 or periodic limb movement index 
>15, during a screening unattended polysomnogram. This study was approved 
by the Washington University Human Research Protection Office. Written, 
informed consent was obtained from all participants. 
Sleep studies
The first four participants each underwent two trial polysomnograms, at least 
one week apart. The trial polysomnograms were used to test and refine the 
SWS disruption protocol parameters. All ten participants then underwent two 
protocol polysomnograms with the final parameters. Four participants therefore 
underwent a total of four polysomnograms, with only the last two included in 
this analysis. The SWS disruption protocol was used for one polysomnogram, 
and a sham protocol used for the other; the order was random and participants 
were blinded to the condition. Sham protocol consisted of identical set up 
including earphones, but no noises were delivered through the earphones 
during the night. Standard polysomnogram channels were used, including 
frontal (F3, F4), central (C3, C4), and occipital (O1, O2) parasagittal electrodes 
referenced to the opposite mastoid (M1, M2) electrodes13. EEG data were 
acquired at 200 Hz and recorded to a MK3 TrackIt™ (Lifelines Neurodiagnostic 
Systems, Illinois, USA) device in European Data Format (EDF). A registered sleep 
technologist, blinded to the condition, performed sleep staging on 30-second 
epochs using standard criteria13. Additionally, the technologist scored 
movement or arousal artifact for each 10-second mini-epoch of sleep. Following 
polysomnograms, participants completed a questionnaire asking “Do you recall 
being woken during the night because of the noises through the earphones?”, 
and “If yes, how many times do you think you woke up because of the noises?”
Development of the SWS disruption protocol
A live, automated protocol to disrupt SWS was developed in Matlab™ (Figure 1). 
Every 10 seconds, or mini-epoch, the protocol accessed the EDF file, extracted 
the most recent EEG data, and calculated spectral power for the delta (0.5-
4 Hz) and the alpha (8-12 Hz) bands from the F4-M1 electrode using a fast 
Fourier transform function over the most recent 10.24 seconds (2048 samples). 
While SWS often is calculated by the amount of N3 (NREM stage 3) sleep, due 
to decreasing EEG amplitude with age, many adults have little to no sleep 
that meets scoring thresholds for N314. Therefore, spectral power in the delta 
band—or “delta power”—serves as a more appropriate and continuous measure 
of SWS. The F4 electrode was chosen rather than an average of multiple 
electrodes because SWS is most prominent in the frontal electrodes15, to reduce 
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computing requirements, and to enable adding this protocol to a standard 
polysomnogram montage which shows F4, C4, and O2 EEG electrodes only13. 
Furthermore, recent SWS disruption protocols using visual scoring have also 
used single electrodes10,16.
Three methods were used to identify artifact (Figure 1). First, if alpha power 
or delta power was above a very high fixed threshold, which is usually due to 
movement or sweat artifact, then the mini-epoch was categorized as artifact. 
Second, if the delta power was relatively higher than the immediately preceding 
epochs, it was also categorized as artifact. Specifically, if the delta power 
was greater than the running average of the delta power for the last five non-
artifactual mini-epochs, multiplied by a specified “running average factor,” then 
the current mini-epoch was considered to be artifact. The running average 
factor therefore identifies as artifact those mini-epochs that demonstrate 
sudden bursts of spectral power, which usually correspond to arousal artifact. 
Since delta power progressively increases over a NREM cycle, outliers can 
be identified and excluded using this method that cannot be identified with 
the fixed thresholds in the first method. A third candidate artifact-detection 
method using the [delta power : alpha power] ratio, to identify EEG data 
with disproportionately high delta power due to eye movements, was tested 
but ultimately found to be ineffective and not used. The cut-off values used 
for artifact detection are all variables that can be adjusted through the user 
interface as indicated in Figure 1; determination of appropriate cut-off values is 
discussed in the next section. 
If the mini-epoch was not categorized as artifact, and delta band power was 
above a specified threshold, then the protocol considered the EEG data to be 
SWS, and delivered an auditory tone through earphones. The tones were pure 
tones of random (selected from a uniform distribution) pitch and duration, to 
prevent habituation; prior studies using auditory disruption of sleep have found 
that there is rapid adaptation if the same tone is used throughout the night17. 
The pitch range was determined by a hearing test at the beginning of the night, 
and was usually in the 25 Hz to 2000 Hz range (approximately the pitch of the 
lowest note on a standard piano to 2 octaves above middle C). The duration 
of each tone varied randomly between 1 and 5 seconds. The first tone in a 
series of tones would start at the lowest detectable amplitude (volume) for the 
participant, determined by a hearing test prior to the polysomnogram, and with 
each consecutive mini-epoch that met criteria for SWS, the amplitude of the 
tone would increase, to a maximum of ~100 dB. The maximum amplitude was 
set to be reached over 12 amplitude levels, or 2 minutes. Every mini-epoch that 
was scored as not-SWS would decrease the amplitude level by one, but no tone 
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Figure 1: Schematic overview of the SWS disruption program. The left box represents the operator 
graphical user interface, which contains two buttons (one to suppress a noise and one to end the study), 
noise parameters, and spectral parameters. All the white boxes can be altered. Noise parameters marked 
with * are determined individually at the beginning of the night to determine the participants hearing 
range, including minimum and maximum pitch, and minimum amplitude (loudness). The maximum 
amplitude used was 100 dB (dB). The duration of noises used was 1–5 s. The same spectral parameters 
were used for every participant, since we determined parameters that were effective in this age group 
(45–65 years) as a whole. “α power max” and “δ power max” indicate values of alpha power (275µV2s) 
and delta power (3450µV2s), respectively, above which EEG data are scored as artifact. “Running average 
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factor” identifies as artifact EEG data with a burst of delta power, defined as greater than the running 
average of the delta power for the last five non-artifactual mini-epochs, multiplied by the specified 
“running average factor” (8). “δ power SWS threshold” is the delta power above which noises will be 
delivered to disrupt SWS; a value of 100 µV2s was used in our protocol. Every 10 s (mini-epoch) the slow 
wave sleep (SWS) disruption protocol 1)extracts electroencephalogram data; 2) performs a fast Fourier 
transformation to calculate delta and alpha spectral power; 3) determines whether the data represent 
artifact;4) assesses if delta spectral power meets a predetermined threshold, and, if so, 5) delivers a noise 
to the participant through earphones. When a mini-epoch is considered SWS, the noise level increases 
one level. When a mini-epoch is considered not-SWS, the noise level decreases one level (unless it is at 
zero), but no noise is delivered.
44
would be delivered. For instance, if there were 5 consecutive mini-epochs of 
SWS (with tones delivered at amplitude levels 1-5), and then 2 mini-epochs of 
not-SWS (with no tones), then the following mini-epoch of SWS would result in a 
tone at amplitude level of 3. This feature of the amplitude level “fading” during 
non-SWS mini-epochs, rather than starting over at 0, was specifically added 
during protocol development with the four initial participants (not included 
in the final analysis). We found that once a participant gets into deep SWS, it 
is very difficult to disrupt SWS without a strong stimulus that would actually 
awaken them. If the amplitude level started over at 1 after just one epoch of 
non-SWS, it could take up to 2 minutes for the amplitude levels to get back to 
where they left off, by which point the person could be in very deep SWS and 
not have any response to the tones. By having the amplitude level increase or 
decrease every 10 seconds, the SWS disruption protocol essentially “tunes” 
the tone amplitude to the participant’s changing arousal threshold throughout 
the night. The amplitude level tracker would adjust regardless of whether 
tones were delivered or whether the amplitude level was at maximum (12). If 
the amplitude level tracker reached 30 (essentially, the participant has SWS 
despite 5 minutes of tones every 10 seconds), the participant was roused by 
the sleep technician speaking into an overhead intercom, “[Participant name], 
wake up.” All participants were roused at least once overnight in this manner. 
No participant required physical stimulation or other measures to awaken. 
The clock time, epoch, mini-epoch, spectral power, auditory tone information, 
and auditory level tracker were all written into a log file live during the 
polysomnogram. 
The SWS disruption protocol was designed to function automatically. A 
technician was required for several roles. One was to assess for sweat artifact or 
other problems with EEG electrodes, and replace them if necessary. Technicians 
also were instructed to push a button on the user interface to suppress tones 
if it appeared that the SWS disruption protocol was delivering tones when a 
participant was awake. This button did not need to be pushed during any of the 
polysomnograms in this study. Lastly, the technician spoke into an overhead 
intercom if a participant remained in SWS despite 5 minutes of tones, as 
described above. Other than these straightforward tasks, the SWS disruption 
protocol did not require additional operator knowledge or training. All Matlab 
scripts required for the protocol are provided in the supplementary material. 
The main script (SWSdeprive2.m) contains a small optional modification that 
allows using an average of F3, F4, C3, and C4 data for the live protocol. If this 
modification is used, then the technician would need to add the left-sided 
EEG electrodes to the viewing montage and assess for problems with these 
electrodes during the study also.
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Figure 2. Development and accuracy of scoring parameters. Electroencephalogramdelta and 
alpha spectral power were used for automated scoring. A) Data from 18 participants from another 
study were used to set the trial parameters. Each dot represents a 30s epoch. The horizontal line 
represents the delta power threshold set at 200 µV2s. B) Data from the 10 study participants for 
both the sham and SWS disruption protocol nights. Each dot represents a 10s mini-epoch. The 
majority of the REM, artifact, and wake mini-epochs in the “SWS” range (above the horizontal 
line) were rejected as artifact via the second artifact identification method described in Methods 
Section 3.2. The final scoring specificity was 83% and sensitivity was 97% for detecting SWS.
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Determination of scoring variables
PSG data from 18 healthy participants (age 45-65) from a separate study were 
used to determine the initial settings for the SWS disruption protocol.  The 
settings were further refined in the first four participants during their first two 
polysomnograms. We elected to determine protocol parameters for the age 
group rather than for each individual participant, because our purpose was to 
develop an easy-to-use protocol that could be applied without multiple nights’ 
data collection. Delta power was plotted against alpha power and divided into 
NREM and not-NREM (REM, wake, or artifact). Values for alpha and delta power 
that encompass NREM were determined visually and set at 200-3450 µV2*s for 
delta power and 0-275 µV2*s for alpha power (Figure 2A). 
The threshold for minimum delta power to deliver auditory tones was lowered 
to 100 µV2*s in the final protocol, because this improved scoring sensitivity 
and the degree of SWS disruption. While an epoch with delta power of 100 
µV2*s would generally be visually scored as N2 rather than N3, we found that 
auditory stimuli had to start at least several minutes before N3 sleep in order to 
effectively disrupt SWS. 
In our participants, these settings resulted in a sensitivity of 97 ± 3% and 
a specificity of 83 ± 11% compared to the gold standard of visual scoring, 
indicating that, on an epoch-by-epoch basis, the ability of the protocol for 
discriminating SWS from other sleep-wake stages is excellent (Figure 2B), and 
superior to prior automated SWS scoring algorithms18.
Data analysis
During the live SWS disruption protocol, a rapid fast Fourier transform function 
(bandpower function in the Matlab Signal Processing toolbox) was performed 
on data from the F4 electrode only, to reduce computing requirements. 
Following data collection, a more detailed spectral analysis was performed on 
all EEG electrodes, including F3, F4, C3, C4, O1, O2, each referenced to the 
opposite mastoid (M1 or M2). Power was normalized to the total power, and 
taken as an average over all electrodes (proportional power). Data for each 
10.24 seconds—with 0.24 seconds overlap between each pair of mini-epochs—
were analyzed using Welch’s method. The 2048 data points in each 10.24 
seconds were divided into 4 sections of 512 data points, with 50% overlap. 
A Hamming window was applied prior to the discrete Fourier Transform to 
calculate the spectral power for every 0.5 Hz bin from 0.5 to 32 Hz. Frequency 
ranges were 0.5-4 Hz for delta, 0.5-2 for low delta, 2-4 for high delta, 4-8 Hz for 
theta, 8-12 for alpha, and 12-18 for beta. Statistical analyses were performed 
with IBM SPSS version 20.0 (SPSS Inc, Chicago, USA). Statistical significance was 
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set at p <0.05. The Kolmogorov-Smirnov test was used to determine whether 
data were normally distributed. Differences in between SWS disruption and 
sham protocols were calculated using paired Student’s t-tests for normally-
distributed variables, and related-samples Wilcoxon signed rank test for 
variables that were not normally distributed, with each participant acting as his 
or her control.
3.3 RESULTS
Our research population (n=10) consisted of five female and five male 
participants, with a mean age of 53 ±4 years, and equal number of Caucasians 
and African-Americans. Delta power over all non-artifactual NREM sleep 
calculated from the mean of the F3 and F4 electrode was significantly 
decreased by an average of 18% in the SWS disruption condition (123 ±57 
µV2*s) compared to the sham condition (149 ±62 µV2*s; p < 0.001) (Figure 3A). 
This decrease was completely driven by reductions in low delta power (0.5-
2 Hz), in which there was an average 20% decrease in spectral power, from 
134±56 µV2*s in the sham night to 108±53 µV2*s in the SWS disruption protocol 
night (p <0.001) (Figure 3B). All 10 participants had decreased delta power 
and low delta power during the SWS disruption protocol compared to sham. 
There were no significant differences in the high delta band (2-4 Hz) between 
conditions (Figure 3C). 
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Figure 3: Specific reduction in low delta band power. Change in spectral power (% compared 
to the sham night) over all non-artifactual NREM sleep for each individual measured from the 
mean of the F3 and F4 electrodes for A) all delta (0.5–4 Hz) B) low delta (0.5–2 Hz) and C) high 
delta (2–4 Hz) bands are displayed. Every participant demonstrated a decrease in delta power with 
the automated SWS disruption protocol (-18% change, p ≤ 0.001); a reduction in the low delta band 
power (−20% change, p ≤ 0.001) entirely accounted for the decrease in delta power. (*p ≤ 0.05).
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The four participants who had previously had polysomnograms during the 
protocol development phase had a 15% decrease in total delta power during 
the SWS disruption protocol condition compared to the sham condition, 
while the remaining six participants had a 19% decrease in total delta power, 
indicating that the protocol was effective for all participants we studied, and the 
protocol and parameters are not specific for the 4 participants. Since spectral 
power may vary by age, sex, and other inter-individual characteristics, we 
normalized the data by analyzing band power as a proportion of total power in 
the entire (0.5–32 Hz) analyzed range.
The proportion of spectral power in the low delta band during NREM sleep 
was again significantly decreased with the SWS disruption protocol compared 
to the sham condition (64±5% versus 69±5%, p=0.007), while the proportion 
of high delta power was no different (Figure 4A). There was a compensatory 
shift of proportional power into the theta and alpha bands (Figure 4B). While 
data from only the F4 electrode were used during the SWS disruption protocol, 
off-line analysis after the polysomnogram showed there was a decrease in delta 
power in all EEG electrodes (Figure 5). Time in N3 sleep was decreased during 
the SWS disruption protocol (20+34 versus 3+6 minutes). Otherwise, there were 
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Figure 4: Shift in spectral power to higher frequencies. The proportion of power (% of 
total power in the 0.5-32 Hz range) is displayed for each band, for all NREM sleep. With the SWS 
disruption protocol, there is a significant reduction in proportional power in the low delta (0.5-2 
Hz) range, and a shift of proportional power to the theta (4-8 Hz) and alpha (8-12 Hz) bands. Note 
the different y-axis ranges in the two graphs. Middle band indicates median, box indicates 
interquartile range, and whiskers indicate maximum and minimum values. (*p < 0.05).
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no significant differences in total sleep time (384 ± 54 versus 381 ± 67 min), 
sleep efficiency (0.79 ± 0.09 versus 0.79 ±0.13), or time in different sleep stages 
between the sham and the SWS disruption condition (Table 1). 
There were 1172 ± 389 tones delivered during the SWS disruption protocol 
nights. Of these, 350 ± 64 tones were followed by a mini-epoch categorized 
as “not-SWS,” and we termed these “effective” tones. On visual scoring, 
the most common EEG response to an “effective” tone was a microarousal, 
meaning a shift from a lower to a higher frequency. The majority of tones were 
delivered during NREM sleep, and, the majority of the time, the following 
Figure 5: Power spectral distributions. Power spectral distributions demonstrate the 
decrease in power in the low delta band, and a slight compensatory shift in power to the higher 
frequencies, indicating selective SWS disruption. Data are averaged for all (F3, F4, C3, C4, O1, 
O2) electrodes over all NREM sleep for all 10 participants. The main graph presents data with 
the y-axis on a log scale, while the inset graph shows the data in the lower frequency range (top 
right) on a linear scale to demonstrate the dramatic reduction in low delta power. Shaded regions 
indicate standard error.
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mini-epoch was also NREM sleep, supporting that the SWS disruption protocol 
does not function by causing awakenings (Figure 6). Post-polysomnogram 
questionnaires assessed how aware the participants were of the tones delivered 
during the protocol. Of the ten participants, one participant did not fill out 
the questionnaire, and, among the remaining nine, two did not recall any 
awakenings due to the tones, while seven were aware of the tones during the 
SWS disruption protocol night. Of the seven who were aware of the tones, two 
did not specify the number of tones they recalled. Combining the five who did 
provide an estimated number of tones, and the two who did not recall hearing 
any tones, on average the participants estimated hearing 7 ± 8 tones (range 
0–20), or 0.5% of the tones they actually received. As expected, no one recalled 
awakenings due to tones during the sham condition.
Total sleep 
time (minutes)
Sleep 
efﬁciency (%)
NREM 
(minutes)
N1 (minutes)
N2 (minutes)
N3  (minutes)
REM (minutes)
384(±54)
79 (±9)
311 (±41)
37 (±23)
250 (±47)
20 (±34)
57 (±26)
302-477
67-94
253-379
16-95
162-351
0-99
17-98
381 (±67)
79 (±13)
287 (±33)
50 (±25)
230 (±39)
3(±6)
63 (±39)
302-489
61-95
245-333
21-101
151-279
0-16
7-144
0.89
0.93
0.20
0.22
0.28
0.03*
0.68
Sham
Mean (±SD) 
Range SWS 
disruption 
protocol
Mean (±SD) 
Range p-value
Table 1: Sleep data for the sham and SWS disruption protocol nights (n=10).
*Related-samples Wilcoxon signed rank test due to non-normally-distributed data, as determined 
by Kolmogorov-Smirnov test. All other comparisons were done with paired t-tests, since data were 
normally-distributed.
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Figure 6: Stage transition due to auditory stimulation in the SWS disruption protocol. An 
average of a total of 1172 (±389) tones were delivered during the SWS disruption nights. The 
upper bar graph demonstrates during which sleep stages tones were delivered, in percentages. 
The majority of tones were delivered during NREM sleep, demonstrated in shades of blue. “A” 
(gray) represents artifact during NREM sleep, due arousal with movement. A small percentage 
of tones were delivered during REM sleep (R, grey). Of the tones categorized as delivered during 
wake (W, light gray), the vast majority were delivered during NREM sleep and caused awakening, 
but the entire epoch was scored as wake according to standard scoring rules. The lower pie charts 
depict the sleep stage following tones, delivered during N3 (left), N2 (middle), and N1 (right) sleep. 
The vast majority of tones delivered during NREM sleep were followed by more NREM sleep, 
rather than wake or arousal (with movement).
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3.4  DISCUSSION
Our live, automated SWS disruption protocol accurately identified and 
specifically suppressed SWS, while preserving normal sleep architecture. These 
results are similar to previous studies using non-automated methods, in which 
total sleep time remained the same, while delta spectral power decreased 
20%10,16,19. With our novel SWS disruption protocol, relative spectral power 
shifted from the low delta range into the high delta, theta, and alpha ranges, 
essentially “lightening” NREM sleep, without affecting macrostructural sleep 
characteristics. This protocol does not exert effect by causing awakenings. 
Rather, participants remained in NREM sleep (Figure 6), albeit lighter NREM 
sleep. We suspect that only low delta power is affected by the protocol because 
our protocol essentially shifts the power spectrum to higher frequencies, and 
the majority of total delta power is within the lower delta band (as illustrated 
in Figure 5). Therefore, the protocol “pushes” what would have been in the low 
delta range into the high delta and theta ranges. It would be difficult to reduce 
power further in the high delta band without awakening a person; some high 
delta activity is inevitable and necessary to score an epoch as NREM sleep. 
Additionally, SWS in the low delta range has also specifically been linked to 
memory function and the presence of Aβ pathology9. Therefore we anticipate 
that our SWS disruption protocol that reduces low delta power would be of 
benefit to investigators interested in assessing the physiological effects of 
experimental SWS disruption. 
Our automated protocol removes the subjectivity and variability inherent in 
prior SWS disruption methods. Our participants received 1172 ± 389 tones 
during the SWS disruption protocol nights, or about 150 tones per hour over an 
8-hour polysomnogram. An extremely highly skilled technician with exceptional 
vigilance would be required to replicate the protocol manually. All equipment 
and software used in our SWS disruption protocol are commercially available, 
the computer processing demand does not require specialized equipment, 
and the Matlab™ scripts are being shared for scientific use. No special training 
is required, allowing a sleep technician to simply apply the protocol during a 
standard polysomnogram. Subsequently, other laboratories can easily adopt 
the SWS disruption protocol into their investigations. 
One of the major challenges of this study was identifying parameters that were 
suitable for a mixed population, in this case, healthy middle-aged participants. 
While it is possible to use an individual’s EEG data from one night to set the 
protocol parameters for another night with SWS disruption, a requirement 
for multiple nights’ recording limits practical application. To overcome this 
limitation, we have identified parameters that are effective at reducing SWS in 
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a middle-aged group, rendering redundant a baseline recording night for each 
participant and thereby decreasing participant burden. We also considered 
using a patient’s EEG data from the beginning of the study to automatically 
set or “tune” protocol parameters for the rest of the night. However, since 
sleep pressure as measured by SWS dissipates over the course of the night, 
particularly in the first 1-2 NREM periods, the EEG features of the first part of 
the night do not reflect EEG features over the entire night for an individual. 
Moreover, auto-tuning protocol parameters based on the beginning of the 
night would require the operator to live-score every 10-second mini-epoch, and 
then that data would need to be entered into the software and analyzed. This 
would add substantially to operator burden and computational load, conflicting 
with our goal of developing an automated SWS disruption protocol that could 
be easily added to a standard polysomnogram. Lastly, since some REM sleep 
would need to be collected to auto-tune the protocol parameters, and the 
first REM sleep period typically occurs after ~1-1.5 hours of NREM sleep (the 
first NREM period), that means that the SWS disruption protocol could not be 
applied for ~1-1.5 hours during the portion of sleep that contains the highest 
amount of SWS. For all these reasons, we decided against using a participant’s 
EEG data from the first part of night to determine SWS disruption protocol 
parameters for the rest of the night. As investigators collect EEG data on other 
target populations (e.g. elderly, people with dementia, or children), different 
sets of parameters will need to be tested to optimally disrupt SWS in each 
population. Of course, investigators can individualize protocol parameters for 
a specific person by using data from a prior polysomnogram to set parameters 
for the SWS disruption protocol, if multiple nights’ studies are practical. 
Furthermore, linear discriminant analysis, support vector machines, or other 
machine learning methods may be applied to group- or individual-level EEG 
data to determine protocol parameters that are more effective at automated 
scoring and SWS disruption than the visually- and empirically-derived 
parameters presented here.
Our study is limited by the small sample size, which can be justified by the 
larger group (n=18) of healthy participants that was used to derive the initial 
protocol parameters, which were then refined during testing. Also, the protocol 
parameters were targeted for an age group of 45-65 years, but the parameters 
can be easily altered for other populations through the user interface of the 
SWS disruption protocol (Figure 1). In addition, the SWS disruption protocol is 
not 100% automated, and some human intervention is required as described 
in the methods section. However, minimal effort is required such that one 
individual can deliver a standardized SWS disruption protocol to several 
participants simultaneously.
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In conclusion, our SWS disruption protocol is an automated and easy-to-use tool 
that effectively reduces SWS without affecting sleep architecture. This protocol 
will be used in future studies to investigate the role of SWS on physiological 
processes. 
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ABSTRACT
Sleep deprivation increases amyloid-β (Aβ), suggesting that chronically 
disrupted sleep may promote amyloid plaques and other downstream 
Alzheimer’s disease pathologies including tauopathy or inflammation. To 
date, studies have not examined which aspect of sleep modulates Aβ or 
other Alzheimer’s disease biomarkers. Seventeen healthy adults (age 35-
65) without sleep disorders underwent 5-14 days of actigraphy, followed by 
slow wave activity disruption during polysomnogram, and CSF collection 
the following morning for measurement of Aβ, tau, total protein, and YKL-40. 
Data were compared to an identical protocol, with a sham condition during 
polysomnogram. Specific disruption of slow wave activity correlated with an 
increase in Aβ40 (r=0.610, p=0.009). This effect was specific for slow wave 
activity, and not for sleep duration or efficiency. This effect was also specific 
to Aβ, and not total protein, tau, or YKL-40. Additionally, worse home sleep 
quality, as measured by sleep efficiency by actigraphy in the 6 nights preceding 
lumbar punctures, was associated with higher tau (r=0.543, p=0.045). Slow 
wave activity disruption increases Aβ levels acutely, and worse sleep quality 
over several days increases tau. These effects are specific to neuronally-derived 
proteins, which suggests they are likely driven by changes in neuronal activity 
during disrupted sleep.
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4.1 INTRODUCTION
Alzheimer’s disease pathology is associated with sleep disruption, even in the 
preclinical stages of disease1. Amyloid plaque formation, an early necessary 
step in Alzheimer’s disease pathogenesis, is associated with sleep disruption in 
a bi-directional manner1. Soluble amyloid-β (Aβ) varies diurnally in both mouse 
and human2,3, where sleep is associated with decreased Aβ and wakefulness 
with increased Aβ. Sleep deprivation acutely increases soluble Aβ and 
chronically increases amyloid plaques in mouse2,4, and one night of total sleep 
deprivation increases soluble Aβ in humans5. However, it is unknown which 
aspect of sleep is responsible for modulation of Aβ. Slow wave activity (SWA), 
which occurs during deep NREM sleep, is a strong candidate for Aβ modulation. 
The EEG slow waves that characterize SWA represent decreased synaptic 
activity6, and soluble Aβ is released into the interstitial space during neuronal 
synaptic activity7. Furthermore, clearance of solutes from the interstitial space, 
including exogenous Aβ, accelerates during SWA-rich sleep8. These data 
lead to the hypothesis that disrupted SWA would cause relatively increased 
neuronal activity, increased Aβ release and decreased clearance, resulting in 
increased Aβ levels measurable in the CSF. Indeed, in cross-sectional studies, 
SWA was negatively correlated with CSF Aβ in middle-aged9 and older10 
individuals. Furthermore, chronic sleep disruption increases tau levels and 
tau phosphorylation in mice11,12. Tau is also released during neuronal activity, 
although clearance from the brain is slower than for Aβ13. 
In this study, we used a novel SWA disruption protocol to test whether specific 
disruption of SWA leads to increased Aβ and tau levels in CSF. 
4.2 MATERIALS AND METHODS 
Participants
We enrolled 22 healthy participants aged 35-65 years from a community-based 
research registry at Washington University. Participants had no comorbidities 
except controlled hypertension, took no neuro-active medications, had normal 
neurological exams, reported <14 alcoholic beverages weekly, had body mass 
index 18-40 kg/m2, and were cognitively normal based on history, neurological 
examination, and MMSE >27/3014. Participants had regular sleep schedules 
with bedtime 8PM-12AM and wake time 4AM-8AM. Participants did not have 
obstructive sleep apnea or periodic limb movement disorder, defined as 
apnea-hypopnea index >5 or periodic limb movement index >15, during a 
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screening polysomnogram. All participants provided informed, written consent. 
All procedures were approved by the Washington University Human Research 
Protection Office. 
Experimental design
All participants underwent two sets of procedures, >28 days apart. Each 
procedure set consisted of a daytime visit with questionnaires, actigraphy for 
5-14 days, overnight polysomnogram with experimental condition, and lumbar 
puncture the following morning. An automated SWA disruption protocol 
was applied for one polysomnogram, and a sham condition was used for 
the other, in random order. SWA disruption was performed with parameters 
and methods determined to be effective in this age group15. Briefly, every 10 
seconds, EEG data were extracted from the live recording. If the data were 
determined to be non-artifactual, and 0.5-4 Hz spectral power was greater 
than 100 μV2*s indicating SWA, a tone was delivered through earphones to the 
participant. The amplitude of the tones would progressively increase, until delta 
power decreased, indicating an arousal out of SWA. During sham condition, 
participants wore earphones but no tones were delivered. The order of the 
two conditions was randomly selected, and participants were blinded to the 
condition. All analyses were conducted blinded to condition. 
Sleep and EEG spectral analysis
Polysomnograms were performed with standard electrodes, and sleep staging 
was performed by a registered polysomnographic technologist according to 
standard criteria16. Lights out was at 10PM and lights on was at 6AM, regardless 
of a participant’s home schedule. EEG spectral power from bilateral frontal and 
central electrodes was averaged for all NREM epochs. SWA was quantified as 
power in the delta (0.5-4 Hz) band, or “delta power,” averaged over all NREM 
epochs. EEG collection and analysis parameters are detailed in Supplemental 
Methods.
Actigraphy data were collected using Actiwatch2™ (Philips-Respironics, 
Murrysville, Pennsylvania) and scored as previously described 17(see 
Supplemental Methods). Participants were instructed to keep regular sleep 
schedules prior to polysomnograms. If actigraphy did not demonstrate 
>6 hours in bed and bedtime 8PM-12AM on the night prior to either 
polysomnogram, the participant was excluded. This criterion excluded 4 
participants. 
To assess home sleep, actigraphy data from 6 nights (polysomnogram night 
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and five preceding nights) were scored using polysomnographically-validated 
criteria18 to derive total sleep time and sleep efficiency (total sleep time divided 
by time in bed). Time in bed was calculated as minutes between bedtime and 
waketime. Mid-sleep was calculated as the halfway-point between bedtime 
and waketime. Three participants wore a defective actigraph that prevented 
determination of total sleep time and sleep efficiency.
CSF analytes and APOE genotype
CSF was obtained by lumbar puncture at 9:30-10AM following 
polysomnography. This time corresponds to the daily nadir of CSF Aβ403, 
and follows the sleep mid-point by ~6 hours, the transit time of Aβ from CNS 
to CSF19. CSF was immediately placed on ice, aliquoted, and frozen at -80oC. 
Aβ40 was chosen as the primary measure of Aβ since it is the most abundant 
Aβ species and less subject to altered levels caused by amyloid plaques. Aβ40, 
Aβ42, and tau, were assessed by INNOTEST ELISA (Fujirebio Europe, Ghent, 
Belgium). Total protein was assessed by Bradford assay (Thermo Pierce). YKL-40, 
a glial marker of neuroinflammation, was assessed by MicroVue ELISA (Quidel, 
San Diego, California)20. Hypocretin-1 was assessed by radioimmunoassay as 
previously described21. All CSF measurements were performed in duplicate or 
triplicate with several internal control samples.
Since existing amyloid plaques abolish the diurnal variation of Aβ related to 
sleep3,22, individuals with abnormally low Aβ42 levels (<608 pg/mL) indicating 
amyloid plaques were excluded. Cut-off level was determined by the Knight 
Alzheimer’s Disease Research Center Biomarker Core by comparison of Aβ42 
values and Pittsburgh compound B PET data from large cohorts23,24. Two 
participants were excluded based on this criterion; one had already been 
excluded for inadequate actigraphically-measured sleep.
Fasted blood 20 mL was drawn following lumbar puncture, and placed on 
ice until centrifugation and storage at -80°C. The Hope Center DNA/RNA 
Purification Core performed DNA extraction and APOE genotyping. Genotype 
was dichotomized as APOE-ε4 carrier or non-carrier.
Questionnaires
The Epworth Sleepiness Scale25 and Pittsburgh Sleep Quality Index26 were 
completed during the daytime visits 5-14 days prior to each polysomnogram to 
assess sleepiness and sleep quality, respectively. Immediately following each 
polysomnogram, participants completed the Stanford Sleepiness Scale27, a 
measure of immediate subjective sleepiness. They also completed a written 
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questionnaire which asked: “Do you recall being woken during the night 
because of the noises through the earphones?”; “If yes, how many times do you 
think you woke up because of the noises?”; Estimated sleep time in hours; and 
Sleep quality on a scale of 1-10 (10 best).
Statistical analysis
All continuous variables were assessed for normal distribution by inspection of 
histograms and the Kolmogorov-Smirnov test. Levene’s test was used to assess 
equality of variances. Differences between SWA disruption and sham conditions 
for continuous variables were calculated using paired t-tests for normally-
distributed variables, and related-samples Wilcoxon signed rank test for other 
variables. Correlations were assessed with Spearman’s correlation coefficient. 
To compare participants grouped by order of polysomnogram condition, APOE 
genotype, or response to SWA disruption (Supplementary Table 1-3), unpaired 
t-tests were used to compare continuous variables and Fisher exact tests were 
used to compare dichotomous variables. Tests were two-tailed, and α was 0.05. 
Statistical analyses were performed with SPSS 24 (IBM). Figures were generated 
in GraphPad Prism (GraphPad Software Inc).
Since inter-individual Aβ variation (~30%) is much greater than intra-individual 
Aβ variation (~10%), and may be subject to APOE genotype, a repeated-
measures design was selected. From preliminary cross-sectional data, the effect 
size for variance in Aβ40 explained by SWA was f=0.25. Assuming a moderate 
(0.7) correlation between repeated measures, α 0.05, and power 0.8, a total 
sample size of 20 was calculated. We stopped enrollment when 20 participants 
had completed the study. Two other participants already enrolled were 
permitted to complete the study, for a total of 22 participants. 
4.3 RESULTS
Twenty-two participants completed the study; five participants were excluded 
for pre-defined exclusion criteria, for a sample size of 17. The study population 
was middle-aged (54.1 +6.7 years) with a slight majority Caucasian race and 
female sex (65% each), and 5 (29%) were APOE-ε4 carriers. Questionnaire-
based sleep measures were in the normal range and Actigraphy showed normal 
home sleep patterns (Table 1).
The SWA disruption protocol decreased SWA as measured by delta power by 
23 (95% confidence interval 14-32) μV2*s. As expected, there was decreased 
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Age (years)
Race White n (%)
Sex female n (%)
BMI (kg/m2)
Total sleep time 
(minutes) 
NREM sleep 
(minutes)
54.1(±6.7)
11 (65%)
11 (65%)
28.2(±4.3)
419 (±47)
311(±39)
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
404(±51) 
300(±49) 
Education (years)
Alcohol 
(drinks/week)
15.8(±1.6)
1.6(±2.1)
MMSE
APOE-ε4 carrier n(%)
29.6(±0.5)
5 (29%) 
0.160
0.244
N1 (minutes)
N2 (minutes)
22(±10)
265(±44)
34(±18) 
254(±43) 
0.007
0.33
N3 (minutes)
REM (minutes)
Sleep Efﬁciency (%)
Number tones 
delivered
7(±42a)
99(±52a)
0(±2a) 
68(±38a) 
<0.001a
0.001a
85.4(±8.5) 82.4(±9.6)
0 1177(±427) 
0.102
n/a
Sham 
condition
Mean ±SD
p-value
Demographics
SWA 
condition
Mean ±SD
Polysomnogram
0.5 – 4 Hz (Delta) (μ
V2*s)
4 – 8 Hz (μV2*s)
118(±51)
12.8(±5.4)
96(±43)
12.0(±5.4)
<0.001
0.215
8 – 12 Hz (μV2*s)
12 – 18 Hz (μV2*s)
6.2(±3.0)
2.7(±1.2)
6.4(±3.7)
3.0(±1.3)
0.535
0.005
18 - 50 Hz (μV2*s) 1.7(±0.8) 2.1(±0.9) 0.008
EEG spectral 
power
continues on next page
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N3 sleep and a compensatory increase in N1 sleep during the SWA disruption 
night, as well as a decrease in REM sleep; otherwise there was no difference 
in other polysomnographic sleep variables (Table 1). The participants who 
underwent SWA disruption first were similar to the participants who underwent 
sham condition first (Supplementary Table 1). Participants estimated sleep was 
of shorter duration and worse quality with SWA disruption, although subjective 
sleepiness was no different in the morning (Table 1).
SWA disruption was strongly and significantly correlated with Aβ40, such that 
Total sleep time (min)
mean 6 nights 
Total sleep time (min)
polysomnogram night  
Sleep efﬁciency (%)
Time in bed (min)b
Pittsburgh Sleep 
Quality Indexc
Epworth Sleepiness 
Scalec
377(±56)
422(±42)
82.6(±7.5)
456(±46)
4.2(±1.6)
5.6(±3.6)
370(±43)
404(±41)
82.0(±6.7)
454(±37)
3.4(±51) 
6.4(±49) 
Mid-sleep (HH:MM)b 03:48am(±00:23) 03:47am(±00:19)
0.059
0.133
Awakened by noise? 
(yes)d
Number tones 
heard? d
1/16
3(n=1)
12/15
11.1(±8.9) 
<0.001
n/a
Estimated sleep 
hours
Estimated sleep 
quality
Stanford Sleepiness 
Scale
7.3(±1.1)
7.4(±1.7)
5.2(±2) 
5.5(±2.7) 
<0.001
0.445
0.117
0.665
0.836
0.836
0.02
2.0(±0.9) 2.8(±1.8) 0.16
Sham 
condition
Mean ±SD
p-value
Actigraphy
(n=14)
SWA 
condition
Mean ±SD
Questionnaires
Table 1: Demographic and sleep characteristics.
a median +interquartile range; p value is for related-samples Wilcoxon signed rank test
b n=17
c completed during daytime 5-14 days prior to polysomnogram nights
d not all participants answered this question 
65
Slow wave sleep disruption increases cerebrospinal fluid amyloid-beta levels
4.
-60-40-20020
-30
-20
-10
0
10
20
30
Change REM time (minutes)
[protocol-sham]
Sham Protocol
-30
-20
-10
0
10
20
30
-60-40-200
-30
-20
-10
0
10
20
30
[protocol-sham]
A
β
40
 ch
an
ge
 (%
)
A
β
40
 ch
an
ge
 (%
)
A
β
40
 ch
an
ge
 (%
)
A
β
40
 ch
an
ge
 (%
)
A
β
40
 ch
an
ge
 (%
)
A
β
40
 ch
an
ge
 (%
)
-100-50050
-30
-20
-10
0
10
20
30
Change total sleep time (minutes)
[protocol-sham]
-80-4004080
-30
-20
-10
0
10
20
30
Change NREM time (minutes)
[protocol-sham]
A B
C D
-20-15-10-50510
-30
-20
-10
0
10
20
30
Change sleep efﬁciency (%)
[protocol-sham]
E F
Change delta power (μV2*s)
Figure 1: Decreased slow wave activity is associated with increased CSF amyloid-β. (A) 
Suppression of slow wave activity, as measured by the change in delta spectral power, was strongly 
correlated with increased amyloid-β40 (r = 0.610, P = 0.009). There was no correlation between 
change in amyloid-β40 levels and (B) total sleep time (r = 0.075, P = 0.782), (C) time in non-REM 
sleep (r = 0.156, P = 0.564), (D) time in REM sleep (r = 0.351 P = 0.168), or (E) sleep efficiency (r = 
0.007, P = 0.978). (F) When participants are divided at the median (20 μV2*s) amount of slow wave 
activity disruption, the ‘responders’ to SWA disruption (blue lines) had a significant increase in 
amyloid- β40 (n = 9, 11562 2603 versus 10562 2868 pg/ml, 95% confidence interval difference 315 to 
1686 pg/ml, P = 0.010) while ‘non-responders’ (grey lines) did not. X-axes in A–E are more negative 
to the right, i.e. values to the right indicate more disruption of slow wave activity or less sleep. 
66
more SWA disruption was associated with greater increases in Aβ40 (Figure 1A). 
This effect was specific for SWA disruption, and not for total sleep time, NREM 
time, REM time, or sleep efficiency (Figure 1B-1E). In the entire group, there was 
no significant difference in Aβ40 levels between conditions although the subset 
with sufficient SWA disruption (greater than median, or >20 μV2*s decrease) 
did have a significant increase in Aβ40 (Figure 1F). These “responders” to SWA 
disruption protocol essentially drove the correlation between SWA disruption 
and Aβ40 change.
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Figure 2: Slow wave activity disruption is not correlated with change in other CSF proteins. 
Slow wave activity disruption, as measured by the change in delta spectral power, was not 
correlated with change in (A) total protein (r=0.098, p=0.708), (B) YKL-40 (r=-0.199, p=0.445), (C) 
tau (r=0.000, p=1.000), or (D) hypocretin (r=-0.250, p=0.333). X-axes are more negative to the 
right, i.e. values to the right indicate more disruption of slow wave activity.
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We then assessed whether the effect of SWA on Aβ40 was specific to Aβ. There 
was no correlation between SWA disruption and change in total protein (Figure 
2A). YKL-40 (an astrocyte-derived inflammatory protein) and tau (a neuronally-
derived protein), both biomarkers increased in Alzheimer’s disease, were not 
correlated with SWA disruption (Figure 2B-2C). Hypocretin, a wake-promoting 
peptide that may modulate Aβ kinetics and has previously been shown to 
be increased after REM sleep deprivation4,28, was not correlated with SWA 
disruption (Figure 2D). Supporting the relationship between SWA and Aβ, in 
addition to the strong correlation between SWA and Aβ40, SWA disruption 
was also strongly correlated with Aβ42 (Supplementary Figure 1). The CSF 
Aβ42:Aβ40 ratio decreased with greater SWA disruption but this was not 
significant (Supplementary Figure 1).
Extracellular levels of tau in the brain, like Aβ, are regulated by excitatory 
neuronal activity, but the half-life of tau in the mammalian brain is long, 11 days 
in the mouse13. As SWA disruption did not lead to changes in tau the following 
morning, we compared actigraphically-measured home sleep over 6 preceding 
nights to CSF tau levels. There was a significant negative correlation between 
home sleep quality and tau, such that worse sleep efficiency was associated 
with higher tau (Figure 3A). Sleep quantity was not correlated with tau (Figure 
3B). A strong trend for a correlation between home sleep quality and Aβ40 
was apparent (Figure 3C). However, this effect was likely diminished by SWA 
disruption immediately prior to the lumbar punctures. There was no association 
between Aβ40 and sleep quantity, or between total protein and either sleep 
quantity or quality (Figure 3D-F).
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Figure 3: Worse home sleep quality over 6 nights is associated with increased CSF tau. 
Home sleep was quantified by actigraphically-measured sleep variables for the 6 nights prior to 
lumbar punctures. Valid actigraphy data were available for n=14 participants. For consistency 
with other figures, sleep variables are shown as the 6 nights that included SWA disruption 
protocol night minus the 6 nights that included the sham condition night; however, the 
differences in total sleep time or sleep efficiency reflect variations in home sleep and are not 
related to the protocol or sham condition. For consistency with other figures, X-axes are more 
negative to the right, i.e. values to the right indicate less or worse sleep. (A) Worse sleep quality, 
as measured as the sleep efficiency, was associated with greater tau levels (r=0.543, p=0.045). (C) 
There was a strong but non-significant trend for an association between worse home sleep quality 
and Aβ40 levels (r=0.481, p=0.081), but (E) there was no correlation between sleep quality and 
total protein (r=-0.218, p=0.455). Change in home sleep quantity, as measured by actigraphically-
determined total sleep time, had no correlation with (B) Tau (r=0.103, p=0.725), (D) Aβ40 
(r=0.218, p=0. 0.455), or (F) total protein (r=-0.103, p=0.725). 
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4.4 DISCUSSION
Our hypothesis was that one night of selective SWA disruption would lead 
to increased CSF Aβ the following morning. We found a strong association 
between SWA and Aβ, where greater SWA disruption was associated with 
increased Aβ. This effect was specific for SWA and not sleep quantity or 
quality, and was also specific for Aβ and not other CSF proteins. Additionally, 
we found that worse home sleep quality was associated with increased CSF 
tau, consistent with sleep disruption affecting CNS tau, but with such changes 
requiring a longer time to detect likely due to the longer half-life of tau. 
Both of these findings support the hypothetical cascade in which decreased 
SWA leads to increased soluble Aβ and tau levels, which eventually increase risk 
of amyloid plaques29 and tau tangle pathology, and subsequent development 
of symptomatic Alzheimer’s disease. Furthermore, the specificity of our findings 
for neuronally-derived proteins (Aβ and tau) and not glial-derived (YKL-40) or 
total proteins suggests that SWA affects Aβ and tau by influencing synaptic 
activity with decreased release of these proteins into the interstitial space, 
rather than by affecting protein clearance mechanisms. While we cannot rule 
out that SWA affects interstitial fluid protein clearance, we did not observe an 
effect on all CNS proteins as would theoretically be expected by disrupting 
interstitial fluid protein clearance. While the CSF Aβ42:Aβ40 ratio decreased 
with greater SWA disruption, this finding was not significant and the study was 
not powered or designed to assess relative clearance of Aβ isoforms. 
A weakness of the study is the relatively small sample size. However, the 
effect size was stronger than predicted by cross-sectional preliminary data, 
with a high r of 0.601 for the association between SWA disruption and Aβ40 
change. In addition, intra-individual analyses strongly increased statistical 
power. Nevertheless, our study was not powered to assess for correlations 
between SWA disruption and other CSF proteins, and larger studies are 
necessary to exclude a relationship between SWA and other CSF proteins. 
Additionally, determining the relative clearance rates of Aβ isoforms, and any 
effect of amyloid plaques, will require larger studies including amyloid positive 
individuals. Similarly, due to the small (N=5) number of APOE-ε4 carriers, 
this study was underpowered to assess the effect of APOE genotype on 
susceptibility to SWA disruption (Supplementary Table 3). Another weakness 
is that SWA disruption did not increase Aβ in some participants. There were 
no significant differences between “responders” and “non-responders” 
(Supplementary Table 2) to the SWA disruption protocol except that “non-
responders” had lower baseline SWA during the sham night (delta power 86 
versus 147 μV2*s, p=0.009). Since the same delta power >100 μV2*s cut-off was 
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used in all participants for delivery of tones during SWA disruption, low baseline 
SWA made it difficult to reduce SWA further. Another minor weakness is that 
amyloid imaging was not used to exclude individuals with amyloid deposition, 
however, low CSF Aβ42 levels correlate very well with amyloid deposition 
detected by PET23,30. Lastly, this experiment tested only the effect of SWA 
disruption; we cannot infer any information about the effect of increasing SWA 
on synaptic activity or protein clearance from this experiment.
Our study supports the hypothesis that SWA and sleep quality modulate Aβ 
and tau levels, respectively. Long-term prospective studies will be required 
to test whether improving sleep quality and increasing SWA by treating 
underlying sleep disorders, medications, behavioral interventions, or acoustic 
enhancement of SWA can reduce Aβ levels, long-term risk of amyloid 
deposition, and subsequent progression to Alzheimer’s disease.
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SUPPLEMENTARY MATERIAL & METHODS
Sleep and EEG spectral analysis
Polysomnograms were performed with standard electrodes and montage for 
sleep staging, including bilateral frontal, central, and occipital parasagittal 
electrodes referenced to opposite mastoid electrodes; bilateral electro-
oculograms, bilateral chin electromyogram, and 2- lead electrocardiogram. EEG 
sampling rate was 200 Hz. Polysomnogram data were acquired using a MK3 
TrackIt recorder (Lifelines Diagnostics, Troy, IL). All sleep staging was performed 
by a registered polysomnographic technologist according to standard criteria 
(Iber, 2007), using Polysmith (Nihon Kohden, Irvine, California). Additionally, the 
technologist and a sleep physician separately visually (manually) scored each 
10-second mini-epoch of sleep for EEG artifact, and any mini-epochs containing 
artifact were excluded from analysis. Live SWA disruption was performed using 
custom Matlab (IBM) scripts as previously described (Ooms, 2017).
EEG spectral power was derived from the right and left frontal and central 
electrodes (F3, F4, C3, C4), referenced to the opposite mastoids. Data for each 
Age (years)
Race white n(%)
Sex female n(%)
Education (years)
APOE-ε4 carrier n(%)
Delta power change 
[protocol - sham]  μV2*s
52.7(±6.9)
7(70%)
6(60%)
15.8(±1.6)
3(30%)
-22.6(±19.6)
55.9(±6.4)
4(57%)
5(71%)
15.8(±1.7)
2(29%) 
-23.2(±15.5) 
MMSE 29.6(±0.5) 29.5(±0.5)
1.000
0.944
0.348
0.644
1.000
0.965
0.517
Sham 
condition ﬁrst
(N=10)
Mean ±SD
54.1(±6.7)
11(65%)
11(65%)
15.8(±1.6)
5(29%)
-22.9(±17.5)
29.6(±0.5)
All (N=17) p-valueSWS 
disruption ﬁrst 
(N=7)
Mean ±SD
Supplementary Table 1: Comparison of participants who had SWA disruption first, to 
the participants who had sham condition first, shows no significant differences in demographic 
characteristics or effectiveness of SWA disruption (delta power change).
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10.24 seconds, with 0.24 seconds overlap between each pair of mini-epochs, 
were analyzed using Welch’s method. The 2048 data points were divided into 
four equal sections with 50% overlap. A Hamming window was applied prior to 
the discrete Fourier Transform to calculate the spectral power for every 0.5 Hz 
bin from 0.5 to 32 Hz. Mini-epochs scored as artifact were excluded. Spectral 
power values were averaged for three mini-epochs for each 30-second epoch, 
then averaged for all NREM epochs. SWA was quantified as mean power in 
the delta (0.5-4 Hz) band, or “delta power,” averaged over all NREM epochs. 
Spectral analysis was performed using custom scripts in Matlab (IBM)
Age (years)
Race white n(%)
Sex female n(%)
Sham delta power (μV2*s)
TST by actigraphy, 
6 nights (minutes)
Sleep efﬁciency by 
actigraphy, 6 nights (%)
Sham Aβ42 (pg/mL)
53.5 (±6.7)
7 (58%)
7 (58%)
131 (±55)
374 (±52) (N=10)
81.3 (±8.4) (N=10)
974 (±153)
55.4 (±7.3)
4 (80%)
4 (80%)
89 (±25)
391 (±64)
86.3 (±2.7)
1005 (±164)
0.619
0.600
0.600
0.122
0.574
0.218
0.714
Sham Aβ42:Aβ40 ratio (%)
Sham Tau (pg/mL)
Delta power change 
[protocol – sham] (μV2*s)
Delta power change 
[protocol – sham] > 20 (μV2*s), n(%)
9.6 (±1.3%)
198.3
-27 (±19)
8 (67%)
9.7 (±0.4%)
219.8
-13 (±7.6)
1 (20%)
0.921
0.513
0.141
0.131
APOE- ε4 
Non-carrier (N=12)
Mean ±SD
APOE- ε4 Carrier 
(N=5)
Mean ±SD
p-value
Supplementary Table 2: Comparison of participants who are APOE-ε4 Non-carriers and 
carriers show no significant differences in demographic characteristics, sleep, or response to SWA.
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Actigraphy
Actigraphy data were collected using Actiwatch2TM (Philips-Respironics, 
Murrysville,
Pennsylvania) in 30-second epochs and manually scored using actigraph time 
stamps and sleep diaries (Ju et al., 2013). Bedtime and Waketime were set as 
when the participant pushed a button on the actigraph indicating that they had 
lain down with the intention of going to sleep, and when they had gotten out 
of bed in the morning, respectively. If the button was not pushed, the sleep 
diary, which queried for the same intended bedtime and waketime, was used. A 
sensitive or “low” cut-off of 20 activity counts was used to detect sleep for each 
epoch between bedtime and waketime. Immobile time of 10 minutes was used 
to determine sleep onset and offset.
Age (years)
Race white n(%)
Sex female n(%)
APOE-ε4 carrier n(%)
TST by actigraphy, 
6 nights (minutes)
Sleep efﬁciency by 
actigraphy, 6 nights (%)
Sham Aβ42 (pg/mL)
54.0 (±7.7)
6 (67%)
7 (78%)
1 (11%)
147 (±52)
388 +48 (N=7)
83.1 +5.3 (N=7)
54.2 (±5.9)
5 (63%)
4 (50%)
4 (50%)
86 (±26)
317 (±63)
82.8 (±9.1)
0.946
1.000
0.335
0.131
0.009
0.554
0.936
Sham Aβ42:Aβ40 ratio (%)
Sham Tau (pg/mL)
Sham Delta power (μV2*s)
973 (±147)
9.5 (±1.3%)
206.1
995 (±147)
9.9 (±0.9%)
203.0
0.784
0.537
0.918
Responders 
(N=9)
Mean ±SD
Non-responders 
(N=8)
Mean ±SD
p-value
Supplementary Table 3: Individuals who had more than 20 μV2*s decrease in delta power 
with the SWA disruption protocol, or “Responders,” are compared to individuals who did not.
74
-60-40-200
-20
-10
0
10
20
-60-40-200
-20
-10
0
10
20A B
-60-40-200
-3
-2
-1
0
1
2
3
-60-40-200
-3
-2
-1
0
1
2
3
-60-40-200
-30
-20
-10
0
10
20
30
-60-40-200
-15
-10
-5
0
5
10
15
Ta
u 
ch
an
ge
 (%
)
-60-40-200
-10
0
10
20
30
40
[protocol -sham]
To
ta
l p
ro
te
in
 ch
an
ge
 (%
)
-60-40-200
-40
-20
0
20
YK
L-4
0 c
ha
ng
e (
%
)
C D
E F
G H
A
β
40
 ch
an
ge
 (%
)
A
β
42
 ch
an
ge
 (%
)
A
β
42
:A
β
40
 ch
an
ge
 (%
)
A
β
42
:A
β
40
 ch
an
ge
 (%
)
A
β
42
 ch
an
ge
 (%
)
Change delta power (μV2*s)
[protocol -sham]
Change delta power (μV2*s)
[protocol -sham]
Change delta power (μV2*s)
[protocol -sham]
Change delta power (μV2*s)
[protocol -sham]
Change delta power (μV2*s)
[protocol -sham]
Change delta power (μV2*s)
[protocol -sham]
Change delta power (μV2*s)
[protocol -sham]
Change delta power (μV2*s)
Supplementary Figure 1: Effect of an outlier on CSF Aβ42 and other CSF proteins.  
(A) When all 17 participants are included, suppression of slow wave activity, as measured by the 
change in delta power, was not significantly correlated with increased Aβ42 (r=0.341, p=0.181).
 However, there is a notable outlier (arrow), who has the lowest Aβ42 (628 pg/mL), just above 
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ABSTRACT
Background: Evidence indicates a bi-directional relationship between poor 
sleep and Alzheimer's disease (AD). While AD may lead to disruption of normal 
sleep, poor sleep in itself may play a causal role in the development of AD by 
influencing the production and/or clearance of the amyloid-beta (Aβ) protein. 
This led to the hypothesis that extended periods (>10 years) of disturbed sleep 
could lead to Aβ accumulation with subsequent cognitive AD related decline
Objective: To study the relationship between chronic sleep disturbances 
due to an extrinsic cause (work related) and cognitive function among healthy 
middle-aged men to investigate the hypothesis that prolonged abnormal sleep 
behavior increases the risk of AD-related cognitive decline. 
Methods: Our study sample consisted of a group of healthy volunteers (n=19), 
aged 49 to 62 years, who have had irregular sleeping patterns for more than 15 
years due to irregular work schedules. This chronic sleep deprivation group was 
compared to a group of healthy, age and education matched controls (n=19) 
with normal sleep, the healthy control group. All participants underwent one 
night of standard polysomnography (PSG), preceded by approximately 10 days 
of actigraphy (Actiwatch 2, Philips Respironics), on top of keeping a sleep-wake 
diary. Cognitive function (including memory consolidation) was assessed with a 
neuropsychological test battery. 
Results: The chronic sleep deprivation group reported significantly worse 
sleep quality in the Pittsburg Sleep Quality Index questionnaire (PSQI) in a 
workweek (PSQI=8.8 (±2.9)) compared to our control group (PSQI=3.2 (±1.4)). 
The same result was found in the actigraphy data, where the chronic sleep 
deprivation group showed worse sleep quality measured by sleep efficiency 
(86% (±3.8)) and more awakenings (37.8 (±10.3)) compared to our controls 
(89.3% (±4.3); awakenings= 33.45 (±11.1)). During normal sleep (PSG), the 
chronic sleep deprivation group showed increased slow wave sleep (N3=16,4 
% (±7.39)) compared to the healthy controls (N3=12 % (±5.61)). There were 
no major differences in cognitive test scores. The chronic sleep deprivation 
group even performed better on a memory consolidation test (short delay) 
(sensitivitty=0.92 (±0.03); hits=27.4 (±1.5)) than the controls (sensitivity=0.88 
(±0.05); hits= 25.8 (±2.11)), p = 0.007). 
Conclusion: We found no negative effects on cognitive function in the chronic 
sleep deprivation group. This could be related to the enhanced slow wave 
sleep in this group the night before the cognitive testing, which might serve 
as a compensatory mechanism. This requires further exploration in follow-up 
research.
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5.1 INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent cause of dementia and currently 
affects approximately 36 million people worldwide1. Thus far, no successful 
treatment is available. One of the major contributors to the neurodegeneration 
seen in the brains of AD patients is amyloid-beta (Aβ)2. The amyloid-cascade 
hypothesis characterizes amyloid accumulation as the fundamental initiating 
pathway for the development of AD3. While memory impairment and 
disorientation are hallmarks of the disease, approximately 44% of people living 
with AD also suffer from some form of sleep disturbance4. AD patients have 
more awakenings during the night, present decreased slow wave sleep (SWS), 
less rapid eye movement (REM) sleep and more frequent daytime napping 
compared to age-matched controls without dementia4. Neurodegeneration in 
the sleep-wake regulating areas of the brain has been identified as a potential 
cause of the frequent sleep disturbances among AD patients5. Recent evidence 
suggests that sleep and AD have a bi-directional relationship, in which 
sleep disturbances are not just a symptom of AD, but also contribute to AD 
pathophysiology6. Elderly people suffering from insomnia are more likely to 
develop AD compared to controls without insomnia7. Furthermore, disrupted 
circadian rhythm among otherwise healthy individuals8 and sleep disordered 
breathing disorders9 increase the chance of developing AD later in life. Poor 
sleep quality specifically has been shown to increase the risk of AD among 
older individuals5, 10-13. A recent meta-analysis of epidemiological studies 
found that poor sleep increased AD risk with a relative risk (RR) of 1.7 and that 
approximately 15% of cases of AD in the population might be attributable to 
sleep problems14. 
The effect of acute sleep deprivation on AD has been shown in both rodent and 
human studies, that investigated the effect of sleep and sleep deprivation on 
Aβ levels. Rodents and humans show fluctuations in Aβ levels over a 24-hour 
rhythm, where levels rise during wakefulness and decrease during sleep15, 16. 
Following acute sleep deprivation, the drop in Aβ levels that would normally 
occur after sufficient sleep the following morning, was absent. Based on this 
evidence, chronic sleep disturbances might lead to a pronounced accumulation 
of Aβ in the brain, which in turn increases the risk to develop AD. To date, 
observational and epidemiological studies have identified a relationship 
between poor sleep and the risk of developing AD. Experimental research 
has found that sleep deprivation and Aβ levels are related in both animals 
and humans. However, the direct effect of chronic sleep deprivation and its 
consequences on cognitive functioning, particularly the risk to develop AD later 
in life, has not been studied before. 
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In the present study, we aim to investigate the effect of chronic sleep 
deprivation on cognitive function by using an unique cohort of healthy subjects 
with long-term sleep disruption due to their occupation as maritime pilots. 
Because of the bi-directional nature of the relationship between sleep and 
AD, poor sleep and sleep disorders could represent an early symptom that 
precedes the clinical manifestation of AD. Therefore, it is especially important to 
investigate the effect of chronic sleep deprivation in a group that experiences 
disrupted sleep which is caused by an external factor (work) and not by an 
intrinsic sleeping disorder (such as insomnia) which could be AD-related. 
Therefore, participants in this study were selected based on their chronic sleep 
disruptions caused by objectifiable external occupational factors. Results and 
insights born from this study could shed more light on sleep disturbance as one 
of the risk factors to develop AD and contribute to new and improved treatment 
strategies. We hypothesize that participants with chronic sleep disturbances 
show less SWS, more fragmented sleep and perform worse on cognitive 
assessment in comparison to a healthy control group.
5.2 METHODS
Participants
We recruited 19 middle-aged (mean age= 53 years), chronic sleep deprived 
participants from a group of maritime pilots and 19 age and education matched 
controls. We selected the maritime pilots as a suitable study population, 
because of their unique highly irregular working schedule. In a usual workweek 
they have a maximum of two hours rest in between 2 hour working shifts for a 
period of 24 hours. This rhythm continues in most cases for 4 or 5 days a week, 
followed by a week off. The week off is also often characterized by limited 
sleep because the pilots use that week to catch up with social engagements. 
Maintaining this work schedule for more than 15 years results in chronic 
sleep deprivation. The group of maritime pilots was then compared to sex-, 
education- and aged-matched healthy volunteers (n=19) with normal sleep, as 
confirmed by a Pittsburg sleep quality index (PSQI) score of < 5 (see Table 1) 
as well as bed times between 8 p.m and 12 p.m and wake up times between 4 
a.m and 8 a.m. Participants were excluded from participation from the study if 
their actigraphy did not demonstrate >6 hours in bed. All enrolled participants 
were male, healthy, did not take neuro-active medications, reported <14 
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alcoholic beverages weekly, had a body mass index 18-30kg/m2 and were 
cognitively normal (Cognitive Failure Questionnaire (CFQ) <43).  This study was 
approved by our institutional review board and performed according to good 
clinical practice (GCP) rules. Written informed consent was obtained from all 
participants.
Experimental Design
All participants (pilots and controls) were scheduled for a total of two visits 
(Figure 1). During the first visit, informed consent was signed and participants 
were asked to complete a general questionnaire about their medical history, 
medication use, smoking habits and alcohol consumptions. On top of this, 
participants completed the hospital anxiety and depression scale (HADS) 
to measure psychological morbidity. Additionally, they completed the CFQ, 
which contains questions about the frequency of minor cognitive problems in 
everyday situations. In order to obtain a comprehensive measure of sleeping 
patterns, we used the Pittsburg Sleep Quality Index (PSQI) with questions about 
average sleeping behavior, and a sleep-wake diary. Additionally, participants 
were given the Actiwatch2 (Philips Respironics; Eindhoven, The Netherlands) to 
Age (years)
BMI
PSQI normal
PSQI shift
CFQ
HADS Anxiety
HADS Depression
57 (±2.9)
25.5 (±2.7)
3.2 (±1.4)
3.2 (±1.4)
26.4 (±10.8)
4.8 (±3)
3.6 (±2.5)
53 (±3.4)
25.7 (±2.7)
4.5 (±2.2)
8.8 (±2.9)
29 (±7.8)
3.9 (±1.7)
3.7 (±2.7)
0.001
0.81
0.049
0.0011
0.32
0.33
0.9
Healthy controls 
(n=16)
Maritime pilots
(n=19)
p-value
Table 1:  overview of participants characteristics
PSQI: Pittsburg Sleep Quality Index. The maritime pilots filled out the PSQI for a shift week and a 
normal week. Healthy controls only filled out the PSQI once.
CFQ: Cognitive Failure Questionnaire
HADS: Hospital Anxiety and Depression Scale
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collect more objective measurements of their sleeping behavior. Participants 
were instructed to fill in the sleep diary and to wear the Actiwatch for 10 
days before the second visit. The second visit took place at the sleep center 
Kempenhaeghe (Heeze, the Netherlands). Participants arrived at the sleep 
center at 7 p.m and completed a memory consolidation test and a test for 
attentional performance (TAP)17, followed by overnight polysomnography 
(PSG). Patients woke up during their normal wake time, and completed a 
neuropsychological assessment after breakfast around 9 a.m. 
Cognitive assessment 
The neuropsychological assessment measured several cognitive domains. 
Episodic memory was assessed using the Wechsler memory scale IV (WMS-IV) 
Logical Memory and the Rey-Auditory Verbal Learning Test (RAVLT). Working 
Visit 1
Screening (general questionnaires)
PSQI
CFQ
HADS
Hand out Actiwatch
Visit 2
Evening
 TAP
 Memory Consolidation Test (short-term recall)
 One night of PSG recording
Morning 
 TAP
 Memory Consolidation Test (long-term recall)
 Neuropsychological assessment
Figure 1:  overview of the experimental design. 
PSQI: Pittsburg Sleep Quality Index
CFQ: Cognitive Failure Questionnaire
HADS: Hospital Anxiety and Depression Scale
TAP: Test for Attentional Performance
PSG: PolySomnoGraphy
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memory and executive function were measured by Wechsler adult intelligence 
scale IV (WAIS-IV) Digit Span, WAIS-IV Digit Symbol and Trail Making Test A 
and B (TMT-A, TMT-B). Semantic memory and language were assessed by letter 
fluency (D-A-T), semantic fluency (animal/profession naming) and the Boston 
Naming Test (BNT-short form)18. Attentional performance was studied using the 
alertness test of the Test of Attentional Performance (TAP 2.3)17. This test was 
conducted twice, once in the evening around 7 p.m and once in the morning 
around 9 AM. 
In order to test overnight memory consolidation, a task was developed 
that was based on the Visual Recognition Memory Doors Test by Baddely 
and colleagues19. We extended this test by using a validated database of 
2000 pictures of doors20. In total we presented 120 pictures of doors which 
participants had to remember. All targets were presented twice in a different, 
pseudo-randomized order. Targets were shown for 5 seconds each, separated 
by a fixation cross presented for 1 second. After approximately 10 minutes they 
were presented with 30 of the target doors and 15 distractors (new pictures 
of doors) which were randomly mixed (see Figure 2). Their task was to indicate 
A
B after 10 minutes C the next morning
5s 5s1s1s
? ? ? ?
Figure 2:  Visual Recognition Memory Doors Test  
A) Encoding trial – 120 doors separated by fixation cross, B) Short-term recognition trial (after 
approx. 10 min) – oral response (pressing spacebar to move to next stimulus), 30 targets and 15 
distracters, C) Long-term recognition trial (after one night) - oral response (pressing spacebar to 
move to next stimulus), 90 targets and 45 distracters.
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whether the door had been presented before (oral response with ‘yes’) or not 
(oral response ‘no’). For the long-term delayed recall, the same procedure 
was repeated in the morning, using the other 90 target pictures, plus 45  new 
distractors. Calculating the hits and false alarms, we were able to compute the 
sensitivity (A') for short-term and for long-term delayed recall (A'= 0.5 + ((hit-rate 
– false alarm rate) × (1 + hit rate – false alarm rate))/ (4 × hit rate × (1 – false alarm 
rate)).
Statistical analysis
All analyses were performed using IBM SPSS version 20.0 (SPSS Inc, Chicago, 
USA). Statistical significance was set at p < 0.05 and all data are shown as mean 
± SD (range). All continuous variables were assessed for normal distribution 
by inspection of histograms and the Kolmogorov-Smirnov test. Levene’s test 
was used to assess equality of variances. An independent samples t-test was 
performed to compare all outcome parameters.
5.3 RESULTS  
19 maritime pilots and 19 healthy controls completed the study. Three controls 
were excluded because of high PSQI scores (>5) and/or the presence of a 
sleeping disorder. No differences were found between the groups in BMI, 
CFQ and HADS (all within normal ranges). The included maritime pilots were 
on average 4 years younger compared to the healthy controls (53 (±3.4) vs. 57 
(±2.9); p=0.001) (Table 1).
The chronic sleep deprivation group showed significantly worse sleep quality 
during 10 days of actigraphy compared to the control group, which they also 
reported in the subjective questionnaire (PSQI) (Table 2). Both groups showed 
normal sleep during their PSG, with no differences in any sleep characteristics 
except N3 sleep (Table 2). Maritime pilots displayed an average of 16 minutes 
more N3 sleep compared to the healthy controls (16.4 (±7.39) vs. 12 (±5.61); 
p=0.06). This difference however did not reach statistical significance.
No differences were found in the domains of episodic memory, working 
memory, executive function, semantic memory and language capacities (Table 
3). Test scores for attentional performance were also similar between the two 
groups. Maritime pilots performed better on the memory consolidation test 
(short delay) (p=0.007 (A'=0.92 (±0.03); hits=27.4 (±1.5)) compared to the control 
group (A'=0.88 (±0.05); hits= 25.8 (±2.11)) (Table 4).
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Regular sleep
Fragmented sleep
(workweek pilots)
Nr awakenings
Sleep efﬁciency (%)
3.2 (±1.4)
33.45 (±11.1)
89.25 (±4.3)
4.5 (±2.2)
8.8 (±2.9)
37.77 (±10.3)
86 (±3.8)
0.24
0.03*
0.049
Healthy 
controls 
(n=16)
p-value
PSQI
Maritime 
pilots
(n=19)
Actiwatch
Total sleep time 
(minutes) 406 (±44) 403 (±51) 0.86Polysomnography
N1 (% of TST)
N2 (% of TST )
11.1 (±4.54)
55.6 (±10.4)
9.9  (±3.15)
51.6 (±6.5)
0.36
0.15
N3 (% of TST )
REM (% of TST )
12 (±5.61)
16.5 (±4.15)
16.4 (±7.39)
18.9 (±3.2)
0.06
0.07
WASO (min) 61 (±26) 53 (±39) 0.48
Sleep efﬁciency (%) 85.82 (±7.1) 86.14 (±9.4) 0.91
Sleep latency (min)
REM latency (min)
8 (±7)
103 (±39)
11 (±9)
91 (±34)
0.32
0.35
Table 2:  Sleep characteristics measured with Pittsburgh Sleep Quality Index (PSQI), 
actigraphy and polysomnography in both the healthy controls and the maritime pilots.
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Logical memory 1
Logical memory 2
Total
Delayed recall
30.4 (±4.4)
44.9 (±8.83)
9.3 (±1.81)
29.4 (±4.1)
24.9 (±5.79)26.4 (±5.7)
46.9 (±10.62)
9.6 (±2.97)
0.56
0.7
Delayed recognition
Sensitivity (A’)
9.3 (±1.81)
0.973 (±0.03)
9.6 (±2.97)
0.982 (±0.02)
0.7
0.31
0.49
0.44
Healthy 
controls 
(n=16)
p-value
Wechsler
memory 
scale-IV
Ep
iso
di
c m
em
or
y
W
or
kin
g 
m
em
or
y Digit Symbol
Digit span
72.4 (±7.24) 76.3 (±15.44)
28.8 (±6.65)
0.37Wechsler adult 
intelligence
scale IV
A
B
28.3 (±6.15) 28.5 (±9.36)
57.3 (±16.21)
0.94Trail making 
test
Cued
Uncued
256.4 (±31.81) 253.2 (±41.73)
248.8 (±29.86)
0.81TAP evening
Cued
Uncued
265.3 (±56.34)
253 (±29.99)
258.8 (±39.96)
241.5 (±32.57)
242.6 (±23.4)
0.13
0.69
0.13
TAP morning
D-A-T
Animal
41.6 (±9.81)
26.4 (±3.31)
61.8 (±17.44)
25.6 (±5.3)
40.5 (±12.45)
26.2 (±6.1)
0.78
0.21
0.44
0.76
Profession 19.7 (±4.14) 22.2 (±5.5) 0.14
Fluency
78.6 (±3.29) 79.2 (±13.47) 0.86Boston namingtest
Maritime 
pilots
(n=19)
Rey-auditory 
visual learning 
test
Table 3:  Results of cognitive assessment for both the healthy controls and the maritime 
pilots, split out between testing for episodic memory and working memory. 
TAP: Test for Attentional Performance
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Table 4:  Results of the memory consolidation test. Short-term recognition was assessed 
approximately 10 minutes after targets were presented. Long-term recognition took place after 
one night of PSG (approximately 10 hours). 
Sensitivity (A’)
Hits
False alarms
Sensitivity (A’)
0.88 (±0.05)
3.7 (±2.18)
0.82 (±0.05)
0.92 (±0.03)
27.4 (±1.5)25.8 (±2.11)
2.7 (±1.7)
0.84 (±0.04)
0.16
0.14
Hits
False alarms
71.7 (±11.93)
16.3 ( ±7.34)
69.1 (±11.03)
11.8 (±6.26)
0.51
0.06
0.007
0.01
Healthy 
controls 
(n=16)
p-value
Short delay 
(10 min)
M
em
or
y c
on
so
lid
at
io
n 
te
st
Maritime 
pilots
(n=19)
Long delay 
(after sleep)
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5.4 DISCUSSION
In the present study, we investigated the effect of chronic sleep deprivation 
on cognition. According to previous research in both animals and humans, 
there is a 24-hour fluctuation in Aβ levels, which rise during wakefulness and 
decrease during sleep. Since previous studies assessed sleep disruption for 
only one or a few days, this study expanded on this by investigating the effect of 
chronic sleep disturbance on cognition in a group of healthy middle-aged men.  
We hypothesized that the chronic sleep deprivation group would have more 
fragmented sleep, and therefore also less SWS, due to their irregular sleeping 
schedules. Over the course of many years, poor sleep could have increased Aβ 
concentrations, which in turn would result in poorer cognitive function, possibly 
due to AD-related neurodegeneration. We would therefore expect this group 
to perform worse on cognitive testing, specifically on the types of memory 
affected by AD early on, such as episodic memory.  Our results however did 
not confirm this hypothesis. No significant differences were found between the 
chronic sleep deprivation group and the healthy controls on the cognitive tests 
(Table 2 & 4). This suggests that prolonged poor sleep had no impact on their 
cognitive function.
While the chronic sleep deprivation group reported worse sleep quality, which 
was also confirmed by the data from 10 days of actigraphy. The chronic sleep 
deprivation group spent more time in sleep stage N3 (SWS) (16.4% (±7.39)) 
during the night of unrestricted normal sleep at the sleep center compared to 
the controls (12% (±5.61)). These results did not reach statistical significance, 
but suggest that our chronic sleep deprivation group does not experience any 
troubles with sleeping efficiently when given enough time to do so. In addition, 
this enhanced SWS may also indicate so-called rebound sleep, to compensate 
for a night of previous poor sleep. However, since we excluded patients with 
poor sleep (<6 hours) the day before their PSG (as measured by actigraphy), this 
is unlikely.
The difference in SWS between the two groups observed during the PSG night 
could explain why the chronic sleep deprivation group did not perform worse 
on the cognitive tests compared to the controls. SWS is important in memory 
consolidation, where every slow wave is correlated to a pause in synaptic 
activity21. Synaptic activity and Aβ levels seem to be strongly related, in which 
Aβ levels increase due to synaptic activity22. More synaptic activity is observed 
during wakefulness, especially in the default mode network (DMN) or other 
highly interconnected brain areas22. During sleep, there is less synaptic activity 
which might lead to a decrease of Aβ levels in the brain22, specifically during 
SWS. Speculating from this, it is possible that the chronic sleep deprivation 
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group is more efficient in generating SWS, since they spent a significant 
proportion of their total sleep time in SWS during their night in the sleep center. 
Spending more time in SWS could lead to better cognitive performance in the 
short term, as supported by our results. On the long term, spending a large 
portion of their time in SWS, despite having fragmented and relatively short 
sleep, would still allow the chronic sleep deprivation group to have sufficient 
lowering of amyloid in their brain despite their relatively poor lifetime sleep due 
to their efficient sleep. Our study was not designed to investigate the potential 
effects of efficient sleep, and these claims therefore remain speculative.       
 
The present study presents a number of strengths. No other previous studies 
have looked into the effect of chronic sleep disturbances on cognition in healthy 
men to this extent. In additon, our study adds to earlier research reporting an 
association between self-reported sleep disorders and cognitive decline10.  
Since sleep disorders might also be early symptoms of pre-AD, it is especially 
important in this age-group to investigate the effect of chronic sleep disruption 
due to an external factor and not a specific disorder. In addition, we measured 
different domains of cognitive function (reaction time, visual memory, executive 
function, semantic memory and episodic memory) using sensitive and well-
validated neuropsychological tasks. In order to get a comprehensive measure 
of sleeping patterns, we made use of four different instruments: two subjective 
and two objective ones. The subjective measurements consisted of the PSQI 
and the maintenance of the sleep-wake diary. The objective assessments 
included the Actiwatch 2 (Philips Respironics) in addition to a night of PSG. The 
actigraphy data was compared to the sleep-wake diary entries. These data were 
then used to check the sleeping behavior of participants, making sure they 
maintain regularity and consistency in their sleeping habits. This was especially 
important the night before the PSG, to be certain that recordings of the PSG are 
valid and not a measurement of rebound sleep.
In contrast, the present study also presents a number of potential limitations 
that could explain the underlying results. First of all, although we purposely 
selected the maritime pilots due to their irregular shift working schedules and 
the underlying sleep disruptions, a selection bias may have influenced our 
results. The chronic sleep deprivation group is a group of men with strong 
personality traits that are favorable for neuropsychological assessment. They 
were highly motivated, enthusiastic and willing to work hard while completing 
the tests. Furthermore, the work of a maritime pilot is physically demanding and 
most of the times outdoors. Evidence shows that physical exercise and fresh air 
might actually have a positive impact on cognition4. Additionally, the chronic 
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sleep deprivation group is used to sleeping under different circumstances at 
various locations. Potentially, sleeping a night in a different environment, could 
have had more impact on the sleep quality for the healthy volunteers compared  
to the pilots. The pilots might also cope better with poor sleep quality and 
quantity, due to the fact that they have been successfully doing their jobs for 
more than 15 years with adequate daytime functioning. Lastly, cognitive decline 
might not be fully reflected in cognitive test scores but neurodegeneration in 
the brain might already be present. An amyloid PET scan or an Aβ measurement 
of CSF could offer some interesting insights about the effect of prolonged sleep 
disturbances on a biological level.
Further research, specifically longitudinal studies following people with poor 
sleep due to their occupation, is needed to explore the specific effect of chronic 
poor sleep on cognition and to investigate its impact on AD-related cognitive 
decline.  
91
The effect of long-term work-related poor sleep on cognition in healthy middle-aged men
5.
REFERENCES
1 Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of 
dementia: a systematic review and metaanalysis. Alzheimer’s & Dementia. 2013;9(1):63-75. 
e62.
2 Jagust WJ, Mormino EC. Lifespan brain activity, β-amyloid, and Alzheimer’s disease. Trends in 
cognitive sciences. 2011;15(11):520-526.
3 Korczyn AD. The amyloid cascade hypothesis. Alzheimer’s & dementia. 2008;4(3):176-178.
4 Vitiello MV, Borson S. Sleep disturbances in patients with Alzheimer’s disease. CNS drugs. 
2001;15(10):777-796.
5 Ju Y-ES, McLeland JS, Toedebusch CD, et al. Sleep quality and preclinical Alzheimer disease. 
JAMA neurology. 2013;70(5):587-593.
6 Ju Y-ES, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology [mdash] a 
bidirectional relationship. Nature reviews Neurology. 2014;10(2):115-119.
7 Osorio RS, Pirraglia E, Agüera-Ortiz LF, et al. Greater risk of Alzheimer’s disease in older adults 
with insomnia. Journal of the American Geriatrics Society. 2011;59(3):559-562.
8 Tranah GJ, Blackwell T, Stone KL, et al. Circadian activity rhythms and risk of incident dementia 
and mild cognitive impairment in older women. Annals of neurology. 2011;70(5):722-732.
9 Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild 
cognitive impairment and dementia in older women. Jama. 2011;306(6):613-619.
10 Benedict C, Byberg L, Cedernaes J, et al. Self-reported sleep disturbance is associated with 
Alzheimer’s disease risk in men. Alzheimer’s & Dementia. 2015;11(9):1090-1097.
11 Sterniczuk R, Theou O, Rusak B, Rockwood K. Sleep disturbance is associated with incident 
dementia and mortality. Current Alzheimer research. 2013;10(7):767-775.
12 Hahn EA, Wang H-X, Andel R, Fratiglioni L. A change in sleep pattern may predict Alzheimer 
disease. The American Journal of Geriatric Psychiatry. 2014;22(11):1262-1271.
13 Potvin O, Lorrain D, Forget H, et al. Sleep quality and 1-year incident cognitive impairment in 
community-dwelling older adults. Sleep. 2012;35(4):491-499.
14 Bubu OM, Brannick M, Mortimer J, Umasabor-Bubu O, Sebastião YV, Wen Y, et al. Sleep, 
cognitive impairment, and Alzheimer’s disease: a systematic review and meta-analysis. Sleep. 
2016;40(1):zsw032
15 Kang J-E, Lim MM, Bateman RJ, et al. Amyloid-β dynamics are regulated by orexin and the 
sleep-wake cycle. Science. 2009;326(5955):1005-1007.
16 Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of 
total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a 
randomized clinical trial. JAMA neurology. 2014;71(8):971-977.
17 Zimmermann P, Fimm B. A test battery for attentional performance. Applied neuropsychology 
of attention Theory, diagnosis and rehabilitation. 2002:110-151.
18 Lezak MD. Neuropsychological assessment. Oxford University Press, USA; 2004.
92
19 Baddeley A, Emslie H, Nimmo-Smith I. Doors and People: A Test of Visual and Verbal Recall 
and Recognition, Thames Valley Test Company, Bury St. Edmunds, UK. 1994.
20 Baddeley AD, Hitch GJ, Quinlan PT, Bowes L, Stone R. Doors for memory: A searchable 
database. The Quarterly Journal of Experimental Psychology. 2016;69(11):2111-2118.
21 Nir Y, Staba RJ, Andrillon T, et al. Regional slow waves and spindles in human sleep. Neuron. 
2011;70(1):153-169.
22 Kang D, Lim HK, Jung WS, et al. Sleep and Alzheimer’s Disease. Sleep Medicine Research. 
2015;6(1):1-9.
93
Treatment of sleep disorders in dementia
6.
6.
Treatment of sleep disorders 
in dementia
Sharon Ooms, MSc, Yo-El Ju, MD MSCI
Curr Treat Options Neurol. 2016 Sep;18(9):40. doi: 10.1007
94
ABSTRACT
Sleep and circadian disorders occur frequently in all types of dementia. Due 
to the multifactorial nature of sleep problems in dementia, we propose a 
structured approach to the evaluation and treatment of these patients. Primary 
sleep disorders such as obstructive sleep apnea should be treated first. 
Comorbid conditions and medications that impact sleep should be optimally 
managed to minimize negative effects on sleep. Patients and caregivers 
should maintain good sleep hygiene, and social and physical activity should 
be encouraged during the daytime. Given the generally benign nature of 
bright light therapy and melatonin, these treatments should be tried first. 
Pharmacological treatments should be added cautiously, due to the risk of 
cognitive side effects, sedation, and falls in the demented and older population. 
Regardless of treatment modality, it is essential to follow patients with dementia 
and sleep disorders closely, with serial monitoring of individual response to 
treatment.  
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6.1 INTRODUCTION
Dementia is associated with sleep and circadian disturbances, worse than the 
expected gradual sleep quality with aging1, which negatively affect patient 
quality of life and increase caregiver burden2. Disrupted sleep and circadian 
functions in dementia are attributed to neurodegeneration of brain regions and 
networks involved in these functions, such as the suprachiasmatic nucleus3,4; 
however, there are additional factors that contribute to the burden of sleep 
disturbances in dementia. Alzheimer’s Disease (AD) is associated with a delay in 
circadian phase, unlike the typical advance in circadian phase with aging5. This 
delay likely contributes to sundowning—agitation and confusion in the evening—
as well as to difficulty sleeping at night. Due to wandering and subsequent 
risk of injury, nighttime insomnia increases morbidity and mortality directly, 
and therefore is a common reason for institutionalization6. During the daytime, 
excessive sleepiness may contribute to worse cognitive function, unintentional 
naps that impact driving safety, and decreased ability to engage in social 
functions and therapies. Given the substantial negative impact of sleep and 
circadian problems in dementia patients, there is keen interest in identifying 
effective treatments, with the hope of reducing caregiver burden, improving 
patient quality of life, postponing institutionalization, and potentially slowing 
cognitive decline.
6.2 DEMENTIA SUBTYPES AND SLEEP 
DISORDERS
Various etiologies of dementia are associated with different types of sleep and 
circadian disturbances. In AD, the most common cause of dementia, 44% of 
patients are affected with a sleep disorder7,8, and the prevalence and severity 
of sleep disorders increase with dementia severity. Sleep disturbance occurs 
very early in AD; even the preclinical stage of AD prior to cognitive symptoms 
is associated with worse sleep quality and shorter sleep duration9,10. There 
is increasing evidence that there is a bi-directional relationship between 
AD pathology, especially amyloid-β plaque accumulation, and poor sleep11.  
Additional sleep disturbances in AD include daytime hypersomnia, delayed 
circadian phase, sundowning, and adverse effects of dementia medications 
such as acetylcholinesterase inhibitors12. Obstructive sleep apnea (OSA), a 
primary sleep disorder, is particularly common in AD13,14.
Dementia with Lewy bodies (DLB) and Parkinson’s disease (PD) with dementia 
(PDD) are pathologically similar and can be grouped together as Lewy 
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Body Disease (LBD). LBD has the highest prevalence of sleep and circadian 
disturbances of any dementia, affecting approximately 90% of patients15. 
Insomnia is the most common sleep disturbance in LBD, a combination of 
prolonged sleep latency, increased sleep fragmentation, nightmares, and early-
morning awakenings16. Daytime hypersomnia, including “sleep attacks,” is also 
common (~50% prevalence) and contributes to worse quality of life and safety 
risks in LBD17,18. Hypersomnia may be related to loss of orexinergic neurons19. 
However, there are no studies correlating orexin (hypocretin) levels with 
hypersomnia severity in LBD. Hallucinations, particularly visual hallucinations 
in the evening or night, may contribute to sleep problems in LBD. In terms of 
primary sleep disorders, REM sleep behavior disorder (RBD), a parasomnia 
characterized by potentially violent or injurious dream enactment behavior, is 
common in LBD and is a supportive diagnostic criterion for DLB. In fact, the 
majority of patients with RBD in “idiopathic” form without dementia develop 
LBD eventually20. Another primary sleep disorder associated with PD is restless 
legs syndrome (RLS), with a prevalence of approximately20,21.
Vascular dementia (VD), the second leading cause of dementia, is commonly 
associated with OSA. In the acute post-stroke period, there is a high prevalence 
of central apneas, which typically resolve22. Otherwise, due to the wide range of 
vascular disease (localization in the brain, micro- versus macro-vascular disease, 
and co-occurrence with other neurodegenerative pathology), there are no other 
characteristic associations with specific sleep disorders or symptoms. 
There is a similar prevalence of sleep disorders in frontotemporal dementia 
(FTD) as in AD, but they differ in their manifestation23. The activity rhythm in FTD 
is more fragmented, and there can be circadian advance or delay24. 
In addition to the sleep and circadian disturbances primarily associated with 
various dementias, there are additional factors that may worsen symptoms 
or complicate treatment. Co-morbidities that cause pain or discomfort, or 
psychiatric conditions such as depression15, worsen nighttime insomnia. 
Medications for the underlying dementia as well as medications for co-morbid 
conditions (e.g. b2 agonist inhalers for pulmonary disease, anti-hypertensive 
medications) may contribute to sleep disturbance. Sleep hygiene, which 
includes the regularity and timing of sleep, napping, bedtime ritual, daytime 
activity, light and nocturnal noise (especially in nursing homes25), may be 
poor in dementia and therefore exacerbate sleep-wake problems8. Due to the 
complex inter-relationships between dementia pathophysiology, dementia 
effect on sleep hygiene, co-morbid primary sleep disorders, medication effects, 
and other factors, a comprehensive approach is necessary for diagnosis and 
treatment of sleep disorders in dementia.
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6.3 ASSESSMENT
Assessment of sleep and circadian disturbances in dementia begins with a 
complete history. Since demented people may not recall symptoms accurately, 
collateral history from caregivers is essential. The clinical history should assess 
for symptoms of primary sleep disorders, such as snoring, hypersomnia, 
witnessed apneas, parasomnias, restless legs, and leg movements during sleep. 
The timing and regularity of nighttime sleep and daytime naps (intentional and 
inadvertent) are important to ascertain. In addition to these clinical features 
typically queried during a sleep evaluation, individuals with dementia should 
be specifically asked about sundowning, hallucinations, sleep attacks, injurious 
parasomnias, and nighttime wandering. If the cause of dementia is known, the 
history should query for sleep-wake problems characteristic of the underlying 
disease. For example, in someone with Parkinson’s Disease, a detailed temporal 
relationship between dopaminergic medication dosing and RLS symptoms 
should be obtained. In all cases, the overall burden of sleep disturbances on 
both patient and caregiver should be taken into account.
Contributory factors should be assessed, including 1) depression and 
anxiety; 2) co-morbidities causing pain or discomfort; 3) co-morbidities that 
cause awakenings (e.g. prostatic hypertrophy causing frequent nocturia); 4) 
medications including supplements and over-the-counter medications; 5) 
current and prior alcohol, tobacco, caffeine, and other substance use; 6) living 
and sleeping arrangements; 7) degree, frequency, and regularity of physical 
activity; 8) social and occupational activity; 9) timing and regularity of meals; 10) 
light and noise exposure during daytime and nighttime. 
Scales typically used for sleep evaluation, such as the Epworth Sleepiness 
Scale (ESS)26 or Pittsburgh Sleep Quality Index (PSQI)27 have not been validated 
specifically for use in dementia, and, caregivers may complete questionnaires 
for patients. Therefore, typical normal/abnormal cutoffs may not be applicable. 
Table 1 (next pages):  Recommended clinical approach to sleep disorders in dementia. 
Current existing evidence and expert guidelines on the evaluation and treatment of sleep 
disorders in dementia are summarized. The approach should proceed in the listed order, starting 
with 'Clinical Assessments', and proceeding downward only if symptoms persist. 'Benefits' listed 
for sleep treatments include only RCT’s and meta-analyses
MMT: multi-modality treatment, 
RCT: randomized controlled trial, 
RLS: restless legs syndrome, 
NBBRA: non-benzodiazepine benzodiazepine receptor agonists, 
BLT: bright light therapy 
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Assessment 
or Treatment
History Collateral source is critical
Collect information about symptoms of 
primary sleep disorders, sleep 
habits/hygiene, co-morbidities, 
medications, dementia-speciﬁc 
symptoms
Assess for depression and anxiety
Time-intensive Obtain information about 
caregiver burden
Sleep scales and questionnaires General: Epworth Sleepiness Scale, 
Pittsburgh Sleep Quality Index, Insomnia 
severity index, etc
Dementia-speciﬁc: Sleep Disturbance 
Inventory, SCOPA sleep scale, etc
Use serially to determine 
response to treatment
Actigraphy Several days to weeks
To assess circadian phase and amplitude
To assess nocturnal sleep variables
Non-invasive, able to get data 
in patient’s usual setting
Usually not reimbursed by 
insurers
Obtain concurrent sleep log
Use serially to determine 
response to treatment
Polysomnogram For suspected obstructive sleep apnea, 
periodic limb movement disorder, RBD 
(or other parasomnia)
Gold standard diagnosis Inconvenient
Demented patients may have 
confusion/agitation
Caregiver should stay with 
patient if possible
Ambulatory (home) studies 
may have high failure rate in 
dementia
Obstructive sleep apnea Positive airway pressure Slower cognitive decline
Less snoring, improved sleep, 
improved daytime alertness
Patients may not be able to 
tolerate PAP
Caregiver burden
Common in AD, vascular 
dementia
No data on non-PAP 
treatments 
Restless legs syndrome Iron supplementation
Dopamine agonists, gabapentin, other 
typical RLS medications
Improve symptoms Sleep attacks with dopamine 
agonists
Sedation with gabapentin
Common in PD
Coordinate dopamine 
agonists with PD doctor
REM sleep behavior disorder Iron supplementation
Dopamine agonists, gabapentin, other 
typical RLS medications
Reduced risk of injury Sedation with clonazepam In DLB and PDD
Hypersomnia Stimulants, sodium oxybate, 
anti-cataplectic agents
Improve alertness Cardiovascular risk, irritability
Sedation with sodium oxybate
Common in DLB and PDD
Only for true primary 
hypersomnia such as 
narcolepsy
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Treat mood and anxiety disorders Anti-depressants, psychotherapy, 
anxiolytics
Improve psychiatric and sleep 
symptoms (usually insomnia)
May cause sedation and worse 
cognition
Worse RLS
Time-intensive
Coordinate with other 
physicians and healthcare 
professionals
Improve sleep Pain and bladder medications 
may cause sedation and worse 
cognition
Varies by co-morbidity
Time-intensive
Assessment 
or Treatment
Treat pain, and other co-morbidites 
causing disrupted sleep
Varies Coordinate with other 
physicians and healthcare 
professionals
Minimize or adjust medications 
causing sleep disruption or 
hypersomnia
Dementia and Parkinsomnism 
medications
Pain medications, stimulants, β2 agonist 
inhalers, anti-hypertensives, bladder 
medications, anti-retrovirals, steroids, etc
Improve sleep Varies by medication
Time-intensive
Coordinate with other 
physicians and healthcare 
professionals
Sleep hygiene education See text
Frequently used in MMT
Modest improvement in TST in 
one study (43)
Caregiver and patient burden May be difﬁcult to implement 
in institutionalized setting
Physical activity Unknown
Better in MMT with physical activity
One small study showed 
improvement in TST and 
reduced daytime sleep (48)
Caregiver and patient burden No standard
Bright light therapy Morning, 2500-10000 lux, 1-2 hours
Can use in MMT
Reduced night-time awakenings 
(meta-analysis; 54)
Increased total sleep time if 
patients have pre-existing sleep 
complaint (meta-analysis; 66)
Caregiver and patient burden
Eyestrain
Ideally assess circadian phase, 
and time therapy to shift 
phase appropriately
Complementary and alternative 
treatments
Varies, see text No large RCT Varies If no adverse effects and low 
cost,  reasonable to try with 
close monitoring
Melatonin 2-5 mg immediate release, at bedtime ~25 minutes total sleep time 
(meta-analysis; 83)
One study showed increased 
depressive symptoms
No data on dosing other times 
of day
Sedating anti-depressants Trazodone 50mg 42.5 minutes total sleep time 
in one study (90)
May cause sedation and worse 
cognition, Worse RLS
Benzodiazepines No data to support speciﬁc treatment No large RCT May cause sedation and worse 
cognition, Falls/injuries
Stimulants No data to support speciﬁc treatment No large RCT
NBBRA No data to support speciﬁc treatment No large RCT May cause sedation and worse 
cognition, Falls/injuries, 
Parasomnias
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However, these and other scales are still useful for following individual trends 
over time. Additionally, dementia-specific scales may be helpful. Examples 
include the Sleep Disturbance Inventory (SDI), which was developed to assess 
caregiver burden due to sleep disturbance in AD28, and the Behavior Pathology 
In Alzheimer’s Disease Rating Scale (BEHAVE-AD). In LBD, the Parkinson’s 
Disease Sleep Scale and the SCOPA-sleep scale may be helpful29.
Objective data about circadian activity patterns and overnight sleep are helpful 
for diagnosing sleep disorders and assessing response to treatment. Sleep logs 
alone may not be accurate in individuals with dementia. Actigraphy, using non-
invasive wearable motion sensors, is helpful for assessing suspected circadian 
disorders. Furthermore, validated sleep-scoring algorithms are available to 
analyze actigraphy data, to calculate objective measurements of nocturnal sleep 
such as total sleep time and sleep efficiency. The standard practice committee 
of the American Academy of Sleep Medicine (AASM) has recommended 
actigraphy and sleep logs to be routinely used to assess for irregular sleep wake 
rhythms in dementia30. 
If there are symptoms of a primary sleep disorder such as OSA, periodic limb 
movement disorder, or RBD, polysomnography (PSG) is the gold standard for 
diagnosis. If possible, a caregiver should stay in the sleep lab to assist with 
PSG, since a strange environment and numerous sensors may cause confusion. 
Ambulatory studies for OSA can be done in the patient’s usual sleeping 
environment, however patients with dementia may have difficulty using the 
home recording devices. Additionally, ambulatory studies are less sensitive for 
mild OSA compared to PSG31.
6.4 APPROACH TO TREATMENT
The treatment approach to sleep problems in dementia is similar to that in the 
general population, but with additional attention paid to avoid exacerbating 
cognitive dysfunction, reducing injury risk, and reducing caregiver burden. 
First, any underlying primary sleep disorders should be assessed for and 
treated. Second, any co-morbid mood and anxiety disorders should be 
addressed. Third, pain, nocturia, or other comorbid conditions that interfere 
with sleep should be addressed to the best extent possible, and medications 
that affect sleep (including those for the underlying dementing disease) 
should be adjusted to optimize sleep-wake functioning. For example, 
acetylcholinesterase inhibitors (e.g. donepezil and rivastigmine) and MAO-B 
inhibitors (e.g. selegiline) may cause insomnia, and dosing should be moved 
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earlier in the daytime. Additionally, dopaminergic medications for Parkinsonism 
should be adjusted to minimize bothersome nighttime motor symptoms 
that may awaken the patient, as well as minimize sedating effects during the 
daytime (especially dopamine agonists). Management of a patient’s co-morbid 
conditions and medications requires close co-ordination with the patient, the 
caregiver, and the patient’s other physicians and other healthcare professionals, 
and is usually the most time-consuming aspect of care of demented patients 
with sleep disturbances. Lastly, if sleep-wake problems persist, non-
pharmacological treatments are preferred, due to the risk of sedation, cognitive 
symptoms, falls, injuries, and medication interactions with pharmacological 
treatments.  In recalcitrant cases, pharmacological treatments can also be 
added cautiously. Ideally, objective measurements such as actigraphy and 
subjective measurements of patient and caregiver symptoms should be 
obtained serially to follow response to treatment. 
6.5 TREATMENT OF PRIMARY SLEEP 
DISORDERS
The treatment of sleep disturbance in dementia should always begin with 
treatment of any primary sleep disorders. Sleep disorders increase with aging, 
and are very common in people with dementia. In the general population, OSA 
contributes to nighttime sleep fragmentation, insomnia, daytime hypersomnia, 
cognitive dysfunction, and decreased mood. Therefore, it is expected that 
in the demented population, OSA would have similar and potentially worse 
effects. OSA is very common in AD, present in 40% of AD patients overall 
and increasing to 70% in the institutionalized setting13,14. In fact, having OSA 
increases risk of dementia. In the Study of Osteoporotic Fractures, OSA 
increased the risk of incident cognitive decline by an adjusted odds ratio of 
1.8532. In the AD Neuroimaging Initiative cohort, participants who reported 
having OSA were diagnosed with mild cognitive impairment and AD about 
13 and 5 years earlier, respectively, than those who did not33. In patients who 
already have dementia, the existing data support treating any OSA. In a small, 
randomized study of demented patients, treatment of OSA with positive airway 
pressure (PAP) helped slow cognitive decline34. Furthermore, in a longitudinal 
extension of the study, PAP was associated with improved subjective sleep 
scores such as ESS and PSQI35. In another nonrandomized study of 23 mild to 
moderate AD patients with severe OSA, there was a slower decline in cognition 
if patients used PAP; the effect as measured by Mini-Mental Status Exam score 
was a decline of 0.7 points annually for PAP versus 2.2 points annually without 
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PAP36. OSA is also common in vascular dementia, however no randomized 
studies of PAP have been published about this population. Non-PAP treatments 
such as mandibular advancement devices have not been tested in randomized 
studies in the dementia population, but may be a reasonable alternative in 
patients who are unable to use PAP.
Restless legs syndrome and periodic limb movement disorder (PLMD) are 
common in LBD, especially PDD. Treatment approach is the same as idiopathic 
RLS and PLMD. Iron deficiency can worsen RLS and PLMD, and should be 
treated with supplementation. Medications typically used for RLS and PLMD 
such as dopamine agonists and gabapentin are effective in the demented 
population, however, since dopamine agonists are also prescribed for motor 
symptoms, treatment regimens should be coordinated between sleep medicine 
and dementia/movement disorders physicians.
REM sleep behavior disorder requires PSG confirmation, showing REM sleep 
without atonia37. Behavioral precautions including removing weapons from 
the bedroom, moving furniture far from the bed, and putting a rug on hard 
floors should be advised. In cases where the patient or bed-partner are at risk 
of injury, both clonazepam and melatonin have been shown to be effective 
for reducing oneiric behaviors38. Melatonin is preferred if there is concern 
for cognitive or sedating side effects of clonazepam. In all patients with PD, 
RBD should be assessed for because it is prognostically useful; RBD predicts 
a PDD phenotype and more rapid progression39. Unfortunately, treatment of 
RBD symptoms has not been shown to slow the progression of the underlying 
neurodegenerative process.
Hypersomnia may persist despite treatment of primary nocturnal sleep 
disorders, particularly in LBD. Some dementia patients meet formal criteria for 
narcolepsy or idiopathic hypersomnia. Treatment with stimulant medications, 
anti-cataplectic agents, or sodium oxybate may be appropriate if patients have 
bona fide narcolepsy, however, exceptional care should be taken to minimize 
side effects, particularly worsening of cognitive symptoms or any co-morbid 
cardiovascular disease.
6.6 NON-PHARMACOLOGICAL TREATMENTS 
Sleep hygiene education
Optimal sleep hygiene includes behaviors that promote consolidated sleep at 
night, including regular and adequate nocturnal sleep periods, minimizing naps, 
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minimizing sleep-disrupting substances (alcohol, tobacco, caffeine, and other), 
obtaining regular vigorous physical activity, avoiding excessive light close 
to bedtime, developing a bedtime routine to transition from wake to sleep, 
sleeping in a sleep-conducive (dark, cool, quiet, no television) environment, and 
using the bed only for sleep (i.e. stimulus control). Educating dementia patients 
and their caregivers about sleep hygiene has generally been used as a control 
group for other interventions, or has been used in combinations with other 
approaches in multi-modality treatment40-42. In one small study of dementia 
patients residing in group homes, sleep hygiene education resulted in a longer 
total sleep time at night as measured by actigraphy, 9.6 hours, as compared 
to controls, 7.8 hours43. Sleep efficiency, the percentage of time in bed that 
is spent asleep, also was improved, 84% in the sleep hygiene group versus 
75% in controls43. However, another study in more severe, institutionalized 
dementia patients, did not find any positive effect of sleep hygiene education 
44. In general, although strong data for sleep hygiene education in dementia 
are lacking, since there are no anticipated adverse effects, good sleep hygiene 
serves as a foundation for insomnia treatment, including in the dementia 
population.
Physical and social activity
Increased daytime physical activity and social interaction have been shown to 
improve daytime alertness and nighttime sleep in the elderly population45-48. 
Potential mechanisms include increase of slow wave sleep following physical 
exertion, stronger circadian zeitgebers from regular physical/social activity, 
psychological factors, or other mechanisms. Many studies of physical and social 
activity as sleep interventions have used multi-modality treatment, therefore 
individual benefits of physical or social activity are difficult to ascertain. In an 
early study, a combination of sleep hygiene education, daily walking for 30 
minutes, and bright light therapy for 1 hour at night decreased wake time at 
night by 36 minutes after 2 months of treatment42. A study of only exercise, 
30 minutes of walking for 5 days per week, in moderately demented nursing 
home patients, showed no benefit on sleep49. McCurry et al compared 
physical activity (daily walking for 30 minutes for 2 months), bright light 
therapy, a combination of both, and control (sleep hygiene instruction) groups. 
They found that there was decreased wake time overnight on actigraphic 
measurement initially, but there were no significant benefits at 6 months50. 
A randomized controlled study in AD and PD showed a positive effect of 
more intense, structured physical activity. In this study, patients had exercise 
sessions for 1 hour, 3 times per week, for 6 months. Exercise routines were 
designed, individualized, and supervised by professionals, to target 60-80% of 
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maximal heart rate. Participants who were able to maintain this level of regular 
physical activity demonstrated benefit in sleep as measured by the Mini Sleep 
Questionnaire, and in daily activities51. 
 Social and occupational activities provide zeitgebers for circadian 
clock entrainment and discourage people from sleeping during the daytime. 
In a demented, nursing-home population, an intervention of only structured 
social activity reduced actigraphically-measured daytime sleep, and—in the 
subset of participants with poor nighttime sleep efficiency—increased nighttime 
total sleep time48. In a larger study that examined general nursing home and 
assisted-living center residents, a combination of structured social activity 
and physical activity improved nocturnal sleep as measured by PSG, however, 
neither intervention alone had a significant effect47.
Overall, structured physical and social activities have neutral to positive effects 
on sleep, with a trend for more benefit with multi-modality treatment and with 
more vigorous physical activity. Again, in the interest of minimizing harm, this 
type of intervention should be encouraged as tolerated in demented patients 
with sleep and circadian disturbances, prior to pharmacological therapies. 
Unfortunately, there are no widespread, standardized programs for structured 
physical or social activity in dementia, although training programs for caregivers 
are under development52. Therefore, in clinical practice, patients should be 
advised to exercise vigorously regularly (3-5 times per week for 30-60 minutes), 
if possible with a professional trainer using a target heart rate. Additionally, 
all demented patients should be advised to have regular social interactions, 
although there are no formal or standard recommendations for frequency, 
quantity, or quality. 
Bright light therapy
Bright light therapy (BLT) is an intervention used to treat circadian disorders. 
BLT involves exposure to light, which activates the retinohypothalamic tract to 
the suprachiasmatic nucleus, thereby entraining circadian phase. The effect 
of light on circadian phase depends acutely on the time the light is delivered: 
light close to bedtime delays phase, while light close to waketime advances 
phase. The AASM has published parameters for the use of BLT in circadian 
disorders53. Studies investigating the effect of BLT specifically in dementia 
patients show mixed results. A systematic Cochrane meta-analysis in 2014 
examined the effectiveness of BLT on sleep disturbance in dementia54, and 
included 10 studies assessing sleep50,55-63. Seven of the studies delivered BLT 
using a light box (2500-10,000 lux) for 1-2 hours50,55-60, while other methods 
were used for the other studies61-63. BLT was administered in the morning57-60,63, 
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evening50, both55,56, or all day61,62. Treatment duration ranged from 10 days 
to 10 weeks. Sleep was measured in all studies with total sleep time, except 
for one that assessed nighttime activity60. Pooled data revealed no effect of 
BLT on nocturnal total sleep time. However, there was a significant decrease 
in night-time awakenings, particularly in the studies using morning BLT. 
There were insufficient data to clearly recommend any of the BLT modalities, 
dose (lux or duration), timing, or treatment duration options tested. Two 
additional small, randomized studies have been published since that review, 
again with neutral to positive effect of BLT64,65. Another meta-analysis, by 
van Maanen et al in 201566, included 5 studies excluded from the Cochrane 
review (for not being randomized controlled trials)67-71, and excluded 5 studies 
included in the Cochrane review (because inclusion criteria required a sleep 
complaints)55,56,59,61,63. This meta-analysis reported a significant benefit of BLT 
for sleep disturbances in dementia, for sleep onset latency, total sleep time, 
time in bed, and sleep efficiency. To summarize, data regarding BLT for sleep 
disturbances in dementia are mixed but generally trend toward a positive 
effect, with the most potential benefit for morning BLT and for individuals with 
sleep disturbances. Since BLT does not have significant adverse effects, it is 
reasonable to try morning BLT (particularly in combination with melatonin as 
discussed below), in demented individuals who have a sleep disturbance or 
delayed circadian phase. 
Complementary alternative medicine
Several complementary and alternative modalities have been tested for sleep 
disturbances in dementia. Two small, non-randomized studies reported an 
improvement of sleep in dementia after acupuncture or accupressure72,73. 
A randomized trial of a 3-minute back massage prior to bedtime showed a 
36-minute, but non-significant, improvement in total sleep time74. A small, 
randomized study of Tai Chi in vascular dementia demonstrated a benefit in 
sleep, as measured by PSQI75. A study of a child-like robot for elderly women 
living alone (not necessarily with dementia) showed significant improvement 
in several sleep variables, including total sleep time, compared to a more 
mechanical robot76. These and other alternative, non-pharmacological 
interventions are under active investigation for sleep disturbance in dementia, 
however, none have been demonstrated to be effective in rigorous, double-
blind, randomized, controlled trials. In general, if a patient or caregiver wants 
to pursue a potential non-pharmacological intervention without anticipated 
adverse side effects or excessive cost, it is reasonable to perform a trial of 
the intervention, with serial objective measurements (such as actigraphy) or 
subjective scales over a short period, to assess response.
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Melatonin
Melatonin is released from the pineal gland in the evening in dim light, and 
mediates the relationship between the circadian clock and sleep. Exogenous 
melatonin has circadian phase-shifting effects opposite to that of light, and 
also exerts a mild soporific effect. Melatonin levels are decreased in AD77,78. 
Melatonin has been shown to improve cognition, emotional performance, and 
sleep-wake patterns in mild cognitive impairment79, suggesting a possible 
beneficial role for melatonin in dementia. However, existing data on melatonin 
in dementia are equivocal. A Cochrane meta-analysis in 2014, including 
3 randomized, controlled studies58,80,81, found no benefit of melatonin in 
dementia patients with sleep complaints82. Dowling et al used melatonin 5 mg 
for 10 weeks, in a mixed-modality treatment with BLT, and found a benefit58. 
Serfaty et al used 6 mg slow release melatonin for two weeks80, and Singer 
et al used 10 or 2.5 mg for 8 weeks81; neither study found any difference 
between melatonin and control groups. Another meta-analysis in 2015 by Xu 
et al included 7 randomized, controlled studies that examined melatonin in 
people with dementia, not necessarily with sleep problems83. This meta-analysis 
included four studies in addition to the three in the Cochrane review61,84-86, 
and found a benefit for melatonin of approximately 24 minutes on TST, small 
(~2%) improvements in sleep efficiency, and no cognitive benefits. The largest 
study included 189 nursing home residents, the majority (87%) of whom 
had dementia. In this study, melatonin 2.5 mg given 1 hour before bedtime 
increased sleep duration by 27 minutes. However, melatonin was associated 
with worse withdrawn behavior and depression; the behavioral effects were 
ameliorated by BLT61. Of the other three studies, one showed no effect of either 
8.5 mg immediate release or 1.5 mg sustained release melatonin at 10PM85, 
one showed a small improvement with 3 mg melatonin at 10:30 PM in total 
sleep time 84, and one did not assess sleep outcomes86. Another more recent 
randomized controlled study using 2 mg slow release melatonin for 24 weeks 
in a multi-site study of mild-to-moderate AD (n=80)87, found that, compared to 
placebo, there was less decline in mini mental state examination (MMSE) and 
instrumental activities of daily living (IADLS) with melatonin. Sleep was assessed 
only with PSQI, and only the sleep efficiency component of this index improved; 
this difference was more pronounced for those starting with insomnia as 
defined by PSQI >6, (n=13)87.
Melatonin receptor agonists such as ramelteon simulate the action of melatonin. 
One randomized controlled trial has been performed with ramelteon. There 
is no publication associated with this study, however the synopsis of the 
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study from the manufacturer88 and a summary of information provided to the 
Cochrane meta-analysis investigators82 were reviewed. There was no benefit of 
ramelteon after 1 week on actigraphically-determined total sleep time in mild to 
moderate AD patients. No data are available regarding outcomes at the end of 
the planned 8-week treatment period. Ramelteon was also assessed in a small 
case study in four PDD patients, in which scores of ESS and PSQI improved in all 
patients after treatment with ramelteon for 8 weeks89. There are several reports 
of a beneficial effect of ramelteon on sundowning or delirium; these studies are 
beyond the scope of this review. 
Altogether, the existing data on melatonin suggest a possible benefit in terms 
of nocturnal sleep of approximately half an hour, and reduced frequency of 
awakenings. There is no known benefit of ramelteon or extended-release 
melatonin. Melatonin is considered a nutritional supplement in the US and is 
not subject to the same standards as a prescription medication. Furthermore, 
different dosages and timing (which affects phase shifting action of melatonin) 
varied between studies. Therefore, it is difficult to suggest a specific dose or 
timing, particularly since many of the studies used dosing at bedtime, which 
is later than would be typically used to advance sleep phase. Additionally, 
there was possible negative effect on mood and behavioral indices in one 
study, except when combined with BLT. In general, melatonin is well-tolerated 
with minimal side effects at low doses. Therefore, in individuals who do not 
respond to maximal behavioral interventions, it is reasonable to try a low dose 
of melatonin (2-5 mg) at night, together with BLT, while closely monitoring for 
depressive symptoms, and objectively following sleep/circadian measurements. 
Sedating anti-depressants
Sedating anti-depressants are prescribed frequently for their soporific qualities, 
but there are very limited data on anti-depressants for sleep in dementia. One 
study of trazodone 50 mg at bedtime in AD demonstrated an improvement 
of 42.5 minutes in total sleep time at night, and there were no significant 
adverse effects—including cognitive—that were reported90. Another study, of 
mirtazapine 15 mg, found no benefit on sleep after 2 weeks in AD patients, 
and there was increased daytime sleepiness91. Interestingly, a meta-analysis of 
cost-effectiveness of depression treatment in dementia found no cost benefit to 
either mirtazapine or sertraline compared to no treatment, however the number 
of caregiver hours required was reduced with mirtazapine, 6.7 versus 12.3 
hours, which the investigators hypothesized was due to improved sleep in the 
mirtazapine group92. Anti-depressants with anti-cholinergic properties (such as 
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tricyclic antidepressants) may worsen cognition in AD and LBD, and most anti-
depressants also worsen RLS. Therefore, while modest data suggest trazodone 
may improve nocturnal sleep in dementia, sedating anti-depressants should be 
used cautiously, with close monitoring of cognitive and RLS symptoms
Benzodiazepine receptor agonists
Typical benzodiazepines, especially long acting ones, have been associated 
with increased risk of falls, anterograde amnesia, daytime sleepiness, 
confusion, negative effect on cognition, and risk of dependence or abuse393. 
Long term usage of benzodiazepines has been suggested to be associated 
with an increased risk of AD94-96, but this association is not conclusive97. Non-
benzodiazepine benzodiazepine-receptor agonists  (NBBRAs, e.g. zolpidem 
and zaleplon) are preferred, since they have a shorter half-life and are generally 
better-tolerated, with less risk of dependence or abuse. However, NBBRAs have 
not been tested specifically in the dementia population. Furthermore, they are 
associated with adverse side effects such as morning sedation and parasomnias 
in the general population, and falls in the older population3,98. Therefore, these 
medications should be used sparingly only in demented patients who have 
attentive caregivers and living/sleeping situations that maximize safety, and 
patients should be seen frequently to assess for potential side effects and to 
ensure objective improvement in sleep.
Other hypnotic medications
In a small (20 treatment vs 22 placebo) post-hoc analysis of a memantine trial 
in LBD, there was less nocturnal activity in the memantine group measured by 
questionnaire, but no differences in ESS. The decrease in nocturnal activity was 
interpreted as reduced RBD, however this finding has not been confirmed by 
PSG99.
In a non-randomized study of newly-diagnosed AD patients, those with 
frequent awakenings per night (n=93) were offered treatment with risperidone 
0.5-1 mg, zolpidem 5-10 mg, melatonin 2.55 mg, or no drug treatment, in 
addition to donepezil 5-10mg. After 5 years, the risperidone group did not 
have deterioration in ESS and PSQI, compared to the other groups, who had 
worsening in both measures100. 
There are no reports of trials of orexin receptor antagonists (e.g. suvorexant) or 
other hypnotic classes in dementia.
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Stimulants
While stimulants such as methylphenidate have been tested in dementia to 
address apathy, there are limited studies examining stimulants for hypersomnia 
in dementia. Daytime hypersomnia is particularly common in LBD, and two 
small studies examined modafinil for this indication. One showed slight 
improvements in physical fatigueability but not hypersomnia101, and the other 
showed no benefit102. Therefore, while stimulants may be used for formally-
diagnosed hypersomnia disorders in dementia patients, there is no evidence 
currently to recommend stimulants for general use in dementia.
6.8 CONCLUSION
Sleep and circadian disturbances are common in all types of dementia, and 
can manifest in symptoms around-the-clock. The clinical approach to sleep and 
circadian disorders in dementia begins with assessing for and treating primary 
sleep disorders, then managing co-morbid conditions and medications that 
may be negatively affecting sleep, then behavioral interventions, and then 
pharmacological treatments. Studies have shown neutral to positive effects 
of sleep hygiene education, physical and social activity, bright light therapy, 
and melatonin supplementation, without significant adverse side effects. 
There are scant data to support the use of hypnotic medications for sleep 
disturbances in dementia, with only one small study showing a benefit of low-
dose trazodone. Due to risk of sedation, falls, and worse cognitive function 
from hypnotic medications, they should be used very cautiously, with frequent 
serial assessments for safety and objective measurements of drug efficacy. 
Well-designed studies using specific criteria for dementia etiology, formal 
assessment for primary sleep disorders, incorporation of circadian phenotype 
into treatment strategy, and treatment dosing and methods appropriate for the 
dementia population are sorely needed to identify truly effective interventions 
for sleep and circadian disturbances in dementia.
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Motivated by the lack of evidence in humans, this thesis focuses specifically on 
the pathophysiological mechanism between disrupted sleep and the risk of AD, 
with a specific emphasis on the role of Aβ. In chapter 2, we describe how one 
night of total sleep deprivation in 26 healthy middle-aged volunteers showed an 
increase in CSF Aβ42 (but not Aβ40 or tau) the following morning, while a night 
of sleep showed a 6% decrease in Aβ. This study showed that sleep deprivation, 
or prolonged wakefulness, seems to interfere with the normal physiological 
morning decrease in CSF Aβ42 in humans, as has previously already been 
shown in rodent studies. In continuation of our study in chapter 2, we were 
interested in examining which specific aspect of sleep modulates Aβ in humans. 
Slow wave sleep (SWS), which occurs during deep NREM sleep, is speculated to 
decrease Aβ levels in the brain as SWS is associated with a period of diminished 
neuronal firing in rodent studies. To investigate the contribution of SWS to Aβ 
modulation in humans, we first had to develop an automated Matlab protocol 
to specifically disrupt SWS with the aid of auditory tones through earphones 
in chapter 3. The SWS disruption protocol was tested on 10 healthy volunteers 
and effectively reduced SWS compared to a sham condition, without significant 
changes in total sleep time, sleep efficiency, or other macrostructural sleep 
characteristics. This protocol was used in chapter 4 to investigate whether 
specific disruption of SWS leads to increased Aβ and tau levels in CSF in 
humans. Specific disruption of SWS correlated with an increase in Ab40. This 
effect was specific for SWS, and not for total sleep duration or sleep efficiency. 
Furthermore, home sleep quality calculated from the average of 6 nights 
preceding lumbar punctures, was associated with higher tau. Our findings 
were specific for neuronally-derived proteins (Aβ and tau) and not glial-derived 
or total proteins, which suggests that SWS affects Aβ and tau by influencing 
synaptic activity with decreased release of these proteins into the interstitial 
space, rather than by affecting protein clearance mechanisms. Although the 
exact mechanism behind the increase of Aβ is suggested to be driven by 
increased production due to neuronal activity during wake, we were not able to 
rule out that SWS affects interstitial fluid protein clearance in this study. We did 
not observe an effect on all CNS proteins as would theoretically be expected by 
disrupting interstitial fluid protein clearance.
After having assessed the effect of one night of sleep disruption in chapter 2 
and chapter 4, we wanted to explore the effect of chronic sleep deprivation in 
humans, which has proven difficult due to the heterogeneity that exists within 
populations with sleep disorders. A well-defined working population with 
irregular sleep caused by their profession enabled us to properly investigate the 
effects of chronic poor sleep in mid-life on cognition by comparing this chronic 
sleep deprivation group to a healthy age and education controlled group. 
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We hypothesized that the chronic sleep deprivation group would have more 
fragmented sleep, and therefore also less SWS, due to their irregular sleeping 
schedules. Over the course of many years, this poor sleep could have increased 
Aβ concentrations, which in turn would result into poorer cognitive function 
(reflected in cognitive test scores) due to AD-related neurodegeneration. In 
contrast to our hypothesis, there were no differences in cognitive test scores 
measuring reaction time, visual memory, executive function, semantic memory 
and episodic memory. Considering the age of the chronic sleep deprivation 
group (average of 53 years), it is highly possible that subtle cognitive changes 
cannot be fully reflected in cognitive test scores, also due to relatively small 
sample size. Furthermore, the chronic sleep deprivation group showed more 
SWS compared to the healthy matched controls. These results did not reach 
statistical significance but suggest this enhanced SWS may indicate so-called 
rebound sleep, to compensate for previous poor sleep. 
Lastly, we aimed to identify the effective treatments of sleep disorders in AD 
patients in chapter 6, with the hope of reducing caregiver burden, improving 
patient quality of life, postponing institutionalization, and potentially slowing 
cognitive decline. We concluded that the clinical approach to sleep and 
circadian disorders in dementia begins with assessing for and treating primary 
sleep disorders, then managing co-morbid conditions and medications that 
may be negatively affecting sleep, then behavioral interventions and bright light 
therapy, and finally if all of these fail, pharmacological treatments.
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8.1 INTRODUCTION
The main topic of this thesis was to explore how poor sleep in midlife affects the 
risk of Alzheimer’s disease (AD) and the pathophysiological mechanism behind 
it, with a specific focus on the role of amyloid β (Aβ). In recent years, several 
rodent studies aimed to explore how poor sleep impacts the risk of AD, by 
investigating the link between Aβ metabolism and sleep. To our knowledge, we 
are the first to explore the effects of total sleep deprivation and slow wave sleep 
(SWS) deprivation on Aβ metabolism in humans. 
In this discussion, I would like to start with discussing the potential mechanisms 
behind the observed effect of disrupted sleep on Aβ metabolism and to a 
lesser extend tau metabolism, as observed in my own research. Furthermore, I 
want to consider the implications of the link between poor sleep and AD. 
8.2 ASSOCIATION BETWEEN SLEEP 
DISTURBANCES AND AD: DECREASED 
CLEARANCE OR INCREASED PRODUCTION?
We have established in chapter 2 and chapter 4 that soluble Aβ levels are 
higher in CSF after wakefulness and lower during sleep (specifically SWS), 
indicating that sleep may influence processes involved in Aβ production, 
Aβ clearance or both. High soluble brain Aβ levels have been tied to an 
elevated risk of developing amyloid plaques in amyloid precursor protein 
transgenic mice. A 20-25% increase in soluble Aβ after chronic sleep restriction 
significantly increased amyloid plaque formation in this rodent model1. Because 
of the potential harmful effect of elevated soluble Aβ levels due to poor sleep, 
it is important to question what mechanism(s) – decreased production and/
or increased clearance – are involved in the drop in brain Aβ levels during 
sufficient sleep, and which of these involved mechanisms are affected during 
sleep loss. In chapter 2 and chapter 4 we showed that sleep disruption 
only seemed to have an effect on Aβ and not total protein, which suggests 
that general clearance mechanisms are potentially not affected after sleep 
deprivation. However, a recent theory on the involvement of the glymphatic 
clearance mechanism of Aβ has been gaining popularity in the field ever since 
a 2012 paper was released on the existence of this clearance mechanism in 
rodents. I would like to discuss the current state of the art in the field regarding 
both clearance and production mechanisms of Aβ and how they are each 
thought to be affected by sleep deprivation.  
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8.3 INCREASED CLEARANCE OF Aβ
As discussed above, one of the popular hypotheses in the field is that increased 
clearance of solutes from the extracellular space during sleep may be an 
important factor in the overnight decrease of Aβ levels in the brain. The normal 
clearance of Aβ is driven by overlapping clearance systems, including 1) local 
degradation by proteases2,3, 2) phagocytosis by glial cells4-6, 3) transport 
across the blood-brain barrier (BBB)7, 4) clearance through interstitial fluid (ISF) 
bulk flow8 and 5) cerebrospinal fluid (CSF) absorption into the circulatory and 
lymphatic systems9-11. Rodent studies demonstrated that the majority (75%) of 
extracellular Aβ is cleared by the BBB, with a substantial smaller portion (10%) 
being cleared by bulk flow12. However, recent studies suggested that ISF bulk 
flow, through the glymphatic pathway, may contribute to a larger portion of Aβ 
clearance than previously thought13,14. The following sections will discuss how 
both BBB and glymphatic clearance are thought to contribute to Aβ clearance 
during sleep.
The role of the blood brain barrier (BBB) in the clearance of Aβ 
Studies have shown that a significant amount of Aβ clearance can be attributed 
to the BBB transport from the ISF into the bloodstream15.  Given their size, 
monomeric Aβ1-40 and Aβ1-42 should be able to pass freely through astrocytic 
end feet clefts16. However, endothelial tight junctions at the BBB prevent free 
passage of Aβ and tau from the brain into the blood, so they must instead be 
transported across the endothelium by specialized transporters either in an 
APOE-dependent or independent manner13,17. Lipoprotein receptor-related 
protein 1 (LRP1) mediates efflux of Aβ and Aβ bound to APOE-ε2, APOE-ε3 
from the brain parenchyma into the blood. LRP1 can do this independently of 
APOE-ε2 and APOE-ε3, while APOE-ε4 has been shown to inhibit this process. 
LRP1 can also eliminate Aβ with the aid of the ATP-binding cassette (ABC) 
transporter18-21. The main ABC transporter responsible for Aβ efflux is ABCB1 
(also known as P-glycoprotein)21,22, and does not directly bind and remove Aβ23, 
but only does so in an APOE dependent manner with the aid of LRP124. Since Aβ 
bound to APOE-ε4 is less rapidly cleared across the BBB through LRP1, these 
complexes are mostly transported through slow internalization and transcytosis 
via very low density lipoprotein receptors (VLDLR)25,26. Lastly, clearance of Aβ 
through the BBB has also been suggested to be mediated by the Glut1 glucose 
transporter27. 
The direct effect of partial or chronic sleep disruption on BBB Aβ clearance has 
not been investigated in either rodent or human studies. Evidence from one 
rodent study suggests that sleep disruption may impair the functioning of the 
126
BBB by reducing the structural and functional integrity of the BBB28. Six days of 
chronic sleep restriction in mice led to a reduced expression of tight junction 
proteins by BBB endothelial cells and increased paracellular permeability28. This 
permeability was determined by measuring the tissue/serum ratio of sodium 
fluorescein tracer (376 Da). This increase of BBB permeability returned to normal 
after recovery sleep, suggesting that this mechanism is reversible. However, the 
consequences of a leaky BBB remain unclear. It would theoretically be expected 
that a reduction of structural integrity of the BBB could cause more Aβ to leak 
out of the brain after periods of sleep deprivation. However, the direct link 
between an impaired BBB due to sleep disruption and Aβ clearance remains 
hypothetical.  This rodent study is the only one in its kind which investigated 
the relationship between chronic poor sleep and the BBB and is limited by its 
small sample size (n=5 for control and n=7 for chronic sleep deprived group). 
More importantly, it is not expected that such changes will have an effect on Aβ, 
which is approximately 4 kDa in size compared to the tracer which is 376 Da in 
size. 
The role of the glymphatic pathway in the clearance of Aβ
In the last couple of years, the existence of a para-vascular circulation in the 
CNS has been demonstrated in mice using in vivo two-photon imaging13. The 
study showed that CSF acts like lymph in the brain parenchyma by flushing out 
interstitial metabolites in a process facilitated by glial cells, and was therefore 
named the ‘glymphatic system’13. According to the hypothesis, toxic metabolites 
are cleared from the ISF during sleep by a process that requires astrocytic 
aquaporin-4 (Aqp4), a water transporter that is expressed on the astrocytic 
end feet29. Several studies have already shown this role of Aqp4-dependent 
trans-astrocytic ISF bulk flow in the clearance of Aβ through the glymphatic 
system12,13,30. This role of Aqp4 was further confirmed with a subsequent 
study using Aqp4-knockout mice which showed reduced Aβ40 clearance that 
resulted in Aβ deposition in the cortex and hippocampus31. 
This line of research was followed up by another study from the same lab in 
which it was found that this CSF-ISF exchange increased during sleep in wild-
type mice32, thereby increasing removal of metabolites that accumulate during 
wakefulness, including exogenously injected soluble Aβ peptides.  Aβ peptide 
clearance rates were doubled during sleep compared to wakefulness32. This 
increase seems to be related to a 60% increase in the interstitial space of brain 
parenchyma in mice during slow wave sleep compared to the space found 
during wakefulness32. This expansion of the interstitial space might explain the 
more efficient removal of substances during sleep compared to wakefulness32. 
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The Nedergaard lab continued their line of research by investigating what 
causes the increased interstitial spaces during slow wave sleep. They speculated 
that this might be because of osmotic forces that control fluid movements.  
The authors proceeded to measure ion concentrations in both waking and 
sleeping mice via microdialysis33. Potassium levels increased immediately after 
waking, and lowered when the animals went into a sleeping state. Calcium and 
magnesium ions moved to the opposite direction of potassium, rising during 
sleep and falling when animals woke up. It was hypothesized that when an 
animal falls asleep, extracellular potassium decreases first, hyperpolarizing 
and silencing neurons, and at the same time fluid volume swells to facilitate 
clearance of toxic solutes, such as has been previously shown with Aβ. 
Aside from osmotic forces that control fluid movements, the glymphatic flow 
has also shown to be pulsatile, where respiration-related pressure cycling 
propels the flow of ISF to CSF34. The involvement of the glymphatic pathway 
in controlling fluid movements was speculated in a study which found that 
patients with obstructive sleep apnea have lower CSF Aβ levels compared to 
the healthy control group35.  The authors hypothesized that the high-pressure 
fluctuations during an obstructive apnea may impede the glymphatic flow of 
metabolites from ISF into CSF. This would result in higher concentrations of Aβ 
and other neuronally-derived metabolites lingering in the ISF rather than being 
transported into the CSF, resulting acutely in lower CSF concentrations. 
In summary, recent findings by the Nedergaard lab suggest that sleep promotes 
the glymphatic system, resulting in enhanced removal of Aβ. The hypothesis 
is compelling, but there are some points that need to be addressed in future 
research. First of all, it remains unclear whether this glymphatic clearance 
of Aβ is also present in humans and whether it can increase the clearance 
rate of Aβ to the same extent as in mice. According to this hypothesis, we 
would theoretically expect a decrease of all CNS proteins after one night of 
total and slow wave sleep deprivation in chapter 2 and chapter 4 due to the 
increase in the interstitial space and glymphatic flow. However, while CSF 
Aβ levels declined in both studies after disrupted sleep, CSF total protein 
remained unchanged. While this does not disprove the glymphatic pathway, 
it does raise more questions regarding the existence of a glymphatic pathway 
in humans. A recent human study found potential evidence for modulation 
of the extracellular space by sleep and wakefulness36. Healthy participants 
showed an increased subcortical but not global gray and white matter volumes 
after 24 hours of wakefulness combined with cognitively demanding task. In 
addition, a decreased volume of the brain ventricles was observed compared 
to the volumes after normal sleep36. These changes reverted after recovery 
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sleep. However, any relationship to a possible glymphatic system or direct 
link to Aβ or other metabolites was lacking. Secondly, the study by Xie et all 
used exogenously administered Aβ to ascertain the clearance function of the 
glymphatic system during sleep32. Thus, it has not yet been shown to which 
extent the function of the glymphatic system during sleep is of relevance 
for clearance of endogenously produced Aβ. Lastly, other labs have up to 
now failed to replicate the results because of the difficulty of the technique. 
Additional research by multiple labs is needed to ascertain which sleep 
stage-specific neurotransmitter and neuro-peptide patterns contribute to the 
clearance of Aβ from the ISF.
8.4 INCREASED PRODUCTION OF Aβ
Another proposed mechanism that might explain the overnight increase of Aβ 
levels in the brain after periods of sleep deprivation, such as in our own work 
in chapter 2 and chapter 4, is the association between increased production of 
Aβ during wakefulness. In recent years, Aβ production has been closely tied to 
the sleep/wake cycle. A major contributor to the production of Aβ seems to be 
neuronal activity, which is higher during wakefulness compared with sleep37-39. 
A first indication that neuronal activity might directly influence soluble Aβ has 
been demonstrated by two studies using mouse models, in which ISF lactate, 
a marker of neuronal activity39, also showed diurnal oscillation in phase with 
ISF Aβ in rodents38,39. A study using transgenic APPswe/PS1δE9 mice showed 
that increasing plaque pathology hampered the diurnal oscillations in both ISF 
lactate and Aβ and were restored again after Aβ immunotherapy40. 
In humans, brain activation has also indirectly been linked to Aβ production41. 
Brain areas that display the highest levels of activity during wakefulness, the 
so-called default mode network, are also the regions that are most prone to Aβ 
aggregation. ISF Aβ concentrations have been shown to increase in patients 
with acute brain damage as their neurological status improves, and conversely 
to fall when their neurological status declines42. 
SWS is associated with a period of neuronal hyperpolarization and diminished 
neuronal firing and might therefore be expected to be associated with less Aβ 
production43.  During sleep, the brain remains metabolically and electrically 
active during stage 1 (N1) and NREM stage 2 (N2) sleep44,45,also regarded as 
light NREM sleep. However, a reduction can be observed in the frontoparietal 
functional connectivity during stage 3 (N3) sleep, the sleep stage with the most 
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SWS, also called deep NREM sleep46. It is therefore possible that Aβ production 
decreases during SWS due to the decreased neuronal activity during N3 sleep. 
Supporting this hypothesis, CSF Aβ42 levels have been shown to be lowest in 
humans at around 10 AM, corresponding to a nadir in ISF levels occurring at 
4 AM (due to the 6 hour lag for brain soluble Aβ to reach the lumbar space47), 
which also corresponds with our own findings in chapter 2, where the biggest 
drop in Aβ was seen at 10 AM (see figure 3 in chapter 2). This represents a time 
point after which most SWS has typically occurred and after which sleep is 
predominated by light NREM sleep and rapid eye movement (REM) sleep. 
The above evidence prompted us to develop a SWS disruption program in 
chapter 3 to test the hypothesis that the decline in CSF Aβ after a night of total 
sleep deprivation as seen in chapter 2 could be attributed to specifically SWS 
in humans. While previous methods exist to manually disrupt SWS by using 
highly-trained individuals subjectively interpreting EEG in real time to deliver 
auditory tones, these are highly subject to inter-operator variability in EEG 
scoring, selection of stimuli, and delivery of stimuli. The aim of chapter 3 was to 
develop an automated SWS disruption protocol to specifically reduce SWS in an 
objective manner. This protocol was used in chapter 4 in healthy participants, 
where we established that specific disruption of slow wave activity correlated 
with an increase in CSF Aβ. Additionally, we found that impaired home sleep 
quality was associated with increased CSF tau. The specificity of this effect for 
CSF Aβ and tau, and not for the glial-derived YKL-40 or total CSF protein levels 
suggests that SWS disruption decreases synaptic activity, reducing production 
of Aβ and tau and resulting in decreased release of these proteins into the 
interstitial space leading to their lower CSF concentrations, rather than by 
influence general protein clearance mechanisms described in paragraph 1.2.
8.5. ALTERNATIVE MECHANISMS
In theory, the increase in Aβ may also be a response to different processes 
related to sleep or sleep deprivation. One such an example is oxidative stress, 
which increases during periods of sleep deprivation and where the increase in 
Aβ may be a physiological response to counter this oxidative stress. In animal 
studies, it was found that loss of sleep leads to increased oxidative stress in the 
brain48,49.  Three nights of extended wakefulness increased superoxide levels in 
the locus coeruleus (LC) neurons48. In addition, 72h sleep loss in mice increased 
oxidative stress in the hippocampus49. In addition, mice with homozygous Clock 
mutations sleep approximately 2 hours less than wild type mice50, and show 
increased signs of oxidative stress51,52.
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8.6 EFFECTS OF SLEEP AND SLEEP 
DEPRIVATION ON TAU 
Focus in this thesis has particularly been on the relationship between sleep 
deprivation and its effect on Aβ. This angle was specifically chosen because 
the bulk of evidence in the current literature on this subject revolves around Aβ. 
However, the tau protein is also an important player in AD pathophysiology. 
The hyperphosphorylation and intercellular aggregation of tau protein is the 
second hallmark of AD and unlike Aβ, total and phosphorylated tau in the CSF 
have been shown to predict and correlate with cognitive decline in preclinical 
and clinical AD53,54. In addition, chronic sleep disruption increases tau levels and 
Figure 1: Proposed mechanisms linking sleep and AD. This schedule summarizes the 
proposed mechanisms by which poor sleep could potentially influence the pathophysiological 
mechanism of AD. Grey boxes depict the key events in this mechanism. 
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tau phosphorylation in mice55,56. Our research in chapter 2 and chapter 4 are 
to our knowledge the first human studies measuring the relationship between 
sleep and CSF tau. We didn’t find an effect of total sleep deprivation on CSF 
total-tau or CSF phosphorylated tau levels in chapter 2. This is possibly due to 
the relatively long in vivo turn-over rate of tau with a half-life of 11 days57, while 
our measurements only included 24 hours. We found a similar effect in chapter 
4, where we did not find an association between SWS and CSF tau the following 
morning. However, when we compared actigraphically-measured home sleep 
over six preceding nights to CSF tau levels, we could see a significant negative 
correlation between home sleep quality and CSF tau, such that impaired 
sleep efficiency was associated with higher tau. Due to the lack of association 
between sleep quantity and tau, this suggest that similar oscillations exist in 
CSF tau, although with a slower frequency due to the longer half-life. This would 
suggest that sleep and sleep deprivation have a direct effect on tau levels 
in the brain, independent of Aβ levels. These oscillations in tau are possibly 
also related to either increased production of tau or decreased clearance 
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during wakefulness. Similar to Aβ, tau is also released during neuronal activity, 
although clearance from the brain is slower than Aβ due to the half-life of 11 
days57. Little is known about the clearance of tau, and seems to mostly rely on 
enzymatic degradation, the glymphatic pathway, and CSF absorption58,59. 
8.7 SUMMARY
As of yet we are neither able to clearly determine the exact contribution of 
sleep and poor sleep on the clearance and production of Aβ, due to the 
complex interplay between these mechanisms. The previously discussed 
mechanisms behind the production and clearance of Aβ are all summarized 
below in  1. Increased wakefulness, causes increased neuronal activity, leading 
to elevated Aβ and tau production. In addition, wakefulness also suppresses 
the glymphatic flow, which could lead to decreased clearance of Aβ and tau. 
The BBB also seems to be affected by prolonged wakefulness, showing less 
expression of tight junction proteins and the GLUT1 transporter. Lastly, sleep 
loss also promotes oxidative stress, and inflammation. Together, these combine 
to promote neurodegeneration, which in turn causes more circadian and sleep 
dysfunction. The discussed evidence is mostly limited to animal studies, and it 
seems that the increased Aβ and tau levels during sleep are likely caused by a 
combination between increased production due to increased neuronal activity 
and decreased clearance mechanisms, where most evidence currently points 
towards the glymphatic pathway. 
8.8  IMPLICATIONS FOR A LINK BETWEEN 
SLEEP AND AD.
We established in the previous paragraphs that the mechanisms that explain 
the link between sleep and AD are complex. Chapter 2 and chapter 4 of this 
thesis are an important translational step in confirming that Aβ fluctuations 
also occur in humans, and are specifically tied to sleep. An important next step 
to consider is that although the mechanisms causing these elevated Aβ levels 
after poor sleep remain unclear, we need to explore how fragmented sleep or 
insomnia leads to AD. Evidence obtained in humans until now mostly consisted 
of epidemiological evidence to show that patients with poor sleep have an 
elevated risk of AD, as showed by a systematic review60, showing a 1.49  (95% CI: 
1.25–1.78) higher risk of AD with sleep disturbances. Most of these studies used 
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self-reported methods to identify their sleep problems, and were therefore 
unable to differentiate between objective and subjective variables on the risk 
of AD. In addition, sleep disturbances are prevalent in dementia patients and 
may be prodromal symptoms of dementia. It is therefore especially important 
to investigate the effect of chronic sleep deprivation in a population that shows 
disrupted sleep caused by an external factor and not due to sleeping disorders. 
In chapter 5, we investigated such a group of healthy middle-aged participants 
who reported a history of disrupted sleep due to external occupational 
factors for more than 15 years to investigate the direct effect of chronic sleep 
deprivation and its consequence on cognitive functioning. To our knowledge, 
we are the first group to investigate such a specific population to this extent. 
No significant differences were found between the chronic sleep deprivation 
group and the healthy controls on the cognitive tests measuring reaction time, 
visual memory, executive function, semantic memory and episodic memory. 
Considering the age of the chronic sleep deprivation group (average of 
53 years), it is highly possible that subtle cognitive changes cannot be fully 
reflected in cognitive test scores, also due to relatively small sample size. 
This is supported by a recent systematic review, which showed that reliable 
Aβ+ related cognitive impairment occurs in several domains of memory in 
cognitively normal adults, but that this impairment was small in magnitude 
with effect sizes ranging from d = 0.15 for episodic memory to d = 0.25 for 
visuospatial function61. In addition, it is known that an asymptomatic period 
exists in the development of AD, where patients still display a heightened Aβ 
load without cognitive dysfunctioning62. It would therefore be interesting to 
perform an amyloid PET scan or measure CSF Aβ42 and tau in this population 
to offer some interesting insights about the effect of prolonged sleep 
disturbances on a biological level. Further research, specifically longitudinal 
studies following populations with poor sleep due to their occupation is 
needed to explore the specific effect of chronic poor sleep on cognition and to 
investigate its impact on AD-related cognitive decline. In order to identify subtle 
cognitive changes, it would be of specific interest to measure cognitive decline 
in these populations around the age of 60-65 years, where subtle cognitive 
changes typically occur.    
It is too early to speculate about potential treatment methods of sleep disorders 
to prevent risk for AD. However, treatment of sleep disorders would be in the 
general interest of the patient, aside from the potential risk of AD, due to the 
association between sleep disorders and the risk for many other morbidities in 
later life such as cardiovascular disease, obesity and diabetes63,64,65. In addition, 
it is important to treat patients who suffer from sleep disorders caused by AD, 
due to the fact that sleep factors are known to contribute to the worsening 
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cognitive decline and contribute to the progression of the disease. Sleep 
disorders are frequent in patients with AD, affecting 44% of all patients66 and 
negatively affecting patient quality of life and increase caregiver burden67. In 
addition, wandering and subsequent risk of injury, due to nighttime insomnia, 
increases morbidity and mortality directly, and therefore is a common reason 
for institutionalization68. We therefore aimed to identify the effective treatments 
in chapter 6, with the hope of reducing caregiver burden, improving patient 
quality of life, postponing institutionalization, and potentially slowing cognitive 
decline. We concluded that the clinical approach to sleep and circadian 
disorders in dementia begins with assessment and treatment of primary sleep 
disorders, then managing co-morbid conditions and medications that may 
be negatively affecting sleep, then behavioral interventions and bright light 
therapy, and finally if all of these fail, pharmacological treatments.
8.9 CONCLUSION AND FUTURE STUDIES
Our studies show that insufficient sleep, specifically poor SWS, is directly 
related to higher CSF Aβ levels in humans. The mechanisms behind this 
increase of Aβ in the CSF are currently still under much debate. Some relate 
this elevation to an increase in Aβ production directly linked to neuronal 
activity during wakefulness, while others contribute this rise in Aβ to a decrease 
of clearance mechanisms during sleep. Among the clearance mechanisms 
discussed, the transport mechanism most tightly linked to sleep disturbance 
seems to be the glymphatic system. However, additional research using 
endogenous Aβ is needed to fully understand the glymphatic system, and if 
this system is at all present in humans since all current research up to this point 
has only been performed on animal models. In addition, it would be of specific 
interest to explore how elevated Aβ levels will contribute to long-term risk of 
amyloid deposition and subsequent progression to AD. Up until now most 
human evidence consisted of epidemiological evidence, and it would therefore 
be important to conduct longitudinal studies in a middle-aged population 
until the remainder of their lifespan. Lastly, long-term prospective studies will 
be necessary to test whether improving sleep quality and increasing SWS by 
treating underlying sleep disorders, medications, behavioral interventions, or 
acoustic enhancement of SWS can reduce Aβ levels and the risk of future AD. 
Such research will reveal if treatment of sleep disorders can reduce the risk of 
AD. Combined with our knowledge of the pathophysiological mechanisms, it 
will give us the tools to treat sleep disorders as a preventable risk factor for AD 
in the future.
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NEDERLANDSE SAMENVATTING
De ziekte van Alzheimer is een neurodegeneratieve ziekte en de meest 
voorkomende vorm van dementie. Deze ziekte kenmerkt zich door een 
opstapeling van het amyloid-β eiwit in de hersenen en het samenkluwen van 
zogenaamde tau vezels in de zenuwcellen. Men denkt dat deze ophopingen 
en kluwen leiden tot schade van de zenuwen en hun verbindingen. Hierdoor 
raakt de werking van de hersenen verstoord, en kan er bij genoeg schade 
symptomen optreden zoals vergeetachtigheid, desorientatie en veranderingen 
in de persoonlijkheid. Deze klachten zijn van grote invloed op het leven van 
de patient en hun naasten. Ondanks veelvuldig onderzoek naar deze ziekte 
is de exacte oorzaak van de ziekte niet bekend en is er momenteel geen 
behandelmethode. Wel zijn er bepaalde risicofactoren bekend die de kans op 
het verkrijgen van de zieke van Alzheimer kunnen vergroten. Voor enkele van 
deze risicofactoren zijn wel behandelmethodes. De belangrijkste risiscofactoren 
zijn leeftijd, een positieve familiegeschiedenis, genetische risicofactoren en 
leefstijl factoren zoals overgewicht, diabetes en een hoog cholesterol. Recent 
onderzoek laat zien dat er mogelijk een verband bestaat tussen slecht slapen en 
een verhoogd risico op het verkrijgen van de ziekte van Alzheimer. 
Slechte slaap als risico voor de ziekte van Alzheimer
Bij veel patienten gaat de ziekte van Alzheimer gepaard met problemen op 
het gebied van hun slaap en dag/nacht ritme. Onderzoek heeft aangetoond 
dat dit verklaard kan worden door schade aan delen van de hersenen die 
slaap reguleren. Interessant genoeg blijkt er omgekeerd uit observationele 
studies dat patienten met slaapstoornissen een verhoogd risico lopen op het 
verkrijgen van de ziekte van Alzheimer. Proefdieronderzoek trachtte dit verband 
te verklaren door een aantal muizen een periode niet te laten slapen. Hierbij 
zorgde te weinig slaap voor verhoogde concentraties van het amyloid-β in de 
hersenvloeistof van muizen. Ook werd er gekeken naar het langdurig effect 
van slecht slapen. Hierbij zagen zij dat chronisch hoge amyloid-β waarden 
in de hersenvloeistof door langdurig slaapgebrek de kans op het neerslaan 
van amyloid- β in de hersenen verhoogde en zodoende ook de kans op het 
verkrijgen van de ziekte van Alzheimer. 
In hoofdstuk 2 laten wij zien dat dit proces ook plaatsvindt in mensen, waarbij 
de amyloid-β waarden in de hersenvloeistof van gezonde proefpersonen dalen 
na een nacht slapen, en verhoogd zijn na een nacht slaap deprivatie. 
Als een volgende stap wilden wij onderzoeken waarom deze amyloid-β 
waarden stijgen na een nacht slecht slapen. Amyloid-β productie staat direct 
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in verband met de zogenaamde neuronale activiteit van de hersenen. Dit 
zorgt ervoor dat de productie van amyloid-β verhoogd is als mensen wakker 
zijn. Tijdens slaap is er verminderde activiteit van de hersenen, en dit zou de 
normale daling in amyloid-β na een nacht slapen kunnen verklaren. Gedurende 
de slaap is er een opbouw van de zogenaamde slow wave sleep, de diepe 
slaap. Deze diepe slaap bestaat uit hoge amplitude delta golven. Elk van deze 
hoge amplitude golven staat voor een pauze in synaptische activiteit van 
neuronen in de corticale gebieden in de hersenen. Wij wilden onderzoeken of 
het verminderen van specifiek alleen de diepe slaap een effect zal hebben op 
de amyloid-β waarden in de hersenvloeistof van gezonde vrijwilligers. Hiervoor 
ontwikkelden wij eerst een geautomatiseerd programma dat met behulp van 
piepjes specifiek de diepe slaap verstoort in hoofdstuk 3. Dit geautomatiseerde 
programma is objectief, en zorgt ervoor dat vrijwilligers wel een normaal aantal 
uren slapen, maar nooit echt in een diepe slaap komen. In hoofdstuk 4 pasten 
wij dit programma toe op een aantal gezonde vrijwilligers, en verstoorden zo 
effectief alleen hun diepe slaap. Hierbij zagen wij een correlatie tussen het 
verstoren van diepe slaap en amyloid- β, waarbij meer verstoring van diepe 
slaap zorgde voor hogere amyloid- β waarden.  
Na het onderzoeken van het effect van een nacht slecht slapen, onderzochten 
wij in hoofdstuk 5 wat het effect is van langdurig slecht slapen op het 
geheugen. Hiervoor werkten wij samen met een beroepsgroep die voor hun 
werk langdurig een verstoorde slaap heeft. Wij onderzochten in een aantal 
van deze personen hun slaappatroon en hun geheugen en vergeleken deze 
met een controlegroep. Onze verwachting was dat deze beroepsgroep door 
hun langdurig verstoorde slaap slechter zal scoren op de geheugentesten in 
vergelijking met de controlegroep. Beiden groepen bleken echter gelijkwaardig 
te scoren op de geheugentesten. Gezien de relatief jonge leeftijd van de 
beroepsgroep is het mogelijk dat wij te vroeg hebben gekeken, en dat de 
subtiele geheugenverschillen nog niet terug te vinden zijn op deze leeftijd. Een 
andere verklaring kan zijn dat deze beroepsgroep selecteert op mensen die 
kunnen compenseren voor weinig slaap.
Behandeling van slaapstoornissen in de ziekte van Alzheimer
Slaapstoornissen in de ziekte van Alzheimer zijn van grote invloed op zowel de 
patient als hun mantelzorgers. Een effectieve behandeling hiervan zal zorgen 
voor minder belasting van de mantelzorgers, betere kwaliteit van leven voor 
de patient, het verlaten van opname in een verzorgingstehuis en mogelijk 
ook het remmen van de cognitieve achteruitgang. In hoofdstuk 6 omschrijven 
wij de meest effectieve behandelingsmethoden voor slaapstoornissen in 
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de ziekte van Alzheimer. In de behandeling van slaapstoornissen in deze 
patientpopulatie is het beangrijk om allereerst een aanwezige primaire 
slaapstoornis te behandelen (zoals slaapapnoe of insomnia). Daarna is het 
belangrijk om te kijken naar het medicatiegebruik van de patient en of enkele 
medicamenten slaap negatief kunnen beinvloeden. Als de patient hierna nog 
steeds slaapproblemen ervaart raden wij aan de patient te behandelen met 
cognitieve slaap therapie en lichttherapie. Medicamenteuze behandeling voor 
slaapstoornissen zal pas ingezet moeten worden als een laatste redmiddel. 
145
CURRICULUM VITAE 
Sharon Ooms was born on the 28th of June 1988 in Nijmegen. After finishing 
secondary school in 2006 at the NSG Groenewoud in Nijmegen, she studied 
biomedical sciences at the Radboud University Nijmegen. She obtained her 
Master of Science in 2011. During her studies, she worked part time as an 
assistant nurse at the Waalboog in Nijmegen, where she assisted in caring 
for elderly and patients with Alzheimer's disease. In 2012 she started her PhD 
project on the relationship between poor sleep and Alzheimer’s disease under 
the supervision of prof. dr. M.G.M. Olde-Rikkert, dr. J.A.H.R Claassen and 
dr. ir. M.M. Verbeek. In 2013, she obtained a grant from the Dutch Alzheimer 
Foundation (Alzheimer Nederland), allowing her to do additional research 
at Washington University School of Medicine in St Louis. During her PhD 
trajectory, she gave different lectures at several international conferences 
such as the Alzheimer's Association International Conference in 2013 and 
Sleep in 2015. Next to her PhD, she was very active as the chairwoman of PhD 
Organisation Nijmegen. In 2017 she started working as a clinical research 
associate at Novartis Pharma in Arnhem. Sharon lives in Berghem together with 
her partner Carl Megens. 
Picture by Jim de Groot
146
LIST OF PUBLICATIONS
S.J. Ooms, S. Overeem, K.T. Besse, M.G.M Olde Rikkert, M.M. Verbeek, J.A.H.R. 
Claassen. Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid 
β-Amyloid 42 in Healthy Middle-Aged Men: A Randomized Clinical Trial. JAMA 
Neurol. 2014;71(8):971-977
S.J. Ooms, J.M. Zempel, D.M. Holtzman, Y.S. Ju Automated selective disruption 
of slow wave sleep J. Neurosci Methods. 2017 Apr 1;281:33-39
S.J. Ooms, Y.S. Ju, C. Sutphen, S.L. Macauley, M. Zangrilli, G. Jerome, A.M. 
Fagan, E. Mignot MD, J.M. Zempel, J.A.H.R. Claassen, D. M. Holtzman MD. Slow 
wave sleep disruption increases cerebrospinal fluid amyloid-beta levels. Brain. 
2017 Aug 1;140(8):2104-211.
S.J. Ooms, Y.S Ju. Treatment of sleep disorders in dementia. Curr Treat Options 
Neurol. 2016 Sep;18(9):40. doi: 10.1007
S.J, Ooms; J. Thomas, J.Doornbosch, J.A.H.R. Claassen, S. Overeem, R. Kessels; 
M M. Verbeek, and M.G.M. Olde Rikkert. The effect of long-term poor sleep on 
cognition of healthy middle-aged men (Submitted to BMC Neurology).
147
ACKNOWLEDGEMENTS 
First of all, I’d like to extend my gratitude and sincerest of thanks to all the 
volunteers who participated in my studies. Without you, your patience, and 
willingness to dedicate some of your time, this research would not have been 
possible. I’d particularly like to thank the volunteers of the Dutch Maritime Pilots 
(Nederlandse Loodswezen) whose enthusiasm and dedication made the SCHIP 
study successful.
Of course, I’d like to thank my doctoral thesis committee: my promotor Marcel 
OR, for his constant guidance and ever prompt feedback, which helped me 
develop as a scientist, but also as a person. And ofcourse my co-supervisors 
Jurgen and Marcel V. You both provided me with insightful criticism from 
different angles. It’s impossible not to be inspired by Jurgen’s endless 
enthusiasm and creative thinking, whereas Marcel would balance it out with 
a pertinent critical note and a solid, realistic approach. Thank you all for your 
support, insight, and advice during my research! 
To the committee who agreed to review this thesis, Indira, Martin and Eus; thank 
you for your time effort that went into reviewing this manuscript for its scientific 
value. I appreciate the opportunity to have you look over this work.
Throughout my time as a PhD student, I’ve had the pleasure to work with 
multiple teams on different aspects of my research. I would like to thank them all 
individually. 
I would like to thank the study team of AWAKE study. Sebastiaan, you have been 
a great inspiration to me and really made me fall in love with sleep research. 
Thank you for your infectious enthusiasm, your critical comments, and passion. 
Kees, you always kept your cool and had a practical solution for everything. And 
of course, my student assistants Poortje, Frederique and Lars, you all not only 
knew how to comfort volunteers, but also myself in highly stressed situations. 
Thank you for kicking me into bed when I insisted on staying awake during 
study weekends. The irony of my lack of sleep was clearly lost on me at the time. 
To the team of the Clinical Research Centre Nijmegen; Adrianne and Simone, 
thank you for sharing your expertise in clinical studies, and showing me the 
ropes. I’ve been able to apply so much of what I learnt from you as I came into 
my own as a researcher.
I have been fortunate enough to also collaborate with people abroad. I will 
always cherish the time I spend at Washington University School of Medicine in 
148
St Louis. David, thank you so much for the opportunity to stay with your lab. The 
way you lead your lab is an example to the field, and will remain an example to 
me that I will likely judge others by. Yo-El, thank you for being my mentor and 
inspiration. You taught me how to believe in myself and never give up on the 
data. It’s hard for me to put into words how much of an impact you made on 
me, not only professionally but as a person. Everyone needs a role model, and 
I feel like I found one in you. When I think of where I want to be, or what type of 
person I want to grow into, I think of everything you have achieved and how I 
hope to be the same to someone else, someday. Thank you for taking me under 
your wing. Many thanks to all the people working in the sleep lab, with a special 
mention for Jill and Matthew. Thank you sticking with me during study nights 
and all the interesting talks we had together!    
My time collaborating with the Dutch Maritime Pilots has been both inspiring 
as well as exciting. I never thought I would have the opportunity to climb on an 
enormous ship on the middle of the sea. Thank you all for showing me around 
and letting me experience what your daily lives look like. Clarinda, thank you 
for being the organizational heart of the study and bringing us in contact with 
all the interested maritime pilots. Your assistance with the collection of the 
actigraphy data significantly reduced the travel burden for the maritime pilots.  
Jetteke, you had to come all the way from Amsterdam but that didn’t stop your 
enthusiasm to assist in the study. Thank you for all your help, you made an 
amazing team with Jana.
Roy, thank you for sharing your expertise in collecting and analyzing cognitive 
tests. You certainly made some of the nitty gritty work easier! 
My years as a PhD wouldn’t have been the same without my colleagues who, 
on top of their own thesis work, always made time to help me out with mine. 
A special thanks to my roommates Gerrita, Daan, Marit and Rianne who were 
always there to lend an ear, or share victories together. You all made me feel 
less alone in this experience that we each tackled in our own way. Anke, Anouk, 
Anne, Aisha,  Esther, Fokke, Franka, Freek, Geke, Kim, Marjolijn, Miriam, Minke, 
Noralie and Teun, I will never forget all the ridiculous ‘challenges’ we thought up 
for new PhDs, our participations in pub quizzes, the drinks (planned or not!) and 
nights out. 
My heartfelt thanks to both my paranymphs, Jolien and Jana. You have both 
closely witnessed my journey from the start of my career in the medical field, 
to my struggles in my last year as a PhD student, to the publication of this 
manuscript. You each supported me through your own strengths. Jolien, you 
149
were always there to listen to my struggles and fears, but able to use your 
objective outlook to put things into perspective for me when I’d lost sight of 
what I needed. Jana, your curiosity and enthusiasm for the field sparked my own 
again, and made me remember what I loved about this field when I started out. 
Without you, I would have struggled to find my passion again, so thank you.
Dear family and friends, thank you for supporting me and being proud of 
me even when you didn’t always understand what I was doing, or what my 
achievements meant. Mom and dad, thank you for always knowing what's best 
for me but always supporting me by empowering me to make my own choices. 
None of this would be possible without you. Tonnie, Carool, Hellen and Joep, 
your door was always open (as I now have learned is tradition in Brabant :) ). A 
special thanks to Hellen for proofreading my manuscript, and sitting through 
all my long sentences. Roy, Ellyne, Camille, Dide and Martijn, thanks for always 
distracting me and letting me blow off steam after work by just sitting on the 
couch or partying. Liz, thank you for always dragging me out of Washington 
University when I insisted on continuing to work. I really enjoyed all the 
adventures we had together in the USA and they shaped me for the better, to 
be more relaxed and forgiving of myself. And last but not least, Gemma. I really 
believe your editing work has shaped my manuscript into something I can be 
confident and proud of. But more importantly, your support during the last 
tough years of my thesis has helped me to push through and never give up on 
or doubt myself. Our time spent together with Ties and Jurre was a well needed 
distraction, and I’m looking forward to see how we can all grow together in the 
years to come. 
And of course, Carl. I had to eat my words when I said I would never date 
someone who watches football or came from Brabant. You have been my 
support for the past three years, and no matter how frustrated, anxious or 
stressed I was, you always knew how to pull me back to earth. Our place 
together in Berghem turned out to be the perfect place for me to write. You 
were already familiar with the struggles of finishing your dissertation, and could 
relate to me in every important milestone I reached in ways a lot of others close 
to me couldn’t. I feel very grateful that you could transform my manuscript into 
something as beautiful as what lays before us now, which makes this book even 
more special to me. Thank you for being there for me, through the good times 
and the bad. 
150
PROEFSCHRIFTENLIJST RAC
Jong, D.L.K. de (2018). Regulation of cerebral perfusion in Alzheimer’s disease: 
from seconds to months
Donkers, H.W. (2018). Social Participation Dilemma’s in dementia.
Richters, A. (2018). Network-based care for people with dementia: a complex 
transition.
Spek, K. van der (2018). Appropriate psychotropic drug use in institutionalized 
people with dementia. The PROPER-study
Wiesmann, M. (2017). Vascular risk factors and Alzheimer’s disease. 
Rijpma, A. (2017). Multi-nutrient interventions and brain metabolism in 
Alzheimer’s disease: a spectrum of effects.
Elsen, G. van den (2016). Tetrahydrocannabinol in the treatment of 
neuropsychiatric symptoms in dementia.
Vermeij, A. (2016). Cognitive plasticity in normal aging and mild cognitive 
impairment: Shedding light on prefrontal activation. 
Müller, M. (2016). Footprints of Alzheimer's disease. Exploring proteins and 
microRNAs as biomarkers for differential diagnosis.
Bruggink, K.A. (2016). Amyloid-β and amyloid associated proteins in the 
pathology and diagnosis of Alzheimer’s disease.
Aalbers, T. (2016). eHealth in the primary prevention of cognitive decline; The 
Brain Aging Monitor study.
Maaden, T. van der (2016). Improving discomfort in nursing home residents with 
dementia and pneumonia. Development, implementation and evaluation of a 
practice guideline for optimal symptom relief.
Millenaar, J. (2016). Young onset dementia, towards a better understanding of 
care needs and experiences.
Döpp, C.M.E. (2015). Making the jump-The translation of research evidence into 
clinical occupational therapy practice.
151
Herbert, M. (2014). Facing uncertain diagnosis: the use of CSF biomarkers for 
the differential diagnosis of neurodegenerative diseases.
Ven, G. van de (2014). Effectiveness and costs of Dementia Care Mapping 
intervention in Dutch nursing homes 
Bakker, C. (2013). Young onset dementia: care needs & service provision.
Meeuwsen, E.J. (2013). Towards efficient dementia care : a comparison of 
memory clinics and general practitioners.
Spijker, G.J.A.A (2013). Systematic care for caregivers of people with dementia 
in community mental health services.
Janssen, D. (2013). The role of nutrition in Alzheimer’s disease : a study in 
transgenic mouse models for Alzheimer’s disease and vascular disorders.
Zerbi, V. (2013). Impact of nutrition on brain structure and function : a magnetic 
resonance imaging approach in Alzheimer mouse models.
Voight-Radloff, S. (2012). Cross-national transfer of community occupational 
therapy in dementia.
Spies, P.E. (2012). The reflection of Alzheimer disease in CSF.
Joosten-Weyn Banning, E.W.A. (2012). Learning to live with Mild Cognitive 
Impairment: development and evaluation of a psychological intervention for 
patients with Mild Cognitive Impairment and their significant others.
Vasse, E. (2012). A stepwise process for developing and implementing quality 
indicators to improve psychosocial dementia care in European countries.
Slats, D. (2012). CSF biomarkers of Alzheimer's disease; serial sampling analysis 
and the study of circadian rhythmicity.
Leontjevas, R. (2012). Act in case of Depression! Validation and effectiveness of 
a multidisciplinary depression care program in nursing homes.
Timmer, N.M. (2011). The interaction of heparan sulfate proteoglycans with the 
amyloid β protein
Schölzel-Dorenbos, C.J.M. (2011). Quality of life in dementia: From concept to 
practice
152
Bruinsma, I.B. (2011). Amyloidogenic proteins in Alzheimer’s disease and 
Parkinson’s disease: interaction with chaperones and inflammation
Perry, M. (2011). Development and evaluation of a Dementia Training 
Programme for Primary care
Derksen, E.W.C. (2011). Diagnostic disclosure: a basic intervention in dementia 
care
Wetzels, R.B. (2011). Neuropsychiatric symptoms in institutionalized residents 
with dementia: Course and interplay with cognition,quality of life and 
psychotropic drug use.
Dado- Van Beek, H.E.A. (2010). The regulation of cerebral perfusion in patients 
with Alzheimer’s disease
Jong, D. de (2010). Anti-inflammatory therapy and cerebrospinal fluid diagnosis 
in Alzheimer’s disease
Persoon, J.W.B. (2010). Development and validation of the Nurses’ Observation 
Scale for Cognitive Abilities – NOSCA
Meulenbroek, O.V. (2010). Neural correlates of episodic memory in healthy 
aging and Alzheimer’s disease
Zuidema, S.U. (2008). Neuropsychiatric symptoms in Dutch nursing home 
patients with dementia
Graff, M.J.L. (2008). Effectiveness and efficiency of community occupational 
therapy for older people with dementia and the caregivers
Claassen, J.A.H.R. (2008). Cerebral hemodynamics in aging: the interplay 
between blood pressure, cerebral perfusion, and dementia
Wilhelmus, M.M.M. (2006). Small heat shock proteins and apolipoprotein E in 
Alzheimer's disease
Van Horssen, J. (2005). Heparan sulfate proteoglycans and vascular pathology in 
Alzheimer's disease
153
DONDERS GRADUATE SCHOOL FOR 
COGNITIVE NEUROSCIENCE
For a successful research Institute, it is vital to train the next generation of 
young scientists. To achieve this goal, the Donders Institute for Brain, Cognition 
and Behaviour established the Donders Graduate School for Cognitive 
Neuroscience (DGCN), which was officially recognised as a national graduate 
school in 2009. The Graduate School covers training at both Master’s and 
PhD level and provides an excellent educational context fully aligned with the 
research programme of the Donders Institute. 
The school successfully attracts highly talented national and international 
students in biology, physics, psycholinguistics, psychology, behavioral science, 
medicine and related disciplines. Selective admission and assessment centers 
guarantee the enrolment of the best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% 
of PhD alumni show a continuation in academia with postdoc positions 
at top institutes worldwide, e.g. Stanford University, University of Oxford, 
University of Cambridge, UCL London, MPI Leipzig, Hanyang University in 
South Korea, NTNU Norway, University of Illinois, North Western University, 
Northeastern University in Boston, ETH Zürich, University of Vienna etc.. 
Positions outside academia spread among the following sectors: specialists 
in a medical environment, mainly in genetics, geriatrics, psychiatry and 
neurology. Specialists in a psychological environment, e.g. as specialist in 
neuropsychology, psychological diagnostics or therapy. Positions in higher 
education as coordinators or lecturers. A smaller percentage enters business 
as research consultants, analysts or head of research and development. Fewer 
graduates  stay in a research environment as lab coordinators, technical 
support or policy advisors. Upcoming possibilities are positions in the IT sector 
and management position in pharmaceutical industry. In general, the PhDs 
graduates almost invariably continue with high-quality positions that play an 
important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses 
please visit:
http://www.ru.nl/donders/graduate-school/phd/
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